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Neural stem cell (NSC) transplantation is a promising therapy for the treatment of 
brain damage. Although the “proof of principle” for NSC transplantation therapy has 
been demonstrated in a variety of animal models of brain injury (stroke, traumatic 
brain injury, ageing) and in a clinical setting (Parkinson’s disease), the mechanisms 
by which grafted stem cells survive, migrate and differentiate in host brain are yet to 
be elucidated. Initial studies have demonstrated that, after transplantation of the 
MHP36 neural stem cell line in a focal ischaemia model, the lipid transport protein 
apolipoprotein E (apoE) is upregulated and co-localised to differentiated cells in 
parallel with functional recovery. ApoE has been shown to have a critical role in the 
response to brain injury and repair processes. Furthermore, in humans, three different 
forms of apoE exist (E2, E3, E4 encoded by the alleles ε2, ε3, ε4) and each of these 
has a different ability to promote repair, with the E4 form associated with an 
impaired capacity. This thesis tests the hypothesis that apoE is critical in stem cell 
integration and investigates whether this effect is APOE genotype dependent, in a 
mouse model of global cerebral ischaemia. This model was chosen as it produces 
diffuse selective neuronal damage in the striatum and hippocampus, which also 
occurs in other conditions such as ageing and Alzheimer’s disease. The studies 
described in this thesis were designed to test the hypothesis and are outlined as 
follows: 
 
I. Characterisation of neural stem cell grafts in a mouse model of 
global ischaemia 
In order to investigate the potential influence of apoE on stem cell grafts, it was first 
essential to characterise stem cells grafts in mouse brain. Thus, the initial aim of the 
thesis was to characterise MHP36 grafts in a mouse model of ischaemic neuronal 
injury. The effect of cyclosporin A (CsA) immunosuppression was also investigated. 
C57Bl/6J mice underwent an episode of transient global ischaemia induced by 
bilateral common carotid artery occlusion. Three days following ischaemia, mice 
received a unilateral striatal graft of fluorescently labelled MHP36 neural stem cells 
or vehicle; the mice also received CsA or saline. The mice were terminated at either 
 XVII
1 or 4 weeks post-transplantation. This study determined that MHP36 grafts survived 
and migrated robustly in host ischaemic brain at both 1 week and 4 weeks post-
transplantation. Grafted MHP36 cells differentiated into neurons and were able to 
reduce the extent of ischaemic neuronal damage. An acute host inflammatory 
response was evoked following MHP36 grafting, but this decreased dramatically by 
4 weeks post-transplantation. CsA immunosuppression did not affect MHP36 
survival and migration or reduce the host inflammatory response. The successful 
transplantation and characterisation of MHP36 grafts in mouse brain allowed for 
future investigation into the genetic factors underlying stem cell graft integration via 
the use of apoE transgenic mice. 
 
II. Influence of apoE on neural stem cell grafts in a mouse model of 
global ischaemia 
The aim of this study was to investigate whether endogenous apoE influenced 
MHP36 survival, migration and differentiation and then to determine potential 
signalling pathways that may be involved. ApoE deficient mice on a C57Bl/6J 
background (APOE-KO) and control wildtype C57Bl/6J (WT) mice were subjected 
to an episode of transient global ischaemia, as in Experiment 1. Two weeks 
following ischaemia, all mice received unilateral striatal and hippocampal grafts of 
MHP36 cells. All mice received CsA immunosuppression. Mice were terminated 4 
weeks post-transplantation. MHP36 survival and migration was significantly 
increased in WT as compared to APOE-KO mice. In addition, neuronal 
differentiation was significantly increased in WT as compared to APOE-KO mice. 
Increased astrocytic differentiation was observed in the hippocampus, but not 
striatum of WT as compared to APOE-KO mice. Measurement of the levels of 
signalling proteins associated with cell survival, extracellular signal-regulated kinase 
(ERKs) and c-Jun amino-terminal kinase (JNKs) and their phosphorylated forms 
(pERK and pJNK), indicated selective alterations in JNK with no change in ERK in 
APOE-KO as compared to WT mice, suggesting that JNK may underlie the apoE 
effects in stem cell integration. This study demonstrated that apoE strongly 
influences the survival, migration and differentiation of grafted MHP36 cells and 
provides initial evidence for the signalling pathways involved. 
 XVIII
 
III. Influence of APOE genotype on neural stem cell grafts in a 
mouse model of global ischaemia 
Following the demonstration that endogenous mouse apoE has a critical role in 
MHP36 graft survival, migration and differentiation, this study sought to investigate 
whether these effects are influenced by human APOE genotype. Transgenic mice 
expressing human APOE-ε3 or ε4, (on an APOE-KO background) and a control 
group of APOE-KO mice underwent transient global ischaemia and two weeks later 
MHP36 cells were transplanted unilaterally into the striatum and hippocampus. 1 
week after grafting the mice were started on a series of tests for motor balance and 
coordination using the rotarod, and taken for histology 4 weeks post-transplantation. 
MHP36 graft survival was significantly improved in APOE-ε3 mice compared to 
APOE-KO and APOE-ε4 mice. However, the migration and differentiation of 
MHP36 cells and motor performance of grafted mice were similar in all three APOE 
groups, indicating a comparable fate and functional activity within a 4 week survival 
time. Thus the data indicate that APOE genotype may influence cell survival with 
minimal effect on stem cell migration and differentiation.  
 
The data presented in this thesis demonstrate that endogenous apoE strongly 
influences MHP36 graft survival, migration and differentiation. Although there was 
minimal evidence that human APOE genotype influences cell migration and 
differentiation, stem cell survival was markedly improved in a human APOE-ε3 
















1.1  Regenerative Strategies  
 
1.1.1  The changing perception of CNS regeneration 
In the last 20 years there has been a dramatic shift in the perception of central 
nervous system (CNS) damage and repair. Classically, the CNS was regarded as a 
non-renewable environment, where growth and plasticity of new neurons and glia 
ceased at the end of development. As recent as a decade ago, neuroscience textbooks 
maintained that damage to neurons in adult human brain and spinal cord was 
irreparable. This prevailing opinion was famously stated by Santiago Ramon y Cajal, 
“In adult centres the nerve paths are something fixed, ended, immutable. Everything 
may die, nothing may be regenerated. It is for the science of the future to change, if 
possible, this harsh decree.” (Ramon y Cajal, 1928). This historical viewpoint of a 
fixed and immutable mature CNS led to the acceptance that loss of CNS cells to 
ageing or brain injury was an inevitable, inexorable outcome. This is in contrast to 
the haematopoietic system, where self-renewal and repair is a continuous and well-
defined process. Therefore, therapies for neurological disorders focused on 
prevention and restriction of further damage. For example, starting in the mid-1980s, 
there was a great deal of research into the use of calcium channel antagonists and 
glutamate receptor antagonists as neuroprotective agents against excitotoxic damage 
(Simon et al., 1984, Lipton and Rosenberg, 1994). However, whilst these compounds 
have been successful in animal models of brain injury, they have failed in all clinical 
trials to date (Ikonomidou and Turski, 2002, Hoyte et al., 2004, Birmingham, 2002). 
However, the discovery of neural stem cells in the adult and foetal brain has led to 
subsequent findings that the mature CNS undergoes dynamic remodelling and 
exhibits regeneration. This was coupled with advances in the understanding of the 
mechanisms involved in neurological disorders, leading to radical, new therapeutic 
approaches for treatment of CNS damage in the field of regenerative medicine.  
 
1.1.2  Principles of regenerative medicine 
Neurodegenerative disorders comprising diseases such as Alzheimer’s, Creutzfeldt-
Jakob’s, Huntington’s, Parkinson’s and conditions including global ischaemia, 
stroke, traumatic brain injury differ in cause of onset, brain regions affected and 
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subsequent damage. However, they all share a common factor, specifically the loss 
of neural cells. While neuroprotection strategies have been successful in the 
laboratory, this has not translated through to the clinic. In the past decade, there has 
been a switch away from neuroprotection towards strategies aimed at repair and 
regeneration of the CNS. The goal of regenerative medicine is to restore and replace 
tissue in order to achieve functional regeneration. In the CNS there are two broad 
strategies: induction of endogenous neurogenesis in vivo, and transplantation of 
exogenous neural stem cells. To date, the strategy of transplantation has shown 
greater evidence for repair and induction of functional recovery. Therefore, this 
thesis will focus on the transplantation of neural stem cells and its therapeutic use in 
a mouse model of global ischaemia.  
 
1.2  Ischaemic Models to Investigate Regenerative Strategies 
 
1.2.1  Cerebral ischaemia 
In order to investigate regeneration, it is necessary to find a model of reproducible 
degeneration in the CNS. One method of inducing CNS damage is via disruption of 
brain homeostasis. The brain has a high metabolic requirement, dependent on energy 
supplied via the aerobic oxidation of glucose. While an average adult brain 
represents around 2% of the total body weight, it accounts for approximately 20% of 
the oxygen used by the body (Clark & Sokoloff, 1999). Cerebral blood flow (CBF) is 
the sole route for delivery of oxygen and glucose to the brain and for the removal of 
metabolic waste, therefore any interruption to this supply can have significant 
consequences. The lack of an adequate blood flow to the brain is referred to as 
cerebral ischaemia. This may be a result of a blood clot, blood vessel constriction or 
a haemorrhage. Cerebral ischaemia can be subdivided into global and focal 
ischaemia, depending on the localisation of the loss of CBF. Global ischaemia is 
characterised by reduction of CBF throughout most or all of the brain, whereas focal 
ischaemia is characterised by a reduction in CBF to a specific, localised brain region. 
Cerebral ischaemia instigates a cascade of pathophysiological processes which 
contribute to ischaemia cell damage (Figure 1.1). The restriction of glucose and 





































































































































































































































































































The loss of membrane potential causes neurons and glia to depolarise and release of 
massive quantities of excitatory amino acids, in particular glutamate (Martin et al., 
1994, Katsura et al., 1994) Coupled with an inhibition of glutamate reuptake 
mechanisms, there is a net increase of glutamate in the extracellular environment. 
The free glutamate activates NMDA and metabotropic glutamate receptors and an 
influx of Ca2+ into cells via receptor and voltage gated Ca2+ channels. Some stores of 
intracellular Ca2+ are also released into the cytosol. This increase in free Ca2+ 
activates a number of enzymes, such as proteases, endonucleases and nitric oxide 
synthase, which damage the membrane, nucleus and other organelles (Kristian and 
Siesjo, 1998). Ca2+ mediated activation of phospholipases and cyclooxygenase 
generates free radical species, which overwhelm endogenous free radical scavenging 
mechanisms. These free radical species subsequently trigger lipid peroxidation and 
later effects such as inflammation and apoptosis. This excitotoxic period is followed 
by a phase of inflammation. There is a migration of neutrophil leukocytes, followed 
by macrophages and monocytes to the ischaemic tissue (Clark et al., 1995). 
Astrocytes and microglia are rapidly activated after ischaemia (Petito et al., 1990). 
Activated astroglia secrete inflammatory cytokines such as interleukin-1β (IL-1β), 
tumour necrosis factor (TNF-α) and inducible nitric oxide synthase (iNOS) which 
can all exert neurotoxic effects (Saito et al., 1996, Sairanen et al., 1997, Barone et al., 
1997, Endoh et al., 1994). Expression of these cytokines starts a few days after 
ischaemia and lasts for up to 1 month. Overlapping and extending past this phase of 
inflammation are apoptotic changes in damaged neurons. The classical markers of 
apoptosis, DNA laddering (Kihara et al., 1994) and caspase activation (Namura et al., 
1998) are upregulated following ischaemia. In the case of a focal ischaemic insult, or 
a particularly severe episode of global ischaemia, the time course of damage may be 
extended through formation of an infarct and atrophy of damaged tissue. 
 
1.2.2  Global cerebral ischaemia  
Global cerebral ischaemia predominantly occurs as a result of cardiac arrest. The 
clinical syndrome associated with global ischaemia is termed hypoxic-ischaemic 
encephalopathy. It is estimated that approximately 220,000 people die from 
cardiovascular related causes annually in the UK, of which a sizeable proportion 
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suffer from a cardiac arrest (British Heart Foundation). Other causes of global 
ischaemia include severe hypotension, cerebral hyperthermia and head trauma. 
Carbon monoxide poisoning or near drowning can also induce hypoxia, although in 
these situations there is no impairment of blood flow. The pathological consequences 
of global ischaemia range from selective neuronal death to infarction (pan-necrosis 
of all tissue elements) in the case of increased severity or prolonged duration. Global 
ischaemia can be either transient or permanent, depending on whether the blood flow 
to the brain is restored. Permanent global ischaemia usually results in death. 
Transient global ischaemia is associated with characteristic pathology of selective 
and delayed neuronal damage in vulnerable regions of the brain. In both animals and 
man, selectively vulnerable regions include the hippocampus, caudate nucleus, 
cerebral cortex and thalamus (Auer and Sutherland, Greenfield’s Neuropathology, 7th 
Edition).  
 
1.2.3  Pathophysiology of global ischaemia 
Depending on the species and model of ischaemia, there is a subsequent hierarchy of 
vulnerability in selectively vulnerable brain. In gerbils, transient bilateral occlusion 
of the carotid arteries results in selective death of hippocampal CA1 neurons (Kirino, 
1982, Kirino and Sano, 1984), whereas in mouse, using a similar model of ischaemia 
results in selective damage of the hippocampal CA2 neurons and caudate nucleus 
(Horsburgh et al., 1999, Gillingwater et al., 2004). Extending the duration of the 
ischaemic episode furthers the extent of damage. In the rat two-vessel occlusion (2-
VO) model, a brief 2 minute episode of ischaemia damages the hippocampus, while a 
4 minute episode extends the damage to the neocortex and a longer 10 minute 
episode causes damage to the caudate nucleus (Smith et al., 1984). The mechanisms 
which underlie selective vulnerability have yet to be elucidated.  
 
It has been suggested that neuronal vulnerability may occur as a result of increased 
susceptibility to excitotoxicity due to the presence of differing glutamate receptors on 
neurons (Rothman and Olney, 1986).  For example, vulnerable CA1 hippocampal 
neurons have an abundance of NMDA receptors in contrast to other subfields of the 
hippocampus (Greenamyre et al., 1985, Monaghan & Cotman, 1985). However, this 
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is not conclusive, as demonstrated by granule cells in the dentate gyrus, which are 
rich in NMDA receptors but do not suffer from the same vulnerability as CA1 
neurons. In other vulnerable regions, there is a different neuronal susceptibility to 
ischaemia. There is selective loss of GABAergic neurons in the caudate nucleus 
(Francis & Pulsinelli, 1982), and thalamus (Ross & Duhaime, 1989), yet GABAergic 
interneurons in the hippocampus appear to be resistant to global ischaemia (Johansen 
et al., 1983). Vascular factors affecting the restoration of CBF may also influence 
selective vulnerability (Hossmann, 1993, Hossmann, 1997). Increased blood 
viscosity, oedema, and post-ischaemia hypotension can all disturb the rate of CBF 
reflow, leading to an increased ischaemic period. A recent study has demonstrated 
that selectively vulnerable regions exhibit a gradual decrease in the apparent 
diffusion coefficient of water, suggestive of impaired energy metabolism and oedema 
(Lythgoe et al., 2005). 
 
The pathology of delayed neuronal damage was first discovered in the hippocampus 
of gerbils and rats subjected to a brief episode of ischaemia (Kirino et al., 1982, 
Pulsinelli et al., 1982, Kirino et al., 1984). CA1 neurons were morphologically viable 
24 hours following ischaemia, but over the next 72 hours, there was a slow and 
progressive deterioration of the neurons towards an ischaemic phenotype. In rodent 
models of global ischaemia, there is a classical maturation of ischaemic damage to a 
maximal point roughly 72 hours after the initial insult (Pulsinelli, 1985). Human 
pathological studies have shown that this phenomenon also manifests after an 
episode of cardiac arrest (Petito et al., 1987, Horn and Scholte, 1992, Collins et al., 
1989). Delayed neuronal damage occurs as the result of deleterious secondary 
processes, although the exact mechanisms responsible are incompletely understood. 
Possible candidates include neuronal hyperactivity (Suzuki et al., 1983), inhibition of 
protein synthesis (Thilmann et al., 1986), changes in mitochondrial gene expression 
(Abe et al., 1995), free radical generation (Siesjo et al., 1989) and continuing 
excitotoxicity (Siesjo, 1992). Importantly, delayed neuronal death does not occur 
solely as a result of apoptotic mechanisms. These neurons are not committed to death 
following the initial ischaemic insult and remain viable for a post-ischaemic 
“window”, during which it may be possible to therapeutically intervene and rescue 
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these neurons. Therefore, the time course of the pathophysiological cascade has 
implications for therapeutic strategies (transplantation and neuroprotective 
approaches). Early intervention has the potential to prevent further damage, although 
this has to be balanced against the hostile pathophysiological environment. 
Conversely, stem cell grafts and neuroprotective agents may be able to exert a 
stronger therapeutic effect at a later time point, but the damage may have progressed 
beyond the stage where therapeutic intervention would be beneficial. 
 
1.2.4  Animal models of global ischaemia 
Models of cerebral ischaemia have been performed in large (cats, dogs, pigs, sheep, 
primates) and small animals (gerbils, rats, mice). The initial models of cerebral 
ischaemia were developed in large animals, due to the similarity of their brains to 
humans. However, there are a number of problematic factors associated with large 
animals, namely the financial and technical costs associated with these models, and 
the public animal welfare concerns regarding the use of large animals. Therefore, 
small animal models are the commonly utilised by researchers. The costs to acquire 
and maintain small animals are significantly reduced compared to large animals. 
Small animals can be bred to genetic homogeneity and in the case of mice, it is 
relatively easy to produce transgenic mice in order to investigate the influence of 
genetic components on the model.  
 
1.2.4.1 Gerbil model 
The gerbil has been commonly used for models of global ischaemia due to their 
unique vasculature. Gerbils lack a posterior communicating artery, which connects 
the anterior circulation (carotid system) to the posterior circulation (vertebrobasilar 
system), resulting in an incomplete circle of Willis (Levine and Sohn,. 1969). 
Therefore, induction of global ischaemia via bilateral common carotid artery 
occlusion (BCCAo) in gerbils results in near total interruption of CBF (Crockard et 
al., 1980), allowing for easily reproducible and reliable induction of global ischaemic 
damage. A BCCAo time of five minutes causes selective and delayed damage to the 
CA1 region (Kirino et al., 1982).  
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1.2.4.2 Rat models 
The four vessel occlusion model (4-VO) was developed by Pulsinelli and Brierley 
(1979). This model is a two-stage procedure commencing with permanent occlusion 
of the vertebral arteries on the first day followed by occlusion of the bilateral 
common carotid arteries on the second day.  While the 4-VO model has been well 
validated and utilised since its inception, it typically has a success rate of 50-75%, 
due to the surgical complexities of a two-stage process. Therefore the simpler two-
vessel occlusion model (2-VO) (Eklof and Siesjo, 1972) was investigated by 
researchers. However, in the rat, occlusion of the bilateral common carotid arteries 
does not reduce CBF below the ischaemic threshold (Eklof and Siesjo, 1973). In 
order to produce an ischaemic insult, it is necessary to reduce CBF at the same time 
as the carotid vessels are occluded. The 2-VO model couples BCCAo with a 
reduction in CBF via systemic hypotension. Hypotension can be induced via 
exsanguination, administration of peripheral vasodilators or a combination of the two 
approaches. Both the 2-VO and 4-VO models produce selective and delayed damage 
in CA1 pyramidal neurons, caudate nucleus and the neocortex (Smith et al., 1984, 
Pulsinelli et al., 1982). 
 
1.2.4.3 Mouse models 
The BCCAo model of global ischaemia has also been used in mice, although 
technical aspects of the model result in high mortality and preponderance towards 
seizures. Part of this disparity is due to the strain of mice and the variability of the 
circle of Willis development. The C57Bl/6J strain of mice is the most susceptible to 
BCCAo compared to several other common mouse strains, including ICR, BALB/c, 
C3H, CBA, ddY, DBA/2, SV-129 and MF1 (Yang et al., 2000, Fujii et al., 1997) 
which is linked to poor development of the circle of Willis and variations in arterial 
blood pressure (Kelly et al., 2001). The pattern of ischaemia damage in mouse is also 
different to that produced in rat and gerbil. In rat and gerbil models, hippocampal 
neurons in the CA1 region are more vulnerable than the CA2/3 region, the caudate 
nucleus and the cerebral cortex. In comparison, BCCAo in the mouse preferentially 
damages the caudate nucleus and the CA2/3 region of the hippocampus (Yang et al., 
2000, Gillingwater et al., 2004). 
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These animal models of global ischaemia have been extensively used for screening 
of pharmacological neuroprotective agents (Weigl et al., 2005). However, as 
described previously, the promise of pharmacological intervention has not been 
translated from the laboratory to the clinic. Unexpected side effects, inconsistent 
results and diminished efficacy are some of the issues pertaining to clinical trials of 
neuroprotective drugs. It is therefore of interest to investigate the alternative 
strategies provided via regenerative medicine. The intrinsic neurogenic capacity of 
the brain is now accepted as fact. Although this self-reparative capability is modest, 
it may be possible to utilise and enhance endogenous neurogenesis for repair of 
ischaemic brain damage. 
 
1.3 Endogenous Neurogenesis for Repair of Ischaemic Brain 
Damage 
 
1.3.1  Evidence for adult neurogenesis       
For over a century, neuroscientific dogma held that that neurogenesis only occurred 
during embryogenesis, and was not possible in adult mammalian brain. During the 
late 1950s, the introduction of [3H]-thymidine autoradiography allowed labelling of 
the DNA of dividing cells. When Altman and colleagues applied this technique to 
adult rats, they found evidence for new neurons in the neocortex, dentate gyrus 
(Altman, 1963) and olfactory bulb (Altman, 1969). However, a lack of cell specific 
markers made it difficult to comprehensively identify the new cells as neurons. 
Altman’s claims for neurogenesis in the adult brain were supported by a series of 
electron microscopy studies carried out by Kaplan and colleagues (1984). Cells that 
incorporated [3H]-thymidine had ultrastructural characteristics of neurons as opposed 
to astrocytes or oligodendrocytes (Kaplan and Bell, 1984, Kaplan, 1985). Kaplan was 
also able to observe mitosis in the subventricular zone of adult macaque monkeys 
using the same techniques (Kaplan, 1983).  
 
A series of experiments carried out by Nottebohm and colleagues on the neural basis 
of song learning in birds led to the discovery of avian neurogenesis. Experiments 
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with tritiated thymidine showed the production of new cells in the avian brain 
(Goldman and Nottebohm, 1983) and ultrastructural observation indicated that these 
new cells were neurons receiving synapses (Burd and Nottebohm, 1985). Finally, 
these new neurons were able to evoke action potentials in response to sound, 
demonstrating that they were functionally integrated into the avian brain. (Paton and 
Nottebohm, 1984) At the time, these studies were viewed as an artefact specialised to 
the avian brain and had little effect in overturning the belief that adult mammalian 
brain was incapable of generating new neurons. 
 
Over the last 20 years, an advent of new techniques has provided increasing evidence 
for adult mammalian neurogenesis. The synthetic thymidine analogue, BrdU (5-
bromo-2-deoxyuridine) allows labelling of proliferating cells and their progeny. 
Unlike [3H]-thymidine autoradiography, detection of BrdU can be carried out using 
immunocytochemistry. The ability to visualise individual cells containing BrdU 
allowed stereological estimation of the total number of cells. This was used in 
conjunction with cell-specific antibody markers for neurons, astrocytes and 
oligodendrocytes such as NeuN, GFAP and O4 respectively, providing a definitive 
identification of BrdU incorporating cells along with phenotype, and confirmed the 
reality of neurogenesis in the adult mammalian brain. Further evidence for 
neurogenesis in higher mammals came with studies that proved the existence of new 
neurons in the dentate gyrus of adult primate and human brains. The human studies 
utilised the fact that BrdU is administered to some cancer patients for clinical 
diagnosis. Post-mortem examination of hippocampal tissue revealed the presence of 
many BrdU-incorporating neurons, which had to have been generated following 
BrdU adminstration and prior to death (Eriksson et al., 1998). Further investigation 
confirmed previous indications that neurogenesis in the adult mammalian brain 
occurs in two specific regions, the sub-ventricular zone (SVZ) which lines the lateral 
ventricles and the sub-granular zone (SGZ) in the dentate gyrus (Figure 1.2). 
Neurogenesis can be modulated by a variety of factors, genetic (Kempermann et al., 
1997), pharmacological (Raballo et al., 2000),  physiological (Kuhn et al., 1996, van 
Praag et al., 1999, Gould et al., 1999) or neuropathological (Parent et al., 1997, 
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Parent et al., 2002, Gould and Tanapat, 1999). Ischaemic damage has also been 
shown to influence neurogenesis.  
 
1.3.2  Neurogenesis following global ischaemia 
Global ischaemia also stimulates enhanced SGZ neurogenesis in gerbil (Liu et al., 
1998,); rat (Kee et al., 2001); mouse (Takagi et al., 1999) and primate brain 
(Tonchev et al., 2005). These studies suggest that the majority of BrdU positive, 
newly generated cells post-ischaemia eventually adopt a neuronal phenotype and 
migrate from the SGZ to the granule cell layer, although there is no direct evidence 
that the new neurons replace those lost following the ischaemic insult. There is also 
evidence that global ischaemia is able to potentiate SVZ neurogenesis (Iwai et al., 
2003) although this has been more thoroughly demonstrated following focal 
ischaemia (Jin et al., 2001, Zhang et al., 2001, Arvidsson et al., 2002).  
 
The mechanisms involved in ischaemia induced neurogenesis are still poorly 
understood. A variety of growth factors, signalling molecules and transcription 
factors may be involved. Administration of exogenous growth factors (e.g. EGF, 
FGF, BDNF, SCF) has been shown to modulate the neurogenic response following 
ischaemia (Larsson et al., 2002, Jin et al., 2002, Teramoto et al., 2003, Matsuoka et 
al., 2003, Nakatomi et al., 2002). The glutamatergic system is also able to regulate 
neurogenesis following global ischaemia (Bernabeu and Sharp, 2000). Adminstration 
of the glutamate receptor antagonists (MK-801 and NBQX) dramatically increased in 
number of BrdU positive cells in non-ischaemic gerbils. However, injections of these 
antagonists at the time of ischaemia prevented the ischaemia-mediated increase in 
neurogenesis but also prevent death of the vulnerable CA1 neurons. Investigation 
into the mechanisms of ischaemia induced neurogenesis and subsequent migration 
may also provide further insight into the ability of transplanted stem cells to survive 






















































































































































































































































































1.3.3  Neurogenesis as a regenerative strategy  
Recruitment of endogenous NSCs is an elegant approach to treating damaged neural 
tissue. The use of endogenous NSCs bypasses the ethical problems associated with 
the use and manipulation of foetal tissue and embryonic stem cells. However, there 
are a number of restrictions to endogenous neurogenesis which must be overcome in 
order to fulfil the regenerative potential. The number of endogenous NSCs in the 
adult brain is a fraction of number of cells typically lost through injury. Endogenous 
NSCs were only able to replace 0.2 % of the lost striatal neuron population after a 
model of stroke (Arvidsson et al., 2002). It is unlikely that this degree of replacement 
would significantly influence functional recovery. The population of endogenous 
NSCs is simply too small to effect any significant replacement. Another pertinent 
point is that even with enhancement of the neurogenic response through growth 
factors, neurotrophins or environmental enrichment, it remains to be demonstrated 
that new neurons are able to functionally integrate and promote recovery. Therefore, 
neural transplantation is currently the only regenerative strategy which has shown 
functional effectiveness. 
 
1.4 Neural Transplantation for Repair of Ischaemic Brain 
Damage 
 
1.4.1  History of neural transplantation 
With all the increased media and public interest in stem cell transplantation, it is 
interesting to note that the rationale for transplantation into the brain is not a new 
concept. The first recorded attempt at transplanting neural tissue was carried out by 
Walter Thompson at the end of the 19th century, who transplanted cortical tissue 
from adult cats into the brain of adult dogs (Thompson, 1890). The first published 
instance of successful neural transplantation came around 30 years later, from the 
work of Elizabeth Dunn, who reported the results of transplantation of neonatal rat 
cortical tissue into the brains of adult rats (Dunn, 1917). This was followed by the 
first successful transplantation of foetal neuronal tissue into a neonatal host brain (Le 
Gros Clark, 1940). Over the next thirty years, there were scattered reports of 
successful neural transplantation, mostly using neonatal and embryonic tissue for 
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transplantation. It is clear that the theoretical use of exogenous tissue in neural 
transplantation was apparent to these early researchers. A number of discoveries 
heralded the beginning of ‘modern’ era of neural transplantation in the 1970s.  The 
first of these discoveries were a series of experiments confirming the presence of 
neurogenesis, and by definition, adult neural stem cells, in the adult brain. 
 
1.4.2  The modern era of neural transplantation 
The proof of principle behind cell transplantation therapy was demonstrated by the 
first human bone marrow transplant for treatment of leukaemia at the beginning of 
the 1970s (Buckner et al., 1970). Around the same time, the first evidence that 
regenerative regrowth of axons was capable in the adult mammalian CNS came from 
Raisman (1969) who studied synaptic rearrangement following the severing of 
individual inputs to the septum in rodents. The medial septum receives two major 
inputs from the brainstem, one via the medial forebrain bundle and the other from the 
fimbria. Severing of one input leads to degeneration of the nerve terminals and loss 
of synapses onto the septum, but over the following weeks the number of synapses 
returns to normal, and are of the type associated with the uncut input. The fimbrial 
input sprouts new terminals to replace those lost after the medial forebrain bundle is 
cut, and vice versa.  
 
These findings were quickly followed by a number of seminal experiments in the 
latter half of the decade. A systematic characterisation study on the conditions for 
favourable survival and development of transplanted brain tissue provided a 
framework for standardised transplantation techniques (Stenevi et al., 1976).  
Transplanted neural tissue was able to form synapses and connections to host tissue 
(Lund and Hauschka, 1976), and subsequently followed by demonstration of 
behavioural recovery following transplantation of foetal dopaminergic tissue in a rat 
model of Parkinson’s disease (Perlow et al., 1979).  Another breakthrough came in 
1981, when embryonic stem (ES) cells were first isolated from the inner cell mass of 
mouse blastocysts (Evans and Kaufman, 1981, Martin, 1981). ES cells are 
pluripotent, meaning that they have the capacity to differentiate into any cell type of 
the three germ layers (ectoderm, mesoderm and endoderm). The isolation of human 
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ES cells arrived nearly 20 years later (Thomson et al., 1998). ES cells revolutionised 
the field of stem cell research, allowing for investigation into the events that occur 
during development (cell division and differentiation), screening for new drugs, and 
most importantly for the purposes of this thesis, application in stem cell therapy. 
 
1.4.3  Embryonic stem cells 
The therapeutic promise of ES cells in the field of tissue replacement and 
regenerative medicine arises from their capacity to differentiate into every type of 
cell and tissue in the body. As described above, all ES cells are initially derived from 
the inner cell mass of the blastocyst. They can be maintained in vitro culture either in 
the presence of leukaemia inhibitory factor (LIF) or on a feeder layer of embryonic 
fibroblasts. Under these conditions, ES cells are capable of undergoing an unlimited 
number of symmetrical divisions without undergoing differentiation. ES cells are 
karyotypically stable, in that they maintain a full, diploid complement of 
chromosomes following division. Pluripotent ES cells can be induced to differentiate 
into cells from all three embryonic germ layers. For the purposes of this thesis, the 
focus is on the differentiation of ES cells into neurons, astrocytes and 
oligodendrocytes. However, as an example of ES cell pluripotency, reports have 
described differentiation in vitro into adipocytes, cardiomyocytes, chondrocytes, 
mast cells, osteoblasts, pancreatic islets and striated muscle (Dani, 1999, Maltsev et 
al., 1994, Kramer et al., 2006, Wiles and Keller, 1991, Buttery et al., 2001, Kahan et 
al., 2003, Dinsmore et al., 1996).  
 
1.4.4  Sources of tissue for neural transplantation 
There are three general sources of tissue for neural transplantation therapy – primary 
foetal tissue, embryonic stem cells and neural stem cells. Each of these sources has 
associated advantages and disadvantages. Primary foetal tissue still represents the 
highest standard for functional recovery after brain damage. Transplants of 
embryonic dopaminergic tissue for patients afflicted with Parkinson’s disease 
reinnervate the striatum, integrate into the patient’s brain and release dopamine, 
inducing a substantial and lasting clinical improvement (Lindvall, 2000). Foetal 
grafts therefore illustrate the ‘proof of principle’ behind neural transplantation as a 
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therapy. However, there are major caveats blocking the widespread use of foetal 
tissue for neural transplantation. Primary foetal tissue is heterogenous, containing a 
mix of differentiated and undifferentiated tissue. Therefore, the number of disorders 
which could potentially be treated is limited. The choice of Parkinson’s disease for 
demonstrating the utility of foetal grafts stems, in part, from the fact that Parkinson’s 
disease pathology is a highly selective degeneration of the nigrostriatal dopamine 
system. This dopaminergic deficit is an easy target for treatment, as opposed to the 
widespread, diffuse damage present in Alzheimer’s disease and global ischaemia. 
The heterogenous nature of foetal grafts also means that the results of grafts will be 
variable from patient to patient. In contrast, embryonic and neural stem cells are 
undifferentiated, with the ability to undergo pluripotent or multipotent 
differentiation. As such, stem cells could theoretically be used to treat the majority of 
neurological disorders. The generation of clonal cell lines from embryonic and neural 
stem cell sources also ensure homogeneity and uniform results between patients. 
Foetal grafts also present ethical and technical problems. In the aforementioned 
Parkinson’s disease trial, each patient required tissue from 6-8 embryos (Lindvall, 
2000). Acquisition of this volume of tissue is a technical hurdle and limits foetal use 
to small-scale experimental studies. In contrast, stem cell lines can be expanded in 
vitro in order to generate near-unlimited quantities for large-scale therapeutic 
application. However, the proliferative capacity of stem cells (particularly embryonic 
stem cells) does raise the risk of tumorigenicity, which is less of a factor with 
differentiated foetal tissue. Transplants of incorrectly directed ES cells may end up 
differentiating into a wholly unsuitable cell type, or give rise to teratomas, as has 
been shown in rodents (Arnhold et al., 2004, Fujikawa et al., 2005). However, stem 
cells can be genetically modified in order to conditionally control cell division. This 
capacity for genetic modification also allows for the incorporation of beneficial 
genes (e.g. neurotrophic factors) into stem cell lines, which is not possible with foetal 
tissue. The regulatory steps involved in the derivation of stem cell lines are highly 
stringent and incorporate appropriate safety checks, whereas the primary nature of 
foetal tissue raises numerous safety issues. Therefore, although primary foetal grafts 
have been invaluable for validating the theory of neural transplantation, it is clear 
that stem cell lines, either from embryonic or neural origins, represent the more 
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viable therapeutic option. The choice between using embryonic stem cells or neural 
stem cells also involves various pros and cons. Embryonic stem cells derived from 
the blastocyst are pluripotent and capable of unlimited self-renewal. However, ES 
cells also raise ethical questions, along with the possible tumorigenicity describe 
earlier. It may also be necessary to restrict these cells to a neural lineage prior to 
transplantation. Neural stem cells (derived from either the embryonic CNS or adult 
neurogenic regions) are committed to a neural lineage. This multipotent capacity 
reduces the risk of tumourigenesis. However, these cells are still capable of self-
proliferation, although their intrinsic capacity for long-term maintenance in vitro is 
less extensive than ES cells. These neural stem cells may also display a certain 
degree of restricted differentiation, depending on the developmental stage and region 
from which they were derived. The reduced ethical issues associated with the use of 
neural stem cells have led to increased investigation into their clinical potential 
(Pollock et al., 2006).  
 
1.4.5  Neural stem cells 
Investigation into regions of neurogenesis led to the discovery of neural stem cells in 
adult mammalian brain. It is now accepted that there are two sites of constitutive 
neurogenesis in the adult mammalian brain: the subventricular zone (SVZ) and the 
subgranular zone (SGZ) of the hippocampal dentate gyrus (Figure 1.2).  Neural stem 
cells (NSCs) can be defined by the following characteristics.  
NSCs are:  
a) undifferentiated,  
b) able to proliferate and self-renew,  
c) able to generate all three lineages of cells in the CNS: neurons, astrocytes and 
oligodendrocytes.  
 
In the two primary neurogenic regions described previously, NSCs from the SVZ 
follow the rostral migratory stream to the olfactory bulb to become interneurons, 
whereas NSCs from the SGZ differentiate into hippocampal granule neurons 
(Garcia-Verdugo et al., 1998). NSCs generate intermediate neural progenitor cells. 













An illustration of stem cells with potential capability for 
neural differentiation
The classes of cells are displayed in a hierarchy of developmental potency and ability 










subsequent cells; neuronal progenitor cells generate only neurons, and glial 
progenitor cells generate only glia. These progenitor cells may also have some 
capacity for self-renewal (Figure 1.3). The discovery of neural stem cells has led to 
the possibility of their use in clinical treatment of CNS damage.  Regenerative 
therapies using NSCs typically focus on:  
I) the recruitment of endogenous NSCs  
II) exogenous transplantation of NSCs.  
 
1.5  Neural Stem Cell Transplantation Therapy 
Neural replacement via endogenous neurogenesis is suitable for turnover 
replacement of neurons in specific regions, but it cannot restore the extent of loss 
associated with the aforementioned disorders. The capacity of the endogenous 
centres of neurogenesis is insufficient to cope with massive loss of neural tissue. 
Neural stem cell therapy is the treatment of neurological disorders by administration 
of neural stem cells that have been selected, expanded and pharmacologically or 
genetically altered ex vivo. 
 
1.5.1  Neurospheres 
A variety of culturing techniques have been developed for the selection and large-
scale expansion of neural stem cells from both embryonic and adult mouse brain. 
The neurosphere assay is the standard assay for detection and isolation of NSCs. 
Tissue from the embryonic brain is a combination of stem, precursor and 
differentiated cells. In order to isolate the stem and precursor cells, the tissue has to 
be cultured in specific conditions; 1) free-floating, in the absence of a substrate for 
the cells to settle on, and 2) with medium supplemented with high levels of 
epidermal and/or fibroblast growth factors (EGF/FGF). Under these conditions, 
differentiated cells die whilst stem and precursor cells survive and proliferate. The 
free-floating stem/precursor cells aggregate to form growing spheres of dividing 
cells, termed ‘neurospheres’ (Reynolds and Weiss, 1992). The population of 
stem/precursor cells can be expanded under these conditions, and induced to 
differentiate by the provision of a substrate in the culture media to which the 
stem/precursor cells can attach. The neurosphere assay can be applied to adult NSCs 
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isolated from the SVZ of adult rodents. Neurospheres dissociated into single cells 
will frequently start to form a new neurosphere. This property of neurosphere 
formation allows experimental, although retroactive, identification of NSCs.  
 
1.5.2  Immortalised neural stem cell lines 
Although the functional efficacy and integration of foetal tissue in neural 
transplantation has been well documented, the ethical and logistical hurdles 
surrounding their use limit widespread therapeutic use (Hoffer and Olson, 1991, 
Widner and Brundin, 1988). An alternative to expansion through neurospheres is to 
use a neural stem cell line. In order for a cell to become the clonal progenitor of a 
cell line, it must bypass the barrier to continued cell division. The property of 
uncontrolled and continual cell division is common to tumours and therefore these 
were one of the original sources examined for neural cell lines. There are a number 
of spontaneously arising neural cell lines, either neuroblastomas or glioblastomas. 
While these are useful for in vitro investigation of differentiation, the inherent 
tumorigenicity of these cells precludes their use in transplantation experiments. 
Another spontaneously arising source is teratocarcinomas, from which it is possible 
to derive embryonal carcinoma (EC) clones. These cells are totipotent, and can 
differentiate into non-neural and neural lineages. However, the uncharacterised 
origins these spontaneously arising cells lines raise issues of safety. Therefore, a 
number of neural cell lines have been transformed by researchers in order to establish 
an immortalised neural cell line. The advantages of these lines is that they are 
derived from a chosen region of the CNS, via a normally occurring source of NSCs, 
maintain the capacity for multipotential differentiation and are now able to withstand 
continued passage in vitro. Whilst the mechanisms responsible for continued cell 
division in tumour-derived cells are unknown, it is possible to exploit oncogenes in 
order to derive specific cell lines. Immortalised NSC lines can be derived by 
infecting the desired NSC population with a retrovirus encoding the immortalising 
oncogene. Individual clones are then isolated, characterised and expanded in vitro. 
Transforming proteins, such as SV40 large T antigen (T-ag) or myc, are 
constitutively expressed, even during cell differentiation. As the therapeutic endpoint 
of these cell lines is neural transplantation, this constitutive expression raises the 
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potential problem of carcinoma formation. It is possible to avoid this problem using a 
conditionally immortalising oncogene, such as the temperature sensitive (ts) mutants 
of SV40 large T antigen (ts-T-ag) or the Rous sarcoma virus (ts-RSV). These 
mutants drive proliferation of the immortalised cells at the permissive temperature 
(33oC), but following a shift to the non-permissive temperature (>37oC), the 
oncogene product is rapidly degraded and unable to promote cell division.  
 
1.5.2.1 The NT-2 stem cell line 
One well-characterised example of a teratocarcinoma derived line is the human 
NTera-2 (NT-2) cell line, (Andrews et al., 1984). Treatment of NT-2 cells with 
retinoic acid and mitotic inhibitor results in an enriched population of differentiated 
neurons (Pleasure et al., 1992). These are referred to as NT2N or hNT cells, and have 
been commercially optioned by Layton Bioscience (LBS-Neurons). NT2N cells 
transplanted into non-lesioned rat brain are able to survive for up to a year and 
express mature neuronal markers (Kleppner et al., 1995, Miyazono et al., 1996). 
However, the transplanted cells did not appear to fully integrate with host tissue. 
Although NT2N cells formed synapse-like structures and developed axo-dendritic 
architecture, these axons remained unmyelinated and no synaptic connections were 
formed with host neurons. NT2N cells have also been transplanted in a rat model of 
traumatic brain injury (Philips et al., 1999, Muir et al., 1999) where they survived but 
did not improve deficits. However, NT2N cells incorporating an eGFP label were 
able to attenuate cognitive dysfunction (Watson et al., 2003) following traumatic 
brain injury in mice. Similarly, NT2N cells survive in a rat model of Parkinson’s 
disease but did not aid functional recovery (Baker et al., 2000, Fricker-Gates et al., 
2004). However, functional improvements were observed following transplantation 
of NT2N cells in rats subjected to quinolic acid lesions in the striatum, with grafted 
rats displaying partial recovery on the skilled forelimb task (Hurlbert et al., 1999).  In 
a focal ischaemia model of MCAo, transplanted NT2N cells were able to ameliorate 
behavioural deficits in passive avoidance and motor function (Borlongan et al., 1998, 
Saporta et al., 1999). The promising results of the NT2N cells in animal models of 
stroke have led to their use in clinical trials in patients with basal ganglia stroke 
(Kondziolka et al., Neurology, 2000). These phase I clinical trials are still ongoing, 
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and initial reports have been promising (Meltzer et al., 2001, Nelson et al., 2002, 
Kondziolka et al., 2005). Importantly, these initial results have underlined the safety 
and feasibility of neural transplantation in the clinical setting, although the lack of 
synaptic integration of NT2N grafts into host tissue raises the possibility that these 
cells exert their therapeutic influence through release of neuroprotective or trophic 
factors, rather than through functional replacement (Whittemore and Onifer, 2000, 
Kleppner et al., 1995, Miyazono et al., 1996). Although the NT2 cell line has 
advantages, namely their human origin and therapeutic effects, there are 
corresponding disadvantages, such as the potential for tumorigenesis, 
uncharacterised origins and the lack of functional integration. Conditionally 
immortalised neural stem cell lines have the advantage of full characterisation during 
construction, whilst displaying the functional integration and differentiation of 
spontaneously arising neural stem cell lines. 
 
1.5.2.2 The C17.2 stem cell line 
The C17.2 cell line was obtained from transformation of neonatal P4 mouse 
cerebellar cells with the avian v-myc oncogene (Ryder et al., 1990). At this stage of 
development, neurons and glia are generated from the external germinal layer of the 
cerebellum. Hence, immortalised C17.2 cells derived from this region are 
multipotent, differentiating into neurons and glia both in vitro and in vivo. Following 
transplantation into the cerebellum of neo-natal mice, the C17.2 cells integrate into 
the developing cerebellum in the correct anatomical location, and differentiate into 
neurons or glia appropriately depending on the region of engraftment. Electron 
microscopy revealed that transplanted cells establish and receive synaptic 
connections (Snyder et al., 1992).  Similar to primary neural tissue, FGF and EGF act 
as potent mitogens for C17.2 cells (Kitchens et al., 1994). The C17.2 line has been 
investigated for therapeutic uses in various models of neurodegenerative disease. 
Following transplantation in a rodent model of traumatic brain injury, C17.2 cells 
survive, differentiate into neurons and astrocytes, and improve the performance of 
the animals on behavioural tests of motor function (Riess et al., 2002). These 
therapeutic effects can be further improved by genetic modification of the C17.2 
cells to secrete glial cell line-derived neurotrophic factor (GDNF) (Bakshi et al., 
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2006). In both intact and 6-hydroxydopamine lesioned rats, C17.2 cells transplanted 
into the striatum express dopaminergic and neuronal markers, suggesting that these 
cells undergo site-appropriate differentiation, irrespective of damage (Yang et al., 
2002). C17.2 cells modified to express firefly luciferase migrate to the infarct region 
following middle cerebral artery occlusion, where they differentiate into neurons and 
astrocytes (Kim et al., 2004). In a similar model of focal hypoxic-ischaemic injury, 
C17.2 cells migrate to the infarct and penumbra, where they engraft and differentiate 
into all three neural cell types (Park, 2000, Park et al., 2002). This study also 
demonstrated that modifying the time of transplantation markedly affect the outcome 
of transplanted cells. No engraftment was observed when C17.2 cells were 
transplanted 5 weeks after the hypoxic-ischaemic injury. Conversely, optimal 
engraftment was observed when transplanting 3-7 days following the insult, 
suggesting that there is a therapeutic window for optimal stem cell transplantation.  
 
1.5.2.3 The RN33B stem cell line 
Another well-characterised example of an immortalised neural cell line is the RN33B 
line established by Whittemore and White (1993). This was derived from E12.5 
embryonic rat medullary raphe nucleus cells infected with a retrovirus encoding the 
temperature sensitive SV40 large T-antigen (ts-T-ag). Unlike the v-myc oncogene 
used for immortalisation of the C17.2 line, the oncogene in the ts-T-ag system is 
linked to a temperature sensitive promoter. This added level of regulation allows for 
greater control over the tumourigenic potential of the oncogene. In vitro, 
differentiated RN33B cells express neuron specific markers but do not express any 
astrocytic or oligodendrocyte specific protein markers. Differentiated RN33B cells 
will express T-antigen when returned to 33oC, but do not de-differentiate and 
recommence mitosis (Whittemore and White, 1993).  Following transplantation into 
undamaged adult and neonatal cortex, RN33B cells stably integrate and differentiate 
into morphologically site-appropriate neurons, i.e. in the cerebral cortex; RN33B 
cells displayed morphologies similar to pyramidal neurons and stellate cells, whilst 
in the hippocampus; RN33B cells assumed morphologies similar to CA1 and CA3 
pyramidal neurons (Shihabuddin et al., 1995). Immunohistochemical evidence also 
supports the notion that differentiation of RN33B cells is region specific, from the 
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expression of site-appropriate markers following transplantation (Shihabuddin et al., 
1996). Transplanted RN33B cells can integrate in lesioned neonatal or adult rat brain 
(Lundberg et al., 1996, Shihabuddin et al., 1996). Functional integration of RN33B 
neurons was verified by electrophysiological recordings of action potentials 
(Englund et al., 2002). 
 
1.5.2.4 The MHP36 stem cell line 
The MHP36 neural stem cell line used in this thesis is an immortalised cell line. 
However, in contrast to the previous two lines described, the MHP36 cell line was 
immortalised prior to derivation. Neuroepithelial tissue was dissected from the 
hippocampus of embryonic day 14 H-2Kb-tsA58 transgenic mice (Sinden et al., 
1997). This ‘immortomouse’ already stably expresses the temperature sensitive 
SV40 large T-antigen described previously, and incorporates a further level of 
regulation by linking control of the ts-T-ag to the inducible promoter of the mouse 
H-2Kb gene (Jat et al., 1991). The H-2Kb gene is present at low levels in a wide 
variety of tissues, and its expression can be upregulated above basal levels by 
exposure to gamma interferon (IFN-γ). Therefore, cell lines isolated from this 
transgenic mouse are conditionally proliferative depending on both temperature and 
application of IFN-γ. The optimal conditions for growth are maintenance at 33oC and 
presence of IFN-γ. Single cell suspensions from the dissected hippocampal tissue 
were plated out, and then transduced with a lac-Z reporter and neomycin-resistance 
selectable genes. 32 clonal cell lines arose from neomycin-resistance selection, from 
which nine were selected for further investigation. Two of these nine lines displayed 
a proliferative response to fibroblast growth factor 2. One of the FGF2 responsive 
cell lines (MHP36) also expressed the neural stem cell marker, nestin, as well as the 
SV40 antigen in permissive conditions. Following transfer to non-permissive 
conditions, these MHP36 cells could be induced to differentiate into PGP 9.5 
positive neurons and GFAP positive astrocytes after treatment with retinoic acid. 
These PGP 9.5 positive neurons also exhibited suitable morphology, with long 
neuritic processes. Although MHP36 cells are nestin positive when in an 
undifferentiated state, once the cells start to undergo differentiation, nestin 
expression is rapidly downregulated (Mellodew et al., 2004). In an in vitro co-culture 
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system, MHP36 cells seeded onto organotypic hippocampal slices stop expressing 
nestin 4 hours after seeding. This loss of expression is controlled by the targeting of 
nestin to the proteasome for ubiqutin-mediated degradation.  
 
1.6  Therapeutic Transplantation of the MHP36 Stem Cell Line 
Neural transplantation of MHP36 cells has been shown to be therapeutic in a variety 
of animal models (primarily rodent) of neurological disorders.  
 
1.6.1  Global ischaemia 
The rodent 4-VO model of transient global ischaemia (Pulsinelli et al., 1982) 
produces selective loss of hippocampal CA1 pyramidal neurons, in addition to 
functional deficits in spatial navigation and working memory (Nunn and Hodges, 
1994). Control rats displayed spatial learning capabilities on a water maze task, while 
ischaemic rats receiving sham grafts showed clear deficits in the same task. 
Ischaemic rats grafted with MHP36 cells or foetal CA1 tissue showed similar 
performance to the control group. This improvement in spatial learning was 
attributed to extensive repopulation of the lesioned CA1 region by the grafted 
MHP36 cells (Sinden et al., 1997). 
 
1.6.2  Focal ischaemia 
MHP36 grafts also promote functional recovery in a rat model of focal ischaemia 
(Veizovic et al., 2001). Rodents subjected to transient middle cerebral artery 
occlusion received grafts of MHP36 cells in the hemisphere contralateral to the focal 
infarct. MHP36 cells were observed to migrate towards the lesioned hemisphere. The 
infarct volume was significantly reduced in grafted rats compared to the sham-
grafted MCAo controls. Behavioural tests showed that the MHP36 grafts ameliorated 
sensorimotor deficits associated with MCAo, but did not rescue spatial learning 
deficits. Further studies showed that the behavioural effects of MHP36 grafts varied 
depending on the site of implantation (Modo et al., 2002). Interestingly, grafts 
delivered via the intraparenchymal route functionally improved bilateral asymmetry 
deficits but did not improve spatial learning. However, the converse was observed 
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were seen following intraventricular grafts, namely an improvement in spatial 
learning but persistent defects in bilateral asymmetry.  
 
1.6.3  Alzheimer’s disease 
MHP36 grafts have been investigated in a model of cognitive deficits associated with 
Alzheimer’s disease (Grigoryan et al., 2000). Rats received bilateral infusions of 
AMPA into the nucleus basalis magnocellularis and medial septum. Lesioning of 
these regions induced discrete, area-specific loss of cholinergic projection neurons, 
similar to that observed in Alzheimer’s disease. These lesions resulted in spatial 
deficits on the water maze task which were reversed by grafts of MHP36 cells. 
Grafted cells displayed both neuronal and glial morphologies and migrated away 
from the injection site towards the lesioned areas.   
 
1.6.4  Ageing 
The process of ageing brings with it progressive cognitive decline, as evidenced by a 
loss of cholinergic neurons and subsequent age-associated memory impairments such 
as memory storage deficits, decline in neurotransmitter function and delayed speed 
of mental processing (Abdulla et al., 1995, Luine and Hearns, 1990). Gross changes 
manifest as a loss in brain weight (Miller et al., 1980), paralleled by 
histopathological changes including neuronal atrophy, synaptic loss and gliosis. 
MHP36 grafts were able to halt this decline as assessed by a spatial learning and 
memory task (Hodges et al., 2000). A group of aged rats (22 months) was trained to 
find a hidden platform in the water maze. The aged rats were subdivided into two 
groups, ‘impaired’ and ‘unimpaired’, based on their performance during training. 
The unimpaired group did not differ in latency times from a group of young (3 
months) controls. The impaired group was further subdivided into MHP36 graft or 
vehicle groups. The unimpaired group and young controls also received vehicle 
grafts. Upon further behavioural testing six to eight weeks post-transplantation, the 
impaired group that received MHP36 grafts now performed at the same level as the 
unimpaired group on latency to find the platform and distance swum. Both these 
groups were significantly better than the impaired group with vehicle grafts, although 
the young controls performed better on the task overall. A parallel study 
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investigating whether aged, non-grafted rats improve over the six to eight week 
period demonstrated no improvement in the task, suggesting that the MHP36 grafts 
do not merely retard age-associated memory impairments, but actually reverse them. 
 
1.6.5  Primate models of damage 
The efficacy of MHP36 grafts was also demonstrated in primates (Virley et al., 
1999). Common marmosets were trained using the Wisconsin General Test 
Apparatus to discriminate between rewarded and non-rewarded objects (simple 
discrimination) and to discriminate between two different pairs of identical objects 
(conditional discrimination). Following training and establishment of a baseline, the 
marmosets were selectively lesioned in the CA1 field of the hippocampus by 
administration of NMDA. As in the rodent study, MHP36 cells appeared to 
reconstruct the lesioned CA1 region. MHP36 grafted primates showed an 
improvement on conditional discrimination tasks to the levels of non-lesioned 
controls and were substantially improved compared to the lesioned group.  
 
1.6.6  Understanding mechanisms for MHP36 graft effects 
Although the regenerative properties of NSC transplantation have been demonstrated 
with a variety of NSC lines, there is still very little known about the host cues which 
serve to inform the transplanted NSCs regarding migration and differentiation. In the 
case of the MHP36 stem cell line, the results of two initial studies implicate various 
mechanisms for MHP36 survival, migration and differentiation. 
 
1.6.6.1 Immunogenic properties of MHP36 stem cells 
Survival of transplanted NSCs is particularly dependent on the immunogenic 
response. Foreign grafted tissue may provoke an acute response from the immune 
system, which can lead to rejection and extensive upregulation of immune system 
mediators. The immunogenic properties of MHP36 cells were investigated in a rat 
model of stroke (Modo et al., 2002). MHP36 grafts were either delivered ipsi- or 
contralateral in MCAo lesioned mice or sham controls. The animals were also 
divided into a cyclosporin A treated group or non-immunosuppressed controls. 
MHP36 grafts did not alter the proliferative response to lymphocytes. There was an 
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increase in the immune markers MHC class I, CD45 and CD11b in the vicinity of the 
injection tract, but this was due to the trauma of injection, not the delivery of vehicle 
or MHP36 cells. The use of immunosuppression did not alter the lymphocyte 
response and surprisingly, greater graft survival was achieved in the absence of 
immunosuppression than the presence. In vitro experiments on the expression of 
MHC class I and II by MHP36 cells shows that when maintained in an 
undifferentiated, proliferating state (33oC), over 90% of MHP36 cells express both 
MHC class I and II antigens (Modo et al., 2003). However, upon switching to the 
non-proliferative temperature of 37oC, there was a marked downregulation of MHC 
class I and II antigens, with approximately 25-30% of MHP36 cells expressing both 
antigens, demonstrating the low immunogenic properties of these cells.  This study 
suggests that MHP36 stem cells manifest an intrinsic ability to escape detection by 
the immune system in vivo, which would improve the likelihood of survival, 
particularly in the hostile, highly immunogenic environment of damaged brain.  
 
1.6.6.2 The role of apolipoprotein E in MHP36 integration 
A recent study suggested a link between the lipid transport protein, apolipoprotein E 
(apoE) and MHP36 graft survival and integration into host tissue (Modo et al., 2003). 
ApoE has been associated with neurodegeneration, regeneration and development 
(see following sections), and has been shown to be upregulated following global and 
focal ischaemia (Horsburgh et al., 2000, Laskowitz et al., 1997, Virley et al., 2000). 
This study investigated the expression and localisation of apoE after MCAo and 
grafts of MHP36 cells into the ipsi- and contralateral hemispheres and ventricles. 
MCAo damage alone induced upregulation of apoE in the ipsilateral somatosensory 
cortex, striatum, corpus callosum and thalamus. Parenchymal MHP36 grafts further 
increased upregulation of apoE, particularly in the contralateral hemisphere, whilst 
this was not observed with intraventricular grafts. Interestingly, this dissociation 
between the sites of grafting paralleled an earlier study in which parenchymal grafts 
promoted sensorimotor recovery, whereas ventricular grafts improved spatial 
learning after focal ischaemia (Modo et al., 2002). This was hypothesized to 
represent a remodelling process which would allow the contralateral hemisphere to 
take over some of the functions of the lesioned hemisphere. The majority of apoE 
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immunostaining was localised to astrocytes, although neuronal expression was 
observed in the lesioned somatosensory cortex. However, only around 15% of 
grafted MHP36 cells were apoE-positive. The expression of apoE on both host and 
grafted cells raises the possibility that apoE may facilitate interaction and integration 
between the cells after ischaemic damage. It remains to the seen whether the increase 
in apoE following MHP36 grafting is from the host or grafted cells. Host astrocytes 
might secrete apoE in response to the grafted stem cells as an attractant, directing the 
MHP36 cells to the regions of damage. Alternatively, the grafted cells could be 
secreting apoE in order to reduce the extent of damage, based on the neuroprotective 
action of apoE. Whilst these initial findings do suggest that apoE does affect the fate 
of transplanted stem cells, it is clear that much more work is required in order to 
elucidate the role of apoE on stem cell integration.  
 
1.7 Apolipoprotein E as a Mediator for the Effects of MHP36 
Stem Cell Grafts 
 
1.7.1  Background 
1.7.1.1 Lipoproteins 
Plasma lipoproteins are assemblies of lipid and protein which facilitate transport of 
insoluble lipids throughout the body. The lipoprotein core consists of insoluble 
triacylglycerides and cholesterol esters. This is surrounded by a phospholipid shell 
which imparts solubility to the particle. Apolipoproteins attach to the surface of the 
lipoprotein and are responsible for stability, directing transport and receptor binding 
of the lipoprotein particle to its target (Figure 1.4). Classification of lipoproteins is 
done by size and density. Listed in order from large, less dense to small, high dense 
are chylomicrons, (transport of dietary triglycerides to the liver), very low density 
lipoproteins (VLDL; transport of freshly synthesised triglycerides from the liver), 
low density lipoproteins (LDL), intermediate density lipoprotein (IDL; transport of 
cholesterol) and high density lipoproteins (HDL; transport of cholesterol from tissue 











































































































































































Apolipoprotein E (apoE: protein, APOE: gene) is a protein constituent of plasma 
lipoproteins that has a major role in cholesterol transport. It was originally identified 
in 1973 by Shore and Shore (1973) as a component of VLDL and was later 
discovered as a constituent of chylomicrons and HDL, where it mediates the 
lipoprotein-specific function described above. In order to mediate this, apoE has 
three binding regions, allowing binding to lipids, receptors and heparin. 
 
1.7.1.3 Structure of apoE 
ApoE consists of 299 amino acids and has a molecular weight of approximately 34 
kDa. The primary structure shows a region increased in basic amino acids, residues 
136-150. This region is responsible for two functions of apoE, receptor binding and 
heparin binding. The secondary structure predicts that apoE has two domains 
separated by a hinge region, which was confirmed by physical and biochemical 
studies (Wetterau et al., 1988, Aggerbeck et al., 1988). The amino-terminal domain 
(residues 20-165) contains the receptor and heparin binding domain, as predicted 
from primary structure, whilst the carboxy-terminal domain (residues 225-299) 
consists of amphipathic α-helices, responsible for the third function of apoE, 
lipoprotein binding. The three-dimensional tertiary structure of apoE was elucidated 
by x-ray crystallography and circular dichroism (Wilson et al., 1991, Barbier et al., 
2006, Clement-Collin et al., 2006). The N-terminal domain arranges as a four-helix 
bundle, with the isoform difference resulting in small structural and functional 
changes.  
 
Human apoE has three isoforms, referred to as apoE2, E3 and E4, which differ from 
each other by single amino acid substitutions at position 112 and 158. The most 
common isoform, apoE3, has a cysteine at residue 112 and an arginine at residue 158 
with a net charge of +1. ApoE2 has cysteine at both positions and a net charge of 0, 
with apoE4 containing arginine at both positions with a net charge of +2. This 
genetically determined polymorphism was discovered via iso-electric focusing 
(Utermann et al., 1977) and two-dimensional electrophoresis (Zannis and Breslow, 
1981, Zannis et al., 1981) based on the charge difference between the three isoforms.  
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The isoform specific functional changes differ according to the binding property of 
apoE. There are no isoform specific differences to heparin binding. ApoE3 and E4 
isoforms have a similar affinity for binding to the LDL receptor, whilst apoE2 has 
only 2% of the affinity of the other two isoforms. Homozygosity for the apoE2 
isoform is a causal molecular defect for type III hyperlipoproteinemia, a genetic 
disorder characterised by enrichment of the abnormal lipoprotein β-VLDL (Mahley 
et al., 1999). However, regarding lipid binding, apoE2 and E3 have a preferred 
affinity for HDL, whilst apoE4 has a preferential affinity for VLDL.  
 
1.7.1.4 The role of apoE in plasma 
The major function of apoE is the transport and redistribution of lipids among cells 
within the body (Mahley, 1988). The liver is the integral organ for lipid metabolism, 
and therefore the bulk of apoE in the body is synthesized in the liver (Elshourbagy et 
al., 1985). ApoE is involved in the transport of dietary lipids from the intestine to the 
liver. Chylomicrons are synthesized and secreted by the small intestine in response to 
dietary fat intake. Upon secretion into plasma, these chylomicrons associate with 
apoE. As these apoE-chylomicron lipoproteins circulate through the capillaries, 
lipoprotein lipase hydrolyses the triglyceride group of the chylomicrons in order to 
generate free fatty acids for metabolic requirements. The chylomicron remnants are 
highly enriched in cholesterol and are eventually cleared from the plasma by the liver 
through LDL receptor uptake (Mahley, 1988). ApoE also redistributes VLDL from 
the liver to peripheral tissues. ApoE is a component of VLDL particles as they are 
synthesized and secreted from the liver. These particles also undergo lipoprotein 
lipase hydrolysis in the plasma, and progress from VLDL remnants to IDL and 
finally LDL. ApoE mediates uptake of these LDL particles into peripheral tissues via 
LDL receptors. ApoE also associates with HDL in order to eliminate excess 
cholesterol from cells. This process is termed reverse cholesterol transport. 
Cholesterol enriched cells release cholesterol into the interstitial fluid. HDL particles 
have a high affinity for cholesterol, and as they become enriched in cholesterol, apoE 
associates with the particle. ApoE then acts as a ligand for delivery to the liver, 
where the cholesterol is eliminated from the body through bile formation. 
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1.7.1.5 The role of apoE in the nervous system 
Although the liver synthesises the largest quantity of apoE in the body, the brain is 
the second largest producer of apoE (Elshourbagy et al., 1985). It is the predominant 
lipid transport protein in the CNS, where astrocytes are the major cell type that 
produce and secrete apoE (Boyles et al., 1985). This localised abundance suggested 
to researchers that apoE may have an important role in neurobiology. Initial evidence 
for the role of apoE in the nervous system came from investigations into peripheral 
nerve system damage. Following peripheral nerve injury to the sciatic or optic nerve, 
apoE is significantly upregulated around the site of injury (Stoll and Muller, 1986, 
Snipes et al., 1986) to the degree that apoE represents 2-5% of extracellular protein 
in the regenerating sciatic nerve sheath three weeks after injury (Ignatius et al., 
1986). ApoE also redistributes lipids among cells within a tissue, such as in 
peripheral nerves following injury (Ignatius et al., 1986, Boyles et al., 1989). ApoE is 
upregulated 100- to 200- fold in rat sciatic nerve following a crush or a cut injury. 
Resident macrophages are responsible for this increase in the production and 
secretion of apoE. ApoE scavenges cholesterol from the damaged environment and 
transports it to the macrophage for storage. Later, apoE mediates redistribution of 
cholesterol to the regenerating axons for use in membrane synthesis and also for 
remyelinization of the axons by Schwann cells (Boyles et al., 1989). A similar 
regenerative role for apoE has been demonstrated in the CNS. In models of 
hippocampal denervation and reinnervation, upregulation of apoE has been 
associated with cholesterol transport for synaptic synthesis and increased mossy fibre 
sprouting (Poirier et al., 1993, Teter et al., 1999, White et al., 2001). 
 
1.7.2  Association of apoE with disease 
 
1.7.2.1 Alzheimer’s disease 
Just under a century ago, Alois Alzheimer published the clinical and 
neuropathological observations of the disease which bears his name (Alzheimer, 
1907). Alzheimer’s disease (AD) is a debilitating neurodegenerative disorder 
characterised by irreversible, progressive loss of cognitive function. It is the most 
common form of dementia and a major public heath challenge in industrialized 
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countries. The flurry of investigation into the role of apoE in the CNS during the 
early 1990s led to the discovery that possession of the ε4 allele was linked to the 
pathogenesis of AD (Saunders et al., 1993, Strittmatter et al., 1993). Initially, this 
association was determined for late-onset familial AD, with the age of onset directly 
linked to the gene dose of APOE-ε4 (Corder et al., 1993). The mean age of onset for 
non ε4 possessing individuals was 84 years, compared to 68 years for individuals 
homozygous for the ε4 allele. These homozygous ε4 carriers were also 
predominantly fated to develop AD by the age of 80. Subsequently, an association 
between apoE polymorphism and sporadic AD was determined, with the ε4 allele 
exhibiting an increased prevalence in AD individuals (Rebeck et al., 1993, Poirier et 
al., 1993). In contrast, the APOE-ε2 allele has been shown to confer a degree of 
protection against late-onset AD (Corder et al., 1994). There are three other risk 
factor genes for AD, namely amyloid precursor protein, presenilin-1 and presenilin-
2. Mutations in these three genes results in an increase in the production of amyloid-
beta (Aβ) peptides and have been linked to early-onset familial AD, which accounts 
for around 5% of all AD cases (Selkoe, 2002). This illustrates the importance of 
apoE in AD, as the two forms associated with apoE, late-onset familial and sporadic, 
therefore account for 95% of all AD cases. ApoE associates with the 
neuropathological markers of AD, namely neuritic amyloid plaques, neurofibrillary 
tangles and amyloid deposits (Benzing and Mufson, 1995, Namba et al., 1991, 
Strittmatter et al., 1993, Wisniewski and Frangione, 1992). APOE-ε4 exerts a dose-
dependent increase in plaque and neurofibrillary tangle formation.  
 
1.7.2.2 Ischaemic stroke 
Ischaemic strokes accounts for approximately 80% of stroke cases and arise from 
blockage of an artery supplying the brain with blood. This blockage usually arises as 
the result of a blood clot. The role of apoE in plasma directly impacts on 
cardiovascular function and has a potent anti-atherogenic effect. The apoE-deficient 
mouse was originally created in order to investigate the effect of apoE on 
atherosclerosis (Piedrahita et al., 1992, Plump et al., 1992). These mice are severely 
hypercholesterolaemic and susceptible to atherosclerotic lesions, even when 
maintained on a low fat diet (Zhang et al., 1994). As atherosclerosis is the underlying 
 34
cause of heart attacks and strokes in the Western world, a large number of studies 
have sought to determine whether apoE polymorphisms affect cardiovascular 
diseases. Possession of an APOE-ε4 allele has been linked to increased risk of 
ischaemic stroke (Couderc et al., 1993, Margaglione et al., 1998, Peng et al., 1999, 
McCarron et al., 1999, Sudlow et al., 2006). However, this association is still 
controversial, with other studies failing to observe any correlation (Kuusisto et al., 
1995, Basun et al., 1996, Ferrucci et al., 1997, MacLeod et al., 2001, Slooter et al., 
2004). Subsequent meta-analyses have suggested the discrepancy between these 
studies is due to variations in cohort selection, ethnic background, age of subjects as 
the main selection biases (Sudlow et al., 2006). There is also accumulating evidence 
for association between apoE genotype and the outcome from ischaemic stroke, 
although this is still inconclusive. No apoE genotype difference in functional 
recovery after stroke was observed in a number of studies (McCarron et al., 1998, 
Catto et al., 2000, McCarron et al., 2000). However, in-depth analysis of particular 
events following ischemic stroke have linked the APOE-ε4 allele with increased risk 
of dementia after stroke (Slooter et al., 1997), declines in information processing and 
recall (Dik et al., 2000), increased progression and expansion of the infarct (Liu et 
al., 2002) and increased prevalence of aphasia after ischaemic stroke (Treger et al., 
2003).  
 
1.7.2.3 Haemorrhagic stroke 
ApoE genotype has also been reported to influence outcome following haemorrhagic 
stroke. An association has been reported between the ε4 allele and a poorer 
neurological outcome after intracerebral haemorrhage (Alberts et al., 1995, 
McCarron et al., 1998). Later studies have revealed that ε4 carriers also suffer from 
increased mortality after a haemorrhagic stroke, although this association is 
independent of haematoma and oedema volumes (McCarron et al., 1999, McCarron 
et al., 2003). A recent case-control study suggested that the ε4 allele is also a risk 
factor for lobar intracerebral haemorrhage (Woo et al., 2005) and also increases 
likelihood of recurrence (O’Donnell et al., 2000). Interestingly, meta-analysis carried 
out on eight studies investigating APOE genotype association with intracerebral 
hemorrhage did not confirm any increased risk associated with the ε4 allele, but did 
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reveal an association with the ε2 allele (Sudlow et al., 2006). Cerebral amyloid 
angiopathy (CAA) is a major cause of lobar intracerebral hemorrhage. CAA is 
characterised by amyloid beta peptide deposition in the cerebral vasculature, which 
accumulate over time and in severe cases, lead to rupture of the blood vessels. 
Investigation into the role of apoE polymorphisms and Alzheimer’s disease 
pathology led to the discovery that the ε4 allele was strongly associated with 
increased vascular deposits of amyloid (Schmechel et al., 1993). Later studies have 
confirmed the association of the ε4 allele with CAA and CAA-related intracerebral 
hemorrhage (Greenberg et al., 1995, Olichney et al., 1996, Kalaria et al., 1996, 
Premkumar et al., 1996). However, it has also been shown that the APOE-ε2 allele is 
also over-represented in cases of CAA-related hemorrhage (Nicoll et al., 1997, 
Greenberg et al., 1998, McCarron et al., 1998. Pathological examinations suggest 
that whilst the ε4 allele promote CAA-related hemorrhage through increased 
deposition of amyloid, the ε2 allele increases the susceptibility of amyloid-laden 
blood vessels to rupture, possibly through increased fibrinoid necrosis (Greenberg et 
al., 1998, McCarrron et al., 1999). Consistent with this hypothesis, individuals with a 
heterozygous ε2/ε4 genotype are particularly predisposed to onset of CAA at a 
young age (Greenberg et al., 1998, McCarron et al., 1998). An association of apoE 
with subarachnoid haemorrhage has also been documented by a number of research 
groups. Patients possessing an ε4 allele were more likely to suffer from an 
unfavourable outcome after subarachnoid haemorrhage (Dunn et al., 2001, 
Niskakangas et al., 2001, Leung et al., 2002, Lanterna et al., 2005). There is evidence 
of an association between the ε4 allele and risk of subarachnoid hemorrhage (Tang et 
al., 2003, Sudlow et al., 2006). Subsequent studies have demonstrated that apoE 
levels in the CSF decrease after subarachnoid haemorrhage, and postulated that a 
poor outcome is linked to lower levels of apoE, although this effect is irrespective of 
genotype (Kay et al., 2003, Kay et al., 2003). 
 
1.7.2.4 Global ischaemia 
Post-mortem analysis of human brain from patients following an episode of global 
ischaemia revealed increased neuronal and glial apoE immunoreactivity in all sectors 
of the hippocampus as compared to controls (Horsburgh et al., 1999). The degree of 
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neuronal apoE immunoreactivity was strongly linked to the extent of neuronal 
damage observed in the global ischaemia patients. However, there was no association 
observed between apoE genotype and neuronal damage or apoE immunoreactivity. 
Two clinical studies have been published investigating the association of apoE with 
outcome after global ischaemia as caused by cardiac arrest, with conflicting results. 
Schiefermeier et al., (2000) demonstrated that patients homozygous for the ε3 allele 
were more likely to survive following cardiac arrest and were also predisposed 
towards a favourable neurological outcome. Possession of at least one ε4 or ε2 allele 
was therefore linked to an unfavourable outcome, although the number of patients 
homozygous for APOE-ε2 and ε4 was too small for in depth analysis of genotype 
effect. In contrast, a later study found no significant association between APOE 
genotype and outcome after cardiac arrest (Longstreth et al., 2003). The reason for 
the disparity between the two studies may have arisen due to the use of a larger, more 
heterogenous group of patients in the Longstreth study.  
 
1.7.2.5 Traumatic brain injury  
Traumatic brain injury (TBI) is defined as when a sudden trauma inflicts damage to 
the brain. TBI cases can be broadly defined into two groups; closed head injuries and 
penetrating head injuries. Closed head occurs when the head violently hits an object 
but there is no penetration of the skull, whereas penetrating head injuries occur when 
an object pierces the skull into brain tissue. Due to the variability in types and causes 
of TBI, there is a broad spectrum of focal and diffuse damage observed in the 
aftermath of TBI. ApoE polymorphism has been associated with a poorer outcome 
after traumatic brain injury (Teasdale et al., 1997, Friedman et al., 1999, Lichtman et 
al., 2000, Liberman et al., 2002, Crawford et al., 2002, Chiang et al., 2003). In the 
first study to demonstrate this association, it was found that the possession of one or 
more APOE-ε4 allele increased the likelihood of an unfavourable outcome after TBI 
to 57%, compared to 27% in the patients without an APOE-ε4 allele (Teasdale et al., 
1997). In a group of veterans and active duty military personnel who had suffered 
from a mild episode of TBI, the presence of an APOE-ε4 allele was found to cause 
impairments in memory, specifically in learning and recall (Crawford et al., 2002). A 
recent study extended on these findings and demonstrated that following moderate to 
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severe TBI, subjects carrying the ε4 allele were impaired on tests of verbal memory, 
motor speed, fine motor coordination, visual scanning, attention and mental 
flexibility (Ariza et al., 2006). Analysis of autopsy material has revealed a number of 
pathological changes in ε4 carriers, particularly an increased presence of cerebral 
amyloid angiopathy and cerebrovascular contusions (Leclercq et al., 2005, Smith et 
al., 2006). A neurological and behavioural study on professional boxers, who 
regularly underwent chronic TBI during their sporting career, it was found that ε4 
carriers were more likely to suffer from chronic neurological deficits (Jordan et al., 
1997). Similarly, in a group of older American football players subjected to repeated 
head trauma throughout their careers, possession of the ε4 allele was linked to 
impaired cognitive performance (Kutner et al., 2000). 
 
1.7.3  Animal models for investigating the role of apoE 
1.7.3.1 Localisation and upregulation of apoE in animal models of 
brain injury 
Further information on the distribution of apoE following brain injury was obtained 
from various animal models. In normal rodent brain, apoE was distributed in 
astrocytic cells of the CNS and within the non-myelinating cells of the PNS (Boyles 
et al., 1985). However, in a model of rat global ischaemia induced by cardiac arrest, 
apoE was observed localized to neurons 6 hours following the insult (Kida et al., 
1995) rising to maximal expression 7 days post-ischaemia. Further investigation of 
the distribution of apoE following global ischaemia in the rat revealed increased 
astrocytic apoE at 24 hours reperfusion, followed by an increase in neuronal apoE at 
72 hours reperfusion (Horsburgh and Nicoll, 1996). These data suggest that apoE is 
produced and secreted by astrocytes for neuronal uptake following injury. 
Interestingly, these changes in apoE upregulation and redistribution mirror the 
progression of damage after global ischaemia. Consistent with this hypothesis, other 
researchers have demonstrated upregulation of apoE protein in neurons, astrocytes 
and macrophages following focal cerebral ischaemia in the rat, while apoE mRNA 
was only found expressed in astrocytes and macrophages (Nishio et al., 2003, 
Kamada et al., 2003). Injury induced alterations in apoE have also been observed in 
other rodent species. Upregulation of apoE protein was observed in the selectively 
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vulnerable hippocampus of gerbils after transient global ischaemia (Hall et al., 1995, 
Ishimaru et al., 1996). A parallel study demonstrated upregulation of apoE and 
GFAP mRNA in ischaemic gerbil brain (Ali et al., 1996). Similarly, upregulation of 
apoE was observed in vulnerable regions associated with global ischaemic damage in 
mouse brain (Horsburgh et al., 1999). Other animal models of brain injury also 
induce spatiotemporal alterations of apoE. Following acute subdural haematoma in 
rat, apoE levels are elevated and rapidly redistributed to neurons (Horsburgh et al., 
1997). Recently, it has been shown that traumatic brain injury induced through fluid 
percussion in rats causes both an acute and chronic upregulation of apoE protein and 
mRNA (Iwata et al., 2005). 
 
1.7.3.2 Transgenic models of apoE-deficient mice 
The development of apoE-deficient mice provided another avenue for investigation 
into the role of apoE in brain injury. ApoE-deficient mice have been developed by a 
number of groups (Piedrahita et al., 1992, Van Ree et al., 1994, Plump et al., 1992). 
These mice have a uniformly poorer outcome after brain injury, as shown through 
models of global ischaemia (Horsburgh et al., 1999, Sheng et al., 1999, Kitagawa et 
al., 2002), focal ischaemia (Laskowitz et al., 1997, Kitagawa et al., 2001), traumatic 
brain injury (Lomnitski et al., 1997, Chen et al., 1997, Lynch et al., 2002) and ageing 
(Masliah et al., 1995). These studies cumulatively demonstrate that apoE exerts a 
neuroprotective effect against brain injury. This neuroprotective role was confirmed 
by a number of studies showing amelioration of neurological and pathological 
deficits in apoE-deficient mice by infusion of recombinant apoE. Infusion of 
recombinant apoE3 and E4 reversed cognitive deficits and participated in restoration 
of neuronal structure (Masliah et al., 1997). Intraventricular infusion of apoE in 
apoE-deficient mice subjected to global ischaemia significantly reduced ischaemic 
neuronal damage by approximately 50%. The neuroprotective effects of apoE 
infusion were also observed in wild-type mice following global ischaemia 
(Horsburgh et al., 2000).  
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1.7.3.3 Differences between human and mouse apoE 
Unlike human apoE, mouse apoE does not exist in multiple isoforms. Mouse apoE is 
285 amino acids in length, 14 shorter than human apoE (Rajavashisth et al., 1982). 
Mouse apoE contains arginine at residue 112 and glutamate at 255, giving it a 
sequence similarity to human apoE4. However, the lack of an arginine at position 61 
on mouse apoE means that mouse apoE cannot display the same domain interaction 
as human apoE4. Therefore, mouse apoE3 has a functional similarity to human 
apoE3, with a preferential binding for HDL rather than VLDL. Replacement of 
mouse threonine at position 61 with arginine via gene targeting introduces domain 
interaction and allows the altered mouse apoE to behave like human apoE4 (Raffai et 
al., 2001). Mouse apoE is predominantly astrocytic, with no neuronal apoE reported 
in normal mouse brains. Human apoE is also principally astrocytic, although 
expression of apoE mRNA has been demonstrated in cortical and hippocampal 
neurons in mice (Xu et al., 1999). 
 
1.7.3.4 Transgenic models of human apoE-expressing mice 
Mice only express one isoform of apoE compared to the three found in humans. 
Therefore, the development of human apoE isoform transgenic mice was an integral 
step in determining isoform specific differences for the role of apoE. Xu et al., 
(1996) introduced human APOE ε2, ε3 and ε4 genes into the apoE-deficient mice 
produced by Piedrahita et al., (1992). These mice were generated through the use of 
genomic fragments which contained the regulatory regions. Therefore, expression of 
apoE was under the control of the human promoter. The expression of human apoE 
normalises the high serum cholesterol observed in apoE-deficient mice. Western blot 
analysis revealed presence of human apoE protein in the expected tissues; serum, 
brain, liver, kidney, spleen, heart and skeletal muscle. Importantly, the pattern of 
apoE immunocytochemical localisation for these mice resembles human and primate 
brain rather than rodent brain. ApoE immunoreactivity was observed in glial cells, 
and to a lesser degree in neurons, as opposed to the rodent pattern, which is strictly 
glial. Therefore, information gleaned on the role of apoE isoform from these mice 
can be reasonably translated to the human situation. Accordingly, these transgenic 
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mice were utilised in this thesis in order to elucidate apoE isoform differences on 
MHP36 stem cell integration.  
 
Other strains of human apoE transgenic mice have been generated in order to 
investigate cell specific localisations of apoE. In the CNS, apoE is synthesized by 
glia, primarily astrocytes (Boyles et al., 1985, Pitas et al., 1987), and also by 
microglia (Nakai et al., 1996, Stone et al., 1997). Therefore, Sun et al. (1998) created 
transgenic mice in which expression of human APOE-ε3 and ε4 is under control of 
the astrocyte-specific GFAP promoter. These GFAP-apoE mice expressed human 
apoE in astrocytes from development into the adult period, with a similar expression 
pattern to endogenous mouse GFAP and apoE. Human apoE levels from adult mouse 
brain forebrain were comparable to levels from human cortex. Another strain of 
transgenic mice was generated with expression of human APOE-ε3 and ε4 under 
control of the neuron-specific enolase (NSE) promoter (Raber et al., 1998, Buttini et 
al., 1999). The rationale for generating these mice was based on the findings that 
apoE physiologically localises to neurons in humans, along with the well 
documented propensity of apoE to redistribute from glia to neurons following 
neuronal damage. Human apoE expression was localised to the brain and testes, with 
no apoE found in plasma. Therefore, these mice had raised cholesterol levels, similar 
to that seen in apoE-deficient mice. A similar pattern of neuronal apoE expression 
was observed for both NSE-apoE3 and NSE-apoE4 lines, with a high intensity of 
staining in the neocortex and hippocampus.  
 
Researchers have utilised these human apoE transgenic mice in order to elucidate the 
role of apoE isoform on brain injury. Human APOE-ε4 transgenic mice exhibited 
increased ischaemic neuronal damage compared to human APOE-ε3 mice from the 
Xu strain following transient global ischaemia (Horsburgh et al., 2000). Similarly, in 
the same strain of mice, APOE-ε4 mice were more susceptible than APOE-ε3 mice 
to various forms of brain damage; namely a larger infarct volume following focal 
ischaemia (Sheng et al., 1998);  increased mortality and poorer neuropathology after 
closed head injury (Sabo et al., 2000); and impaired neuronal plasticity following 
entorhinal cortex lesion (White et al., 2001). Neuronal specific expression of human 
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apoE3, but not apoE4, protected against excitotoxin induced neuronal damage 
(Buttini et al., 1999). These results confirm clinical studies that the APOE-ε4 allele is 
associated with a poorer outcome after brain injury. Taken together, these studies 
provide a wealth of evidence that apoE has a role in regulating the response and 
outcome following injury to the CNS. Whilst the mode of action by which apoE 
exerts these beneficial effects remains to be elucidated, researchers have implicated 
apoE in a variety of possible mechanisms.  
 
1.7.4  Mechanisms of apoE in moderating brain damage 
1.7.4.1 Excitotoxicity 
In the past few years, there has been increasing evidence that apoE influences 
excitotoxic damage and that this is isoform dependent. In vivo studies have shown 
that kainic acid injections induce upregulation in apoE mRNA (Montpied et al., 
1999) and protein, coupled with subsequent localisation to neurons (Boschert et al., 
1999). Following kainic acid challenge in human apoE3 and apoE4 transgenic mice 
in which apoE is under the control of the NSE promoter, it has been shown that 
apoE3 exerts neuroprotective effects against excitotoxic damage, whilst no 
protection was conferred through apoE4 expression (Buttini et al., 1999). Application 
of physiologically relevant concentrations of apoE partially protected against NMDA 
induced excitotoxicity in both primary mixed neuronal-glial cultures and in a 
neuronal cell line (Aono et al., 2002). Further investigation suggested that the 
receptor binding region of apoE was responsible for mediating the neuroprotective 
effect (Aono et al., 2003). In primary neuronal-glial cultures exposed to hydrogen 
peroxide, treatment with apoE confers partial protection (Lee et al., 2004). ApoE 
treatment does not affect the release of glutamate induced by hydrogen peroxide, but 
instead increases the rate of glutamate reuptake, suggesting that apoE protects 
against oxidative stress by reducing secondary glutamate excitotoxicity. Co-
application of recombinant human apoE3 or apoE4 with NMDA on primary 
hippocampal neurons revealed an isoform specific effect on calcium response (Qiu et 
al., 2003). ApoE4 significantly increased both the resting calcium levels and the 
calcium response to NMDA, whilst apoE3 exerts an opposite effect. This was 
coupled with an increase in neurotoxicity with apoE4 treatment. However, 
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subsequent work demonstrated that alteration of calcium influx through NMDA 
receptors is due to ligand binding to apoE receptors, such as LRP or apoER2 
(Bacskai et al., 2000, Ohkubo et al., 2001, Qiu et al., 2002). 
 
1.7.4.2 Anti-oxidative capacity 
A variety of studies have suggested that apoE may have anti-oxidative properties. 
Purified apoE, commercially purchased recombinant apoE and apoE conditioned 
media were all able to protect B12 cells from peroxide free radical induced 
cytotoxicity in vitro (Miyata and Smith, 1996). There was an isoform specific effect 
in the anti-oxidative potential of apoE, with apoE2 > apoE3 > apoE4. As well as 
protecting against chemically induced oxidative stress, apoE is also able to modulate 
beta-amyloid (Aβ) induced oxidation (Lauderback et al., 2002). In vivo studies on 
apoE-deficient mice demonstrated that plasma and lipoproteins obtained from these 
mice are more susceptible to lipid peroxidation, both in the presence or absence of a 
free radical generating substance (Hayek et al., 1994). Further studies have attributed 
this susceptibility to decreased levels of antioxidants in apoE-deficient mice, leading 
to a deleterious imbalance in oxidant/antioxidant levels (Ramassamy et al., 2001, 
Shea et al., 2002). Oxidative stress is a common feature of ischaemia and traumatic 
brain injury. The poorer outcome of apoE-deficient mice after closed head injury is 
therefore partially attributable to a diminished ability to counteract the deleterious 
effects of oxidative damage (Lomnitski et al., 1997, 1999). Pre-treatment of apoE-
deficient mice with the anti-oxidant vitamin E markedly ameliorated ischaemic 
neuronal damage (Kitagawa et al., 2002). Infusion of apoE also reduces the extent of 
4-hydroxynonenal (4-HNE) immunoreactivity in mouse brain following global 
ischaemia (Horsburgh et al., 2000). 4-HNE activity is a toxic marker for lipid 
peroxidation and has been associated with the pathology of Alzheimer’s disease and 
global ischaemia (McKracken et al., 2001). Taken together, these studies strongly 
suggest that apoE exerts its neuroprotective effect through anti-oxidative action. The 
aforementioned effects of apoE on excitotoxicity have also been linked to the anti-
oxidative properties of apoE (Buttini et al., 1999, Lee et al., 2004). 
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1.7.4.3 Cytoskeletal support 
The neuronal cytoskeleton consists of three major components; actin filaments, 
microtubules and neurofilaments. Preservation of the neuronal cytoskeleton is an 
important factor for maintaining structural and functional stability. Ultrastructural 
examination of synapses from apoE-deficient mice revealed a disruption of dendritic 
structure, characterised by extensive dendritic vacuolation. This was coupled with a 
decrease in immunostaining for the cytoskeletal markers microtubule associated 
protein 2 (MAP2), alpha and beta-tubulin (Masliah et al., 1996), strongly suggesting 
that the presence of apoE is required for maintenance of the synapto-dendritic 
structure. ApoE demonstrates isoform specific interactions with several cytoskeletal 
proteins, including actin, MAP2, tau and neurofilament-M (Strittmatter et al., 1994, 
Huang et al., 1994, Fleming et al., 1996). Specifically, apoE3 undergoes high affinity 
binding to these proteins whilst apoE4 does not. It has been hypothesized that apoE3 
binding to tau prevents self-aggregation of tau to form paired helical fragments and 
neurofibrillary tangles, whilst promoting the association of tau with beta-tubulin for 
increased microtubule stability (Roses et al., 1996). Conversely, the inability of 
apoE4 to modulate this results in accumulation of hyperphosporylated tau in humans 
and mice expressing the APOE-ε4 gene (Tesseur et al., 2000, Brecht et al., 2004, 
Thaker et al., 2003). ApoE3 stimulates β-tubulin polymerisation and stabilisation of 
microtubules, whilst apoE4 destabilises microtubule assembly (Nathan et al., J Biol 
Chem, 1995). Microtubule reorganization and assembly is strongly associated with 
the maintenance and modulation of neurite outgrowth. Cell culture studies have 
shown that apoE is able to modulate neurite outgrowth in Neuro-2A cells (Bellosta et 
al., 1995, DeMattos et al., 1998), rabbit dorsal root ganglion cells (Handelmann et 
al., 1992, Nathan et al., 1994), and adult mouse cortical neurons (Nathan et al., 
2002). This modulation is dependent on apoE isoform, with apoE3 and apoE2 
inducing neurite outgrowth, whilst apoE4 acts in an inhibitory manner. However, it 
has been shown that apoE does not escape from the endocytic pathway into the 
cytosol, and is therefore unable to interact directly with any of the cytoskeletal 
components (DeMattos et al., 1999). This raises the issue of how apoE is able to 
mediate cytoskeletal changes. It has been postulated that apoE may exert cytoskeletal 
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influence through binding to cell surface receptors and susbsequent signal 
transduction (Nathan et al., 2002, Ohkubo et al., 2001, Hoe et al., 2005) 
 
1.7.4.4 Immune modulation 
ApoE also has also been shown to exhibit immunomodulatory properties. ApoE 
suppresses proliferation of both CD4+ and CD8+ T cell lymphocytes and it exerts this 
inhibition by partially reducing the activity of interleukin-2 (Kelly et al., 1994). In 
mixed neuronal-glial cultures from apoE-deficient mice, preincubation with human 
recombinant apoE blocked glial secretion of tumour necrosis factor α (TNF-α). This 
effect was independent of cell viability (Laskowitz et al., 1997). Microglial 
activation and release of TNF-α was also suppressed by biologically relevant 
concentrations of apoE (Laskowitz et al., 2001). Other inflammatory molecules 
downregulated by apoE include interleukin 1β and interleukin 6 (Lynch et al., 2001). 
The immune modulation properties of apoE also manifest on a biologically relevant 
level, with apoE-deficient mice exhibiting increased susceptibility to endotoxaemia 
after lipopolysaccharide injection and impaired immunity after infection with 
Klebsiella pneumonia (de Bont et al., 1999) or Listeria monocytogenes (Roselaar and 
Daugherty, 1998). ApoE-deficient mice did not differ from control C57Bl/6 mice in 
thymic, splenic or bone marrow lymphocyte populations. However, apoE-deficient 
mice had significantly higher levels of antigen-specific IgM and impaired delayed 
type hypersensitivity after immunisation with tetanus toxin, suggesting that apoE 
modulates the humoral and cell-mediated immune response (Laskowitz et al., 2000). 
ApoE has also been hypothesized to exert an anti-inflammatory role in the CNS 
through attenuation of Aβ induced glial activation (Hu et al., 1998).  
 
1.8  Role of ApoE Receptors in Cellular Communication 
1.8.1  The LDL receptor family 
ApoE binds to members of the LDL receptor family. The LDL receptor family is an 
evolutionary ancient gene family of structurally conserved cell-surface proteins. In 
mammals, there are seven core members of the LDL receptor family (Figure 1.5). 
These are the LDL receptor (LDLR), the LDL receptor-related protein (LRP1), the 
VLDL receptor (VLDLR), the apoER2 receptor, megalin (a.k.a. gp330, LRP2), the 
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LRP1b receptor and multiple epidermal growth factor repeat containing protein 7 
(MEGF7). ApoE has been demonstrated to be a ligand for the majority, but not all of 
these receptors. Members of the LDL receptor gene family share five common 
motifs: 1) a ligand binding type cysteine-rich repeat domain, 2) epidermal growth 
factor type cysteine-rich repeats, 3) a YWTD (tyrosine, tryptophan, threonine, 
aspartate) domain that fold in β-sheets to form a propeller structure, 4) a single 
transmembrane segment, 5) a cytoplasmic tail containing one or more “NPxY” (Asp-
Pro-x-Tyr) motifs which function as endocytosis signals and are involved in signal 
transduction. Some members of the LDL receptor family contain an O-linked sugar 
domain directly preceding the transmembrane segment, but otherwise there is an 
absence of other structural domains. Extended members of the LDL receptor family 
include LRP5, LRP6 and LR11 (a.k.a SORLA). These receptors are closely related 
but do not fulfil the stringent structural requirements to be classified as a core family 
member. The primary function of LDL receptor family members is to regulate 
cholesterol homeostasis by receptor-mediated endocytosis of lipoproteins particles. 
However, there is growing experimental evidence that the LDL receptor family may 
also have an additional role in signal transduction. The following members of the 
LDL R family are able to bind apoE. 
 
1.8.1.1 LDLR 
The LDL receptor (LDLR) was the first member of the LDL receptor family to be 
identified by Brown and Goldstein whilst investigating the genetic background of the 
disease familial hypercholesterolaemia (Brown and Goldstein, 1986). It is 
ubiquitously expressed in all tissues are varying levels, including the brain. The main 
physiological function of the LDLR is to regulate cholesterol homeostasis by 
transporting lipoprotein particles into cells. Unlike the following members of the 
LDL receptor family, the LDLR does not appear to have a critical role in the 
development of the nervous system. In a strain of rabbits (Kita et al., 1982) with a 
defective LDLR gene and transgenic LDLR knockout mice (Ishibashi et al., 1993), 























































































































































































































































































LRP1 is an extremely large protein (~600 kDa) ubiquitously expressed throughout 
the body, although primarily abundant on hepatocytes and neurons. LRP1 can 
recognize over 30 different ligands. Physiologically, LRP1 acts as a receptor for 
endocytosis of chylomicron remnants and signal transduction (Herz and Strickland, 
2001). Lrp1-deficient mice do not undergo normal neural development and are 
embryonic lethal (Herz et al., 1992), demonstrating that the LRP1 has an integral role 
in embryogenesis. Transgenic mice selectively lacking LRP1 in exhibit severe 
behavioural and motor abnormalities including tremor, ataxia, hyperactivity and 
eventually suffer from premature death. However, the CNS of these animals is 
histoanatomically normal, suggesting that this phenotype is a result of a functional 
defect in LRP1-deficient neurons (May et al., 2004). Interaction of α-2-
macroglobulin with LRP1 regulates calcium response to NMDA in primary cultured 
neurons (Qiu et al., 2002), implicative of a role in synaptic transmission. Further 
evidence arises from the finding that LRP1 lies in close proximity to the NMDA 
receptor in dendritic synapses and co-precipitates with PSD-95 and subunits of the 
NMDA receptor from neuronal cell lysates (May et al., 2004). LRP1 is also involved 
in the proteolytic processing of amyloid precursor protein (APP) to generate Aβ, 
providing a possible link with Alzheimer’s disease (Pietrzik et al., 2002).  
 
1.8.1.3 Megalin / LRP2 
Megalin (a.k.a. LRP2) is another large member of the LDL receptor family with a 
similar size to LRP1. It is commonly expressed on absorptive and secretory epithelia, 
with the highest level of expression on the epithelial cells that line the proximal 
tubules in the kidney. Megalin can bind a variety of ligands, including lipoproteins, 
vitamin-binding proteins, and hormones and signalling molecules. Physiologically, 
megalin functions as a scavenging receptor for reuptake of low molecular weight 
proteins. One well-characterised example is the reuptake of vitamin D binding 
protein from the glomerular filtrate in the proximal renal tubules, with megalin 
deficient mice suffering from proteinuria and vitamin D deficiency (Nykjaer et al., 
1999). These knockout mice also suffer from a defect in forebrain development, 
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resulting in a fusion of the forebrain hemispheres termed holoprosencephaly 
(Willnow et al., 1996). Mutations in the sonic hedgehog (Shh) gene also cause a 
holoprosencephalic syndrome (Belloni et al., 1996, Roessler et al., 1996), implying 
that megalin may be involved in Shh signalling. Initial studies suggested that a 
conditional deletion of megalin in the neuroepithelium leads to a loss of Shh 
expression in the ventral forebrain, which occurs due to an increase in Bmp4 
signalling, a negative regulator of Shh (Spoelgen et al., 2005). It appears that megalin 
is able to regulate signal transduction of the Shh signalling pathway, and it may do 
this by directly binding to Bmp4 (Spoelgen et al., 2005). 
 
1.8.1.4 VLDLR 
The VLDLR has a very similar primary structure to LDLR, differing only in an 
additional cysteine-rich repeat domain in the ligand binding motif. This similarity 
results in a similar binding affinity to apoE as LDLR. However, there is no 
expression of VLDLR in the liver. Instead, VLDL receptors are located in 
developing and adult brain, heart and skeletal muscle. The expression pattern of the 
VLDLR suggest a minimal role in lipoprotein metabolism, a fact borne out by 
VLDLR knockout mice, which do not suffer from any deficiency in VLDL 
metabolism and have a similar lipoprotein profile to normal mice (Frykman et al., 
1995). The main physiological role of the VLDLR is regulation of migration and 
layering of neurons in the cortex and cerebellum during development, a role also 
performed by the apoE receptor 2 (apoER2) in association with the reelin ligand. 
 
1.8.1.5 ApoER2 
ApoER2 has a close structural similarity to the LDLR and therefore also to the 
VLDLR. Similar to VLDLR, it is not expressed in the liver, suggestive of a primary 
role other than lipoprotein metabolism. Instead, apoER2 expression is limited to the 
brain and testes (Novak et al., 1996, Stockinger et al., 1998), and is abundantly 
expressed on neurons (Stockinger et al., 1998, Wolf et al., 1992). Knockout mice 
deficient in apoER2 appear normal, but the males are virtually sterile, demonstrating 
that apoER2 is critical for sperm production or survival. These mice also suffer from 
a developmental defect in the neocortex and hippocampus, evidenced by a failure of 
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the neurons to migrate to their proper positions. This defect is also manifest in 
VLDLR knockout mice, and has a striking phenotype similar to reeler mutant mice 
(Trommsdorff et al., 1999).  
 
1.8.1.6 ApoER2 and VLDLR interact with the Reelin signalling 
pathway 
Reeler mutant mice were originally discovered in the early 1950s (Falconer, 1951). 
This genetic mutation manifests by incomplete development of the foliation pattern 
of the cerebellum. Reelin is a large secreted protein expressed primarily in nervous 
tissues. Functional mutations in reelin result in disrupted formation of the neocortex, 
cerebellum and spinal cord during development (D’Arcangelo et al., 1995). On a 
microscopic level, the loss of reelin expression interferes with radial migration and 
final positioning of the neurons in the regions affects, resulting in the classical 
laminated appearance of the cortex. Aside from VLDLR / apoER2 deficient mice; 
there are two other mutant strains which are phenotypically indistinguishable from 
reeler mice, but have a mutation located on a different gene. The genetic defect on 
these mice, termed scrambler and yotari, was mapped to the Disabled-1 (dab1) gene 
(Sheldon et al., 1997, Ware et al., 1997). As expected, Dab1 deficient mice also 
exhibit the same phenotype (Howell et al., 1997), but a strain of mice deficient in 
both Reelin and Dab1 did not suffer from a compounded phenotype, suggesting that 
Reelin and Dab1 are components in a linear pathway that determines cortical 
development. As Reelin is a secreted, extracellular protein, and Dab1 is a 
cytoplasmic adaptor protein, the discovery of the VLDLR / apoER2 knockout mouse 
phenotype strongly suggested that both these neuronal apoE receptors could function 
as receptors for Reelin (Tromsdorff et al., 1999). Reelin binding to apoER2 and 
VLDLR is inhibited by the presence of apoE (D’Arcangelo et al., 1999). Supporting 
evidence for the roles of VLDLR and apoER2 in the Reelin signalling pathway came 
from blockade of Reelin binding with recombinant receptor associated protein, a 
universal inhibitor of ligand binding for members of the LDL receptor family. In the 
absence of Reelin binding to the apoE receptors, no tyrosine phosphorylation of 
Dab1 occurred, which is an essential step in the Reelin signalling pathway (Howell et 
al., 2000). The Reelin signalling pathway can also affect microtubule stabilization, 
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with Reelin and VLDLR / apoER2 deficient mice exhibiting hyper-phosphorylation 
of the microtubule stabilizing protein, tau (Hiesberger et al., 1999). Two downstream 
signalling pathways have been implicated in this process. Reelin can activate the 
phosphatidylinositol-3-kinase (PI3K) / protein kinase B (PI3K/AKT) pathway, which 
then inhibits the tau kinase, glycogen synthase kinase 3β (GSK3β) (Beffert et al., 
2002, Bock et al., 2003). Alternatively, Reelin can bind to the Ser/Thr kinase cyclin-
dependent kinase 5 (cdk5) pathway. Cdk5 can bind to a number of substrates that 
regulate microtubule assembly, including tau and NUDEL (Ohshima et al., 2001, 
Beffert et al., 2004). Interestingly, Reelin has also been implicated in synaptic 
plasticity. The VLDLR / apoER2 knockout mouse displays long-term memory 
deficits for contextual fear conditioning, and slice electrophysiology on these animals 
reveals moderate to pronounced impairments in LTP. In a converse experiment using 
slices taken from wildtype mice, application of Reelin enhanced tetanus dependent 
LTP. This enhancement in LTP required the presence of apoER2 and VLDLR 
(Weeber et al., 2002). Further work has shown that apoER2 associates with NMDA 
receptors at the postsynaptic density, and that Reelin is able to increase NMDA 
receptor mediated whole cell current dependent on the splicing of apoER2 (Beffert et 
al., 2005).  
 
1.8.1.7 LRP5 and LRP6  
Other LDL receptor family members involved in cell signalling are LRP5 and LRP6. 
These receptors are intimately involved in the Wnt signalling pathway; although at 
the current time there is inconclusive evidence that apoE can act as a ligand (Kim et 
al., 1998). A recent paper has shown that apoE4 was able to inhibit the canonical 
Wnt signalling pathway in vitro through the LRP5 and LRP6 receptor (Caruso et al., 
2006).  
 
1.8.2  Role of apoE in cell signalling pathways 
The fact that the majority of these LDL receptors can bind apoE raises the possibility 
that apoE is able to modulate various signal transduction pathways. ApoE has been 
shown to inhibit smooth muscle cell migration and proliferation (Ishigami et al., 
1998, Ishigami et al., 2000, Hui and Basford, 2005). ApoE binds to heparan sulphate 
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proteoglycans through its primary role in lipoprotein transport. However, through 
this binding and subsequent activation of inducible nitric oxide synthase, apoE is also 
able to regulate inhibition of cell proliferation (Ishigami et al., 2000, Swertfeger and 
Hui, 2001). In contrast, inhibition of cell migration by apoE appears to be mediated 
by binding to LRP1 and subsequent activation of cyclic AMP-dependent protein 
kinase A (Swertfeger et al., 2002, Zhu and Hui, 2003). Binding of the LRP1 receptor 
by certain ligands such as apoE and α2-macroglobulin has been shown to increase 
neurite outgrowth through activation of the extracellular signal-regulated kinase 1 
and 2 (ERK1/2) (Qiu et al., 2004). Phosphorylation of ERK1/2 leads to translocation 
of ERK1/2 to the nucleus of the cell, where it can then phosphorylate the cyclic AMP 
response binding element protein (CREB). CREB is a multipurpose transcription 
factor that has been implicated in a wide variety of mechanisms, such as synaptic 
plasticity, cell proliferation and protection of the brain from neurodegeneration 
(Deisseroth et al., 1996, Della Fazia et al., 1997, Mantamadiotis et al., 2002), 
suggesting that apoE binding can influence a large variety of events. However, 
Ohkubo et al., (2001) suggested that the activation of CREB by apoE was isoform 
dependent, with apoE4 but not apoE3 able to stimulate CREB transcription through 
the ERK1/2 cascade. Interestingly, CREB activation by apoE4 induced a number of 
genes including the anti-apoptotic gene Bcl-2, suggesting a possible route by which 
apoE could influence cell survival. ApoE has also been suggested to influence 
quiescence and survival of human neural progenitor cells through regulation of 
chemokines (Krathwohl and Kaiser, 2004). Activation of CCR3 and CXCR4 
receptors by their respective chemokines eotaxin and SDF-1 inhibited cell 
proliferation and induced cellular quiescence. These quiescent progenitor cells 
maintained their multipotential ability to differentiate into neurons and astrocytes. 
However, apoE3 but not apoE4 was able to reverse the inhibitory effects of the 
chemokines. This suggests that apoE may be able to regulate cell proliferation and 
differentiation in an isoform-dependent manner. 
 
As described previously, apoER2 and VLDLR interactions with Reelin have been 
implicated in synaptic plasticity. Reelin binding to apoER2 and VLDLR serves to 
enhance synaptic transmission in the hippocampus (Weeber et al., 2002) and this 
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enhancement can be modulated by splicing of apoER2 (Beffert et al., 2005). Another 
association between apoE and Reelin ligands has been demonstrated by Ohkubo et 
al. (2003). Upon mating of Reelin deficient mice to apoE deficient mice, that 
discovered that tau phosphorylation increased as the amount of apoE protein 
decreased. These alterations in tau phosphorylation were paralleled with an increase 
in the activity of the protein kinase glycogen synthase kinase-3β (GSK-3β). These 
data suggest that the ligand binding of apoE and Reelin to the receptors apoER2 and 
VLDLR mediates tau phosphorylation through a signal transduction cascade 
involving activation of GSK-3β.  
 
These findings were substantiated by a recent comprehensive study that directly 
implicated apoE in three major signalling pathways; the ERK, c-jun N-terminal 
kinase (JNK) and Dab1 pathways (Hoe et al., 2005). Treatment of primary neurons 
with apoE or an apoE-derived peptide for the receptor binding domain significantly 
increased ERK1/2 and Dab1 phosphorylation whilst decreasing activation of 
JNK1/2. The activation of ERK1/2 and Dab1 are dependent on the calcium influx via 
the NMDA receptor. Co-immunoprecipitation experiments demonstrated that the 
apoER2 receptor interacts with the NMDA receptor in a multi-protein complex with 
PSD-95 (Hoe et al., 2006). These results were consistent with previous findings that 
apoE receptors and by implication their ligands, are able to influence calcium influx 
through NMDA receptors (Qiu et al., 2003, Beffert et al., 2005, Ohkubo et al., 2001, 
Bacskai et al., 2000). Taken together, these results suggest that apoE may influence 
molecular mechanisms of memory. ApoE mediated regulation of JNK1/2 required γ-
secretase and G protein activity. Interestingly, apoER2 and LRP can be cleaved by 
the γ-secretase complex so that the intracellular component is released into the 
cytoplasm (May et al., 2003), suggesting that regulation of JNK signalling is through 
the production of soluble fragments of these LDL receptors.  
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1.9 Potential Role of ApoE in Survival, Migration and Differentiation 
of Grafted MHP36 Stem Cells 
 
1.9.1  Key factors indicative of apoE-mediated support 
The previous sections have demonstrated the integral role of apoE in providing 
support and promoting a favourable outcome after brain damage. ApoE may exert a 
neuroprotective influence, reducing the extent of damage in a variety of neurological 
disorders (Saunders et al., 1993, Strittmatter et al., 1993, Horsburgh et al., 1999, 
Sheng et al., 1999, Kitagawa et al., 2002, Laskowitz et al., 1997, Kitagawa et al., 
2001, Lomnitski et al., 1997, Chen et al., 1997, Lynch et al., 2002, Masliah et al., 
1995). The support role of apoE is also illustrated through synaptic remodelling of 
damaged circuitry (Poirier et al., 1991, 1993, Petit-Turcotte et al., 2005). Alternative 
mechanisms exist through which apoE could modulate protection and plasticity, such 
as excitotoxicity (Boschert et al., 1999, Buttini et al., 1999), anti-oxidation (Miyata 
and Smith, 1996, Pederson et al., 2000), cytoskeletal support (Masliah et al., 1996) 
and immune modulation (Laskowitz et al., 1997, Laskowitz et al., 2001). ApoE may 
also influence cell signalling pathways which are implicated in survival, migration 
and differentiation (Ishigami et al., 1998, Ishigami et al., 2000, Swertfeger et al., 
2002, Zhu and Hui, 2003, Hoe et al., 2005). In particular, apoE promotes the survival 
of human neural progenitor cells (Krathwohl and Kaiser, 2004).  
 
1.9.2 Initial evidence for the association of apoE with MHP36 
stem cell grafts 
The previously referenced study by Modo et al., (2003) was the first to postulate a 
link between apoE and MHP36 neural stem cell graft integration. MHP36 grafts 
induced an upregulation of apoE contralateral to the focal ischaemic lesion, 
suggesting that the stem cell grafts act in conjunction with apoE to promote 
reorganization and remodelling of the brain circuitry after damage. Another 
preliminary study has confirmed upregulation of apoE in association with MHP36 
grafts (Dr Iris Reuter, Personal Communication). Intriguingly, these upregulated 
levels of apoE were maintained over a period of 6 weeks, during which time the 
animals exhibited functional recovery. These preliminary studies have demonstrated 
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that there is an association between apoE and MHP36 stem cell integration. This 
thesis will extend on previous findings and investigate the interaction between apoE 
and MHP36 neural stem cell graft survival, migration and differentiation in 
mammalian brain. 
 
1.10  Aims of Thesis 
This thesis tests the hypothesis that apoE is critical in stem cell integration and 
investigates whether this effect is APOE genotype dependent, in a mouse model of 
global cerebral ischaemia. The specific aims to test this hypothesis are as follows: 
 
1. To characterise neural stem cell grafts in a mouse model of global ischaemia  
 
2. To investigate the influence of apoE on MHP36 neural stem cell grafts in a 
mouse model of global ischaemia  
 
3. To investigate the influence of APOE genotype on MHP36 neural stem cell 














Materials and Methods 
2.1  Animals 
Mice were communally housed in a conventional unit with a twelve-hour light/dark 
cycle and given unrestricted access to food and water.  All procedures were carried 
out under licence from the Home Office with the approval of the University of 
Edinburgh Ethical Review Panel and subject to the Animals (Scientific Procedures) 
Act 1986. 
 
2.1.1  C57Bl/6J mice 
Adult male C57Bl/6J mice weighing between 25-30g were purchased from Charles 
River. C57Bl/6J is the most widely used inbred strain, due to the fact that they breed 
well and are long-lived. It is commonly used as the background strain for the 
production of transgenic mice.  
 
2.1.2  APOE transgenic mice 
Two strains of apoE transgenic mice were used in this thesis.  The apoE-deficient 
mouse (also referred to as the APOE-KO mouse) generated by Dr Nobuyo Maeda 
(Piedrahita et al., 1992) and the human apoE3 and E4 isoform specific transgenic 
mice generated by Dr Allen Roses (Xu et al., 1996).  Piedrahita et al., (1992) used a 
targeting plasmid to inactivate the endogenous mouse APOE gene in mouse 
embryonic stem (ES) cells. Chimeric mice heterozygous for the disrupted mouse 
APOE gene were generated by blastocyst injection. Mice homozygous for the 
disrupted APOE gene were bred from two sets of heterozygous mice. Both 
homozygous and heterozygous were born at the expected frequency and were in 
good health. Immunodiffusion tests confirmed that the homozygous animals were 
unable to synthesize mouse apoE.  The APOE-KO mice used in this thesis were 
purchased from Charles River UK and bred at the University of Edinburgh. 
 
Xu et al., (1996) isolated and purified human genomic DNA from the lymphoblasts 
of individuals verified to be homozygous carriers for the APOε2, ε3 and ε4 alleles.  
This DNA was used to form cosmid libraries, which were screened with APOE and 
APOC1 cDNA in order to identify clones that contained all the regulatory elements 
required for APOE transcription.  The selected clones were digested with restriction 
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enzymes to generate APOE genomic fragments, which were microinjected into single 
cell embryos fertilized by APOE-KO mice from the Maeda strain.  The mothers were 
on a background strain of C57Bl/6J x DBA/2J.  The offspring were checked for 
expression of the human APOE transgene through use of the polymerase chain 
reaction (PCR).  Founder mice were bred to APOE-KO mice to produce animals 
homozygous for the human APOE transgene, and backbred further into APOE-KO 
strains in order to remove the genetic influence of the DBA/2J background strain. 
Three transgenic mouse lines were generated for APOE-ε2 (ε2-205, ε2-222, ε2-267), 
five lines for APOE-ε3 (ε3-393, ε3-414, ε3-428, ε3-437, ε3-453) and four lines for 
APOE-ε4 (ε4-20, ε4-43, ε4-64, ε4-81). Each of these lines carries multiple copies (1-
8) of the respective gene, and expression of APOE mRNA was confirmed in serum, 
along with expected organs such as the brain, liver, kidney, spleen and heart. In this 
thesis, the transgenic lines used were APOE ε3-437 and APOE ε4-81 which both 
carry two copies of the respective gene. 
 
2.2  In vivo Mouse Model of Transient Global Ischaemia 
Induction of global ischaemia was carried out by Dr Karen Horsburgh. Mice were 
anaesthetised with halothane (4% induction, 1.5% maintenance) in a mixture of 
oxygen and nitrous oxide (30:70).  Core body temperature was monitored using a 
rectal probe and strictly maintained at 37oC using a heating lamp.  Global ischaemia 
was induced via occlusion of the bilateral common carotid arteries (BCCAo) (Kelly 
et al., 2001, Horsburgh et al., 1999).  A small incision was made along the neck, and 
both common carotid arteries were carefully exposed.  Micro-aneurysm clips were 
used to occlude both arteries for a set period of time (15 or 17 minutes).  The clips 
were removed, and restoration of blood flow was confirmed before the animal was 
sutured closed.  After surgery, the animal recovered in a heated incubator (30oC) for 
2 hours before being returned to the housing unit. Animals were provided with soft 
food following surgery and monitored on a daily basis. 
 
2.3  Stereotaxic Surgery 
Mice were anaesthetised with halothane (4% induction, 1.5% maintenance) in a 
mixture of oxygen and nitrous oxide (30:70) and securely mounted on a stereotaxic 
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frame (Kopf Instruments). An incision was made along the midline and the skull 
exposed.  All the coordinates are based on bregma as a reference point (Table 2.1). 
The coronal plates at the caudal and hippocampal levels are shown in Figure 2.1 
 
Direction Caudate coordinates Hippocampus coordinates 
Medial / Lateral +2 mm +1.5 mm 
Anterior / Posterior +0.26 mm –2 mm 
Ventral –3 mm –1.5 mm 
 
Table 2.1 Stereotaxic coordinates for the location of caudate and 
hippocampal injections 
 
A burr hole was drilled at each target coordinate, the dura carefully exposed and a 
blunt-tip Microliter 7002 syringe (25 gauge, 2μl capacity, Hamilton Company), 
descended to the required depth.  The cell suspension or vehicle (0.5μl at 25,000 
cells/μl) was injected over 5 minutes, and the syringe was left in place for another 5 
min after injection to allow diffusion of the contents away from the tip.  The syringe 
was removed, and the animal sutured closed.  After surgery, the animal recovered in 
a heated incubator (30oC) for 1 hour before being returned to the housing unit. 
Animals were provided with soft food following surgery and monitored on a daily 
basis. In order to achieve reproducible proficiency at stereotaxic injection at the 
correct co-ordinates, syringe placement was assessed using ink injections prior to 
definitive studies of cell transplantation. A representative ink injection is shown in 
Figure 2.2. 
 
2.4  The Rotarod Behaviour Test 
The rotarod test is a measure of motor balance and coordination (Jones and Roberts, 
1968). The animal was placed on the drum and allowed to orient itself against the 
direction of rotation before rotation commenced.  On the day prior to the first test 
session, animals received one training session in which they were acclimatised to the 
rotarod testing environment and taught to run on a rotarod at low speeds (2-6 rpm).  




Coronal plates of the caudate nucleus (A) and hippocampus (B) 
illustrating the location of the stereotaxic
 
injections
The depth to which the syringe is descended in outlined in red. (Plates taken from 
Paxinos
 






Representative micrograph of the ink injection
The ink injection demonstrates correct use of the stereotaxic
 
frame for placement and 
descension
 
of the Hamilton syringe.
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The time taken for the animal to fall off the drum was recorded.  Animals received 
two sessions per week on the rotarod, starting on the week after grafting.  One 
session comprised of three trials at each rotation speed.  The rotarod used in this 
thesis was a Series 8, manufactured by IITC Life Science. This model utilises 1¼ 
inch diameter textured drums for mice and has the capacity to run 5 lanes as a time.  
 
2.5  Perfusion and Micro-dissection 
Mice were anaesthetised with halothane (4% induction, 1.5% maintenance) in a 
mixture of oxygen and nitrous oxide (30:70) and a sternotomy performed.  The 
diaphragm and ribcage were cut in order to expose the heart.  A butterfly needle 
attached to a syringe pump (Harvard Apparatus) was inserted into the left ventricle.  
Approximately 25ml of heparinized, ice-cold saline (5000 units / 100ml) was 
perfused through the animal at a rate of 2.5ml/min-1.  The right atrium was cut 
following infusion in order to ensure complete flow through the animal.  Loss of 
colour in the liver and paws were considered as the sign of a good perfusion.  
Following the saline perfusion, the animal was subsequently fixed by perfusion of 
approximately 25ml of 4% paraformaldehyde in phosphate buffer.  Satisfactory 
fixation was observed by rigidity of the extremities.  After fixation the animal was 
decapitated and the skull stored in 4% paraformaldehyde for 24 hours. The brain was 
then removed from the skull and post-fixed in 4% paraformaldehyde for a further 24 
hours.  In the event of an unsatisfactory perfusion fixation, the brain was 
immediately removed and post-fixed in paraformaldehyde for 48 hours.   
 
If micro-dissection and freezing of tissue was required, the animal was rapidly 
perfused with heparinized ice-cold saline and decapitated. The brain was rapidly 
removed, transferred to a pre-chilled petri dish on ice and rinsed with ice-cold saline.  
It was then placed in a pre-chilled mouse brain matrix and 2mm coronal sections at 
the level of the caudate and hippocampus were cut.  The coronal sections were 
transferred back to the petri dish for micro-dissection.  The ipsilateral (hemisphere 
receiving the graft) and contralateral caudate nucleus and hippocampus were 
carefully removed using a pair of forceps and placed in individual, labelled 1.5ml 
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Eppendorf tubes before snap-freezing in liquid nitrogen.   Frozen tissue was stored at 
–80oC. 
 
2.6  Brain Processing and Sectioning 
Following post-fixation, brains were cryoprotected by graded immersion in 10, 20 
and 30% sucrose in phosphate buffer. The brains were then frozen by one of two 
methods. In the first method, the brain was rapidly immersed into liquid nitrogen for 
approximately five seconds until frozen. Although this method prevented slow 
freezing artefacts from water ice crystal formation, the lack of observation and fine 
control during the freezing process meant it was prone to poor morphology from 
overfreezing. The second method used is described by Callis (2004). Briefly, the 
cryoprotected brain was placed in a mouse brain matrix and 3mm coronal blocks 
were cut at the level of the caudate and hippocampus, taking into accounts the 
location of the injections. These coronal slices were embedded in OCT 
cryoembedding media (Sakura) in a plastic freezing mould. A plastic petri dish was 
floated on a pool of liquid nitrogen. The freezing mould containing the embedded 
brain was placed on top of the petri dish and allowed to freeze for five minutes. This 
method allows for fine control of the freezing process since the sample can be 
observed during freezing. Frozen brains were stored at –20oC. Coronal cryostat 
sections were cut at a thickness of 10μm. 
 
2.7  MHP36 Cell Culture 
MHP36 cells were obtained as a gift from ReNeuron Ltd. They were thawed from 
frozen stock and cultured in filtered DMEM:F12 (containing human serum albumin: 
0.03%, Grifols, apo-transferrin: 94 μg/ml, Sigma, putrescine dihydrochloride: 16.2 
μg/ml, Sigma, human recombinant insulin: 5 μg/ml, Sigma, L-thyroxine: 400 ng/ml, 
Sigma, Tri-iodo-thyronine: 337 ng/ml, Sigma, progesterone: 60ng/ml, Sigma, L-
Glutamine: 2 mM, Sigma, sodium selenite: 40 ng/ml, Sigma, heparin: 10 units/ml, 
Sigma, gentamicin: 50 μg/ml, Invitrogen), supplemented by bovine fibroblast growth 
factor (bFGF: 1μg/ml media, Sigma) and interferon-γ (1μg/ml media, Peprotech).  
Cells were fed by changing half of the media every other day, and split by discarding 
the medium and washing with Hank’s Balanced Salt Solution (HBSS, Invitrogen) 
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without Ca2+ and Mg2+ to remove debris and aid detachment.  Cells were then 
incubated at 33°C with 5ml Versene (Invitrogen) containing 10μl 2% ethylene 
glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA) per ml until 
dislodged.  An equal amount of HBSS was added to inactivate the solution.  Cells 
were spun down in a centrifuge at 1500 rpms for 5 mins.  The pellet was aspirated 
and diluted in an appropriate volume of media for passaging. The cell suspension 
was plated into fibronectin coated tissue culture flasks and returned to the incubator 
at 33oC.  Before grafting, cells were labelled with the red fluorescent marker PKH26 
(Sigma). The PKH26 cell marker comprises a fluorescent dye with a long aliphatic 
tail allowing for stable incorporation into cell membrane. The labelling vehicle used 
(Diluent C) is an iso-osmotic aqueous solution which contains no physiological salts 
or buffers, detergents or organic solvents. A suspension of MHP36 cells was counted 
on a haemocytometer and then resuspended in diluent C at a density of 2.0 x 106 
cells/ml. The PKH26 staining solution was prepared by diluting PKH dye in diluent 
C (working concentration of 10μm). The suspension of MHP36 cells was diluted 
with an equivalent volume of PKH26 staining solution (final concentration of 5μm) 
and immediately mixed in order to ensure homogenous staining. The cells were 
incubated in staining solution for 4 minutes. The staining reaction was stopped by 
addition of an equal volume of 1% bovine serum albumin in HBSS. The labelled 
cells were separated from the staining solution by centrifugation at 1500rpm for 10 
minutes. The cell pellet was then washed by centrifugation at 1500rpm for 5 minutes 
in fresh HBSS. Labelled cells were suspended in 0.5mM N-acetyl-L-cysteine (NAC) 
in HBSS without Ca2+ or Mg2+ at a concentration of 25,000 cells/µl. Cells were 
aspirated to form a single cell suspension and checked for incorporation of the 
PKH26 label prior to grafting (Figure 2.3).  Viability was assessed using trypan blue 




Representative images of PKH26 labelled MHP36 stem cells
Incorporation of the red fluorescent PKH26 marker into the membrane of MHP36 




2.8  Immunohistochemistry 
2.8.1  Principles 
Immunohistochemistry combines anatomical, immunological and biochemical 
techniques for the identification and localisation of specific tissue components by 
means of a specific antigen/antibody reaction tagged with a visible label.  This thesis 
uses the avidin-biotin complex (ABC) method of immunohistochemistry (Figure 
2.4).  The ABC method (Hsu et al., 1981) utilises the high binding affinity (four 
binding sites per molecule) of avidin or strepavidin, a large glycoprotein from egg 
white, to biotin, a low molecular weight vitamin found in egg yolk.  In brief, a 
biotinylated secondary antibody is bound to the primary antibody.  While this takes 
place, a biotinylated enzyme (horseradish peroxidase or alkaline phosphatase) is 
incubated with avidin, forming the large avidin-biotin complex.  This complex then 
binds to the biotinylated secondary antibody through one of the free binding sites on 
avidin, and a colourimetric substrate for the bound enzyme added in order to 
visualise the antigen.  The tetravalent properties of avidin serve to amplify the 
reaction and increase signal intensity and sensitivity.  
 
2.8.2  Protocol 
Fixed sections were removed from the freezer and allowed to air dry for at least 1 
hour. The slides were placed in a slide rack and rinsed in phosphate buffered saline 
(PBS) for 3 x 5 minutes. This served to equilibrate the sections and remove OCT, if 
present. Sections were dehydrated in graded alcohols (70%, 2 min, 90% 2 min, 
100%, 2 x 5 min) and blocked for endogenous peroxidase activity in 0.5% hydrogen 
peroxidase in methanol for 30 minutes.  Sections were rinsed in running tap water for 
10min followed by a rinse in PBS.  The dehydration and peroxidase steps were 
omitted for sections undergoing fluorescent immunostaining. If required, sections 
underwent antigen retrieval by boiling in a microwave in citric acid buffer, pH 6.0 
for 2 x 5 minutes. Sections were left to cool for 30 minutes before proceeding.   
Sections were blocked in 2% bovine serum albumin, 10% normal serum in PBS for 1 
hour.  The normal serum was chosen to match the species of the secondary antibody. 
Primary antibodies were diluted in blocking solution and incubated overnight at 4oC. 





























Binding of the primary antibody to the antigen.
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Binding of the biotinylated secondary antibody to the primary antibody.
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Binding of the ABC complex to the secondary antibody.  Enzymatic
 
reaction with the 





Binding of the fluorescently-conjugated avidin
 
to the secondary antibody.
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immunohistochemistry experiments. For negative controls, primary antibody solution 
was omitted and sections incubated in blocking solution alone.  Sections were rinsed 
in PBS for 2 x 10 minutes before incubation with the biotinylated secondary antibody 
for 1 hour at room temperature.  Sections were rinsed in 2x10 min PBS prior to 
incubation with the avidin-biotin complex (Standard or Elite ABC kit, Vector, UK) 
or the fluorescent conjugate Strepavidin Alexa 488 (1:200, Molecular Probes) for 1 
hour at room temperature.  Fluorescent sections were rinsed in PBS, optionally 
counterstained with the nuclear DNA marker To-Pro-3 (Invitrogen) and cover 
slipped with Vectashield (Vector).  Light microscope sections were rinsed in PBS for 
3 x 5 minutes and visualised with diaminobenzidine (DAB, Vector).  Sections were 
rinsed in water and counterstained with haematoxylin if required, then dehydrated 
through graded alcohols, cleared in xylene and cover slipped with DPX mountant. 
 
2.9  Histology 
2.9.1  Haematoxylin and Eosin staining 
Haematoxylin and eosin staining was carried out in order to visualise ischaemic 
neurons. Fixed sections were removed from the freezer and allowed to air-dry for 1 
hour. The slides were placed in a slide rack and rinsed in running tap water for 5 
minutes. This served to equilibrate the sections and remove OCT, if present. Sections 
were dehydrated in graded alcohols (70%, 2 min, 90%, 2 min, 100%, 2 x 5 min, 
90%, 2 min, 70%, 2 min) and rinsed in running tap water for 5 minutes. Sections 
were stained in haematoxylin (Gills, Surgipath) for up to 1 minute. After a quick 
rinse in running tap water, sections were differentiated in acid alcohol (1% HCL in 
70% EtOH) and rinsed in running tap water for 2 minutes. The haematoxylin stained 
sections were then “blued” by immersion in Scots tap water for 2 minutes, followed 
by another rinse in running tap water for 2 minutes. Sections were stained in eosin 
(Surgipath) for up to 4 minutes. After a quick rinse in running tap water, sections 
were dehydrated in graded alcohols (70%, <2 min, 90%, 2 min, 100%, 2 x 5 min) 
and cleared in xylene for 15 minutes. Slides were coverslipped with DPX mountant. 
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2.9.2  Quantification of ischaemic damage 
Haematoxylin and eosin stained sections were used to assess the extent of ischaemic 
damage using a 100mm2 grid (attached to the microscope optics) at 400x 
magnification.  Ischaemic neurons were defined by an intense, darkly stained 
pyknotic nucleus surrounded by eosinophilic cytoplasm (Figure 2.5).  The number of 
morphologically normal neurons and neurons exhibiting ischaemic cell change were 
counted in a 25mm2 region of the grid.  Within the caudate nucleus, six regions 
surrounding the injection tract were assessed. These were selected in order to capture 
medial, lateral and ventral aspects of the caudate nucleus. Within the hippocampus, 
ischaemic damage was assessed in the CA2 pyramidal cell layer. Two sections were 
assessed for each animal and these sections were quantified twice in order to confirm 
reproducibility. 
 
2.9.3  Quantification of MHP36 graft survival  
MHP36 stem cell survival was assessed using either a semi-quantitative method 
based on fluorescence microscopy (Chapter 3) or a fully quantitative method based 
on confocal laser scanning microscopy (Chapters 4 and 5). The semi-quantitative 
method assessed MHP36 graft survival based on the extent of red fluorescence on the 
stem cells labelled with PKH26. Sections were assessed for MHP36 graft survival in 
selected regions in the caudate nucleus using a 100mm2 grid (attached to the 
microscope optics) at 200x magnification. The degree of cellular red PKH26 
fluorescence based on percentage coverage of the grid was assessed using a scoring 
system as follows; 0, no labelled cells, 1, <25% labelled cells, 2, 25-50% labelled 
cells, 3, 50-75% labelled cells, 4, >75% PKH26 labelled cells. Following the 
completion of the study described in Chapter 3, confocal assessment was preferred 
for quantification of MHP36 graft survival as it allowed for fully quantitative 
assessment. Confocal z-series images were captured in selected regions in either the 
caudate nucleus or hippocampus. These z-series images were analysed for the 








































































































































































































































































































































































Representative images highlighting the morphological features of
 
mouse global ischaemia in the caudate nucleus and 
hippocampus
Normal and ischaemic neurons (arrows) are shown in sections taken from the 
caudate nucleus in sham and ischaemic mice. Ischaemic neurons are identifiable by 
their triangular morphology and darkly stained pyknotic
 
nuclei.  Mouse global 
ischaemia is also characterised via a loss of neurons in the CA2
 








2.9.4  Quantification of MHP36 graft migration 
Migration of PKH26 labelled MHP36 cells was assessed in a medial, lateral and 
ventral direction away from the injection tract.  The distance of migration in each 
direction was measured using a 100mm2 grid (attached to the microscope optics) at 
200x magnification. At this magnification, the length of one side of the grid is 
equivalent to 0.5mm. Two sections were assessed for each animal and these sections 
were quantified twice in order to confirm reproducibility. 
 
2.9.5  Quantification of GFAP immunoreactivity 
Sections were assessed for GFAP immunoreactivity in selected fields in the caudate 
nucleus and hippocampus using a 100mm2 grid (attached to the microscope optics) at 
400x magnification.  GFAP positive reactive astrocytes with defined cell bodies and 
processes were counted within each grid.  Two sections were assessed for each 
animal and these sections were quantified twice in order to confirm reproducibility. 
 
2.9.6  Quantification of F4/80 immunoreactivity 
Sections were assessed for F4/80 immunoreactivity in selected fields in the caudate 
nucleus using a 100mm2 grid (attached to the microscope optics) at 400x 
magnification.  Individual microglia / macrophage were difficult to define with 
precision and thus a semi-quantitative assessment was used.  The degree of F4/80 
immunostaining based on percentage coverage of the 100mm2 grid was assessed 
using a scoring system as follows; 0, no staining, 1, < 25% staining, 2, 25-50% 
staining, 3, 50-75% staining, 4, > 75% staining.  
 
2.9.7  Immunofluorescent analysis 
Sections were assessed for co-localization of phenotypic markers for neurons 
(NeuN), astrocytes (GFAP) and microglia / macrophage (F4/80) with PKH26 as a 
marker for transplanted MHP36 cells in selected fields in the caudate nucleus and 
hippocampus using a confocal laser scanning microscope (Zeiss).  Confocal z-series 
images were captured at the selected fields. Neuronal and astrocytic differentiation 
was determined by counting the number of labelled cells co-localizing with PKH26 
after counting the number of PKH26 positive cells within the same field. In addition, 
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confocal laser microscopy was used to assess the co-localisation of PKH 26 labelled 
cells with the DNA marker To-pro-3. 
 
2.10  Protein Analysis 
2.10.1  Tissue homogenisation 
Tissue samples were removed from the –80oC freezer, weighed immediately and 
placed on dry ice. One protease inhibitor tablet (Roche) was dissolved in 25ml ice-
cold modified radioimmunoprecipitation (RIPA) buffer. The tissue was placed in a 1 
ml glass-glass Dounce homogeniser and 5X volume of modified RIPA buffer was 
added (5 ml per 1 g). The tissue was homogenised with ten controlled strokes of the 
pestle and left for 15 minutes on ice. The homogenised tissue was transferred to a 
1.5ml Eppendorf tube, centrifuged at 10,000 rpm and 4oC for 10 minutes. The 
supernatant was removed, aliquoted into a separate 1.5ml tube and frozen at –80oC. 
 
2.10.2  BCA protein assay 
Protein concentration of homogenised tissue was determined using the bicinchoninic 
acid (BCA) protein assay kit (Pierce). The kit utilises the capacity of protein to 
reduce Cu2+ ions to Cu+ ions in an alkaline medium. Subsequently, the levels of Cu+ 
are detected in a colourimetric reaction with BCA. The purple-coloured reaction 
product formed by the chelation of one Cu+ ion with two molecules of BCA exhibits 
a strong absorbance at 562nm. The absorbance of the reaction product has a near-
linear relationship with increasing protein concentration, allowing for accurate 
detection of protein levels in the range of 20 to 2000 μg/ml. 
 
A standard curve ranging from 20 to 1500 μg/ml was prepared in triplicate using 
bovine serum albumin (BSA, 2000μg/ml) diluted in homogenisation buffer. 50 parts 
of BCA reagent A (Sodium carbonate, sodium bicarbonate, bicinchoninic acid and 
sodium tartrate in 0.1M sodium hydroxide) was added to 1 part BCA reagent B (4% 
cupric sulphate) to form the BCA working reagent (WR). Homogenised tissue 
samples were removed from the freezer and thawed on ice. Triplicate dilutions of 
each sample (1:10 or 1:15) were prepared in homogenisation buffer. 50μl of each 
sample replicate or BSA standard was added to 1ml WR in a 1.5ml Eppendorf tube 
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and incubated for 30 minutes at 37oC. The tubes were allowed to cool to room 
temperature. The reaction product was aliquoted into spectrophotometer cuvettes and 
the absorbance measured at 562nm. The protein concentration of each unknown 
sample was calculated from the standard curve.  
 
2.10.3  SDS-PAGE electrophoresis 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) allows 
separation of polypeptides based on molecular weight rather than intrinsic electrical 
charge. SDS is an anionic detergent that denatures the polypeptide backbone, 
destabilises hydrogen bonds and unfolds tertiary and secondary structures. SDS binds 
to protein in a ratio of approximately 1.4g SDS to 1g protein, and therefore imparts a 
net negative charge in proportion to polypeptide length. Addition of a reducing agent 
such as 2-mercaptoethanol breaks disulphide bonds, which converts the protein into a 
linear structure with a uniform negative charge.  
 
SDS-PAGE electrophoresis was carried out using a Mini-PROTEAN II 
electrophoresis cell (BioRad).  The glass plates were thoroughly cleaned in 70% 
ethanol and distilled water before use.  The longer rectangular plate was laid on a flat 
surface, and two spacers placed along the short edges of the plate.  The shorter plate 
was laid on top of the spacers to form the glass plate sandwich.  The sandwich was 
slid into the clamp assembly and aligned so that the sandwich and the assembly were 
flush against a flat surface.  The screws on the clamp assembly were tightened to 
secure the sandwich.  The assembly was transferred to the casting stand for gel 
casting.  A comb was placed into the gel sandwich and a mark made 0.5 cm below 
the teeth of the comb.  The comb was removed and the resolving gel pipetted in to 
the level of the mark.  SDS-saturated water was overlaid on top of the resolving gel 
to prevent it drying out.  The 10% polyacrylamide resolving gel was left to 
polymerise for 1 hour.  Following polymerisation, the SDS-saturated water was 
rinsed off with distilled water.  The 4% polyacrylamide stacking gel was pipetted on 
top of the resolving gel to the top of the sandwich and the comb inserted.  The 
stacking gel was left to polymerise for 45 minutes, and the comb was carefully 
removed.  The wells formed by the comb were rinsed with running buffer and the 
 73
gels were transferred from the casting stand to the inner cooling core.  The inner 
cooling core was placed into the Mini-PROTEAN II electrophoresis cell and the 
upper and lower buffer chambers were filled with the required amount of 1X running 
buffer.  20μg of protein homogenate was prepared to a volume of 10μl in the 
appropriate homogenisation buffer.  An equal volume of 2-mercaptoethanol in 
Laemmli sample buffer (1:9 ratio) was added to each protein sample and boiled at 
>95oC for 5 minutes in order to denature the protein.  The samples were spun down 
before loading.  The protein samples were loaded into each well.  A pre-determined 
molecular weight marker was loaded into one well.  The lid was placed on top of the 
cell, attached to a power supply and run at 60mA for 45 minutes. 
 
2.10.4  Protein transfer 
After separation of the protein sample by SDS-PAGE electrophoresis, the proteins 
were transferred to a membrane in a pattern replicating the original separation. The 
transferred membrane has a number of advantages to the original gel. The proteins 
are concentrated on the surface of the membrane rather than spread throughout the 
thickness of the gel, allowing easier detection via antibodies. Membranes are easier 
to handle than gels, and permit stripping and reprobing with different antibodies. 
Finally, the membrane provides a permanent record of the original gel. 
Polyvinylidene difluoride (PVDF) membranes are commonly used for transfer, as 
they offer a high protein binding capacity and are physically and chemically stable. 
 
Once the gel had finished running, the sandwich plate was disassembled and the 
stacking gel cut away.  The resolving gel was floated into transfer buffer and left to 
equilibrate for at least 15 minutes.  The PVDF membrane and filter paper were cut to 
the dimensions of the gel.  The filter paper and fibre pads were soaked in transfer 
buffer and the PVDF membrane activated by soaking in methanol. The transfer 
sandwich was assembled as shown in Figure 2.6, so that the proteins would transfer 
towards the anode and bind to the PVDF membrane.  Care was taken to ensure no air 
bubbles were present in the transfer sandwich.  The cassette was closed and placed in 
the transfer tank containing transfer buffer.  The Bio-Ice cooling unit and a magnetic 
stirrer were added to the tank.  The transfer buffer was stirred at a high speed in order 
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keep the ion distribution even.  The lid was placed on top of the cell, attached to a 
power supply and transferred at 30V overnight. 
 
2.10.5  Coomassie Blue staining 
After transfer, the acrylamide gel was stained in Coomassie blue (BioRad) in order to 
check for equivalent loading of protein samples.  The gel was immersed in 
coomassie blue and agitated on a rotary shaker for 1 hour.  The coomassie blue stain 
was removed, and the gel destained in 10% methanol / 10% acetic acid overnight.  
An image was captured of the stained gel the following day. 
 
2.10.6  Western blotting 
Following transfer, the membrane was removed and marked for reference.  The 
membrane was washed in 0.1% Tween 20 in PBS (PBS-T) at room temperature, 
before blocking in 10% non-fat dried milk in PBS-T overnight at 4oC.  All washing 
and incubation steps took place on an orbital shaker.  After blocking, the membrane 
was rinsed in PBS-T before application of the primary antibody (Table 2.3) diluted in 
10% non-fat dried milk in PBS-T.  The membrane was incubated in primary 
antibody for 1-2 hours at room temperature.  Following primary antibody incubation, 
the membrane was rinsed, and then washed for 3 x 5 minutes in PBS-T.  The 
membrane was incubated in the appropriate HRP-labelled secondary antibody (Table 
2.3) was diluted in 5% non-fat dried milk in PBS-T for 1-2 hours at room 
temperature, after which the membrane was rinsed and then washed 3 x 5 minutes in 
PBS-T. 
 
Enhanced chemiluminescent (ECL) detection is a non-radioactive, highly sensitive 
and high-resolution method for detecting immobilized specific antigens conjugated 
to a HRP antibody.  An equal volume of ECL detection solution 1 was mixed with 
detection solution 2 to obtain sufficient volume to cover the membranes.  The 
membrane was drained of PBS-T and placed on a flat surface, protein side up and 
incubated in ECL reagent for 1 minute.  Excess ECL reagent was drained off, and the 
membrane placed protein side down on a clean piece of cling film, wrapped up and 
air bubbles smoothed out using a glass rod.  The wrapped membranes were taped 
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down, protein side up in an X-ray film cassette and transferred to a dark-light room. 
A sheet of autoradiography film (Hyperfilm ECL, Amersham) was placed on top of 
the wrapped membrane and the cassette closed for 15 seconds.  The film was then 
removed and exposed using an automatic developer.  Depending on the appearance 
of the first film, subsequent films were exposed to the membrane for varying times 
and developed. 
 
2.10.7  Membrane stripping 
Following ECL detection, membranes were stripped to remove primary and 
secondary antibodies in order to re-probe with a different antibody. An acidic pH 
solution alters the structure of the antibody so that the binding site is no longer 
active. Membranes were submerged in stripping solution (25mM Glycine-HCL, 1% 
w/v SDS, 0.1% Tween 20, pH 2.2) on an orbital shaker at room temperature for 1 
hour. Membranes were then thoroughly washed for 3 x 5 minutes using large 
volumes of PBS-T. The membrane was then blocked in 10% non-fat dried milk in 
PBS-T before reprobing. 
 
2.10.8  Image analysis 
Developed films were visualised on a stable intensity desktop illuminator and bands 
were semi-quantified by measuring their Relative Optical Density (R.O.D.) using an 
AIS Image Analyser system (Imaging Research, Canada). Readings were normalised 
to background levels. 
 
2.11  Statistics 
Differences between two groups were assessed using the non-parametric Mann-
Whitney U test. Differences between three groups were assessed using the non-
parametric Kruskal-Wallis test and followed with Dunn’s post-test. Non-parametric 
tests were chosen due to the fact that data obtained following global ischaemia does 
















































































































































































































































































































































































































Assembly of the gel transfer sandwich
Negatively charged proteins transfer from the gel towards the positive anode and 














Characterisation of neural stem cell grafts 
in a mouse model of global ischaemia 
3.1   Introduction 
The “proof of principle” of neural stem cell transplantation as a therapy for brain 
damage has been shown by a number of different groups and with a variety of NSC 
lines. MHP36 grafts have been shown in rats to reverse age-associated deficits in 
spatial learning and memory as assessed by the water maze (Hodges et al., 2000), 
resolve motor associated deficits and reduce lesion volume following transient 
intraluminal middle cerebral artery occlusion (Veizovic et al., 2001, Modo et al., 
2002, Modo et al., 2002).  Following transplantation into lesioned primate brain, 
MHP36 grafts were shown to be as functionally effective as foetal grafts in 
promoting recovery (Virley et al., 1999).  MHP36 cells have been shown to migrate 
across the corpus callosum towards an ischaemic lesion induced by tMCAo 
(Veizovic et al., 2001) and differentiate into site appropriate phenotypes (Modo et 
al., 2002).   
 
The majority of studies to date have examined the survival and migration of stem 
cells in response to a focal injury (Veizovic et al., 2001, Kelly et al., 2004, Saporta et 
al., 1999, Riess et al., 2002).  However, if the effectiveness of these stem cells is to 
be realised in human neurodegenerative diseases then it would be advantageous to 
characterise these cells in models of diffuse neuronal injury. Additionally, 
mechanisms of stem cell mediated recovery have yet to be elucidated. It is also 
possible that transplanted stem cells may also interact with various genetic factors. 
The investigation of stem cell transplants in genetically modified mice would provide 
an insight into selective genetic influences, and build on the information gained so 
far from studies utilising non-transgenic rat and primate models.  In order to extend 
from the information obtained for neural stem cell studies in rat models, the first step 
would be to characterise neural stem cell grafts in a mouse model of diffuse neuronal 
injury. It is also important to verify whether the use of CsA immunosuppression has 
a significant effect on stem cell transplantation. Whilst CsA immunosuppression is 
commonly used clinically in order to prevent graft rejection during organ and bone 
marrow transplantation, chronic administration of CsA results in nephrotoxic side-
effects. It has been demonstrated that CsA treatment did not influence the 
lymphocyte proliferation or expression of immune markers following MHP36 
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transplantation in a rat model of focal ischaemia (Modo et al., 2002). It will be 
interesting to discover whether the low immunogenicity of MHP36 cells is also 
evident in a mouse model of brain injury.  
 
3.2   Aim 
The aim of the study was to characterise neural stem cell grafts in a mouse model of 
diffuse neuronal injury induced by global ischaemia. We determined whether 
MHP36 grafts influenced the extent of ischaemic neuronal damage and the effects of 
the immunosuppressive agent cyclosporin A on graft survival, migration, 
differentiation and the host inflammatory response.  Mice were assessed at a short-
term (1 week) and long-term (4 week) time point post-transplantation.   
 
3.3   Materials and Methods 
 
3.3.1   Animals 
Adult male C57Bl/6J mice weighing between 25-30g were purchased from Charles 
River.  Animals were communally housed on a twelve-hour light/dark cycle with free 
access to food and water.  All procedures were carried out under licence from the 
Home Office with the approval of the University of Edinburgh Ethical Review Panel 
and subject to the Animals (Scientific Procedures) Act 1986. 
 
3.3.2   Bilateral common carotid artery occlusion 
Dr Karen Horsburgh carried out the BCCAo procedure.  Transient global ischaemia 
was induced by bilateral occlusion of the common carotid arteries for 17 minutes.  
This duration of ischaemia is associated with moderate and reproducible neuronal 
damage in the caudate nucleus.  The procedure is described in detail in Chapter 2, 
Section 2.2. 
 
3.3.3   Immunosuppression 
Starting two days post-ischaemia, mice received daily injections of CsA (n = 21) 
(kindly donated by Novartis, 10mg/kg in saline, s.c.) or the equivalent volume of 
sterile saline (n = 25), for up to two weeks or until perfusion.  
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3.3.4   MHP36 stem cell transplantation 
MHP36 cells were obtained as a gift from ReNeuron Ltd.  They were cultured from 
frozen stock and maintained in an undifferentiated state at 33oC.  (Passage number 
52-70).  Before grafting, cells were labelled with the membrane bound fluorescent 
marker PKH26 (Sigma).  Labelled cells were suspended in 0.5 mM N-acetyl-L-
cysteine (NAC) in Hank’s balanced salt solution without Ca2+ or Mg2+ at a 
concentration of 25,000 cells/µl. Cells were aspirated to form a single cell suspension 
and checked for incorporation of the PKH26 label prior to grafting.  Vehicle grafted 
mice received injections of NAC solution.  Viability was assessed using trypan blue 
exclusion in a haemocytometer.  Pre-graft viability averaged 90% and post-graft 
viability averaged 76%.  Three days post-ischaemia, mice received a unilateral 
striatal graft of either MHP36 neural stem cells (n = 25) or vehicle (n = 21) as 
described in Chapter 2, Section, 2.3.   
 
3.3.5   Histology 
After 1 (n = 24) or 4 weeks (n = 22) post-transplantation, mice were transcardially 
perfused as described in Chapter 2, Section 2.5.  The brains were post-fixed, 
cryoprotected in 30% sucrose and frozen by rapid immersion into liquid nitrogen.  
Coronal cryostat sections (10μm) were mounted onto poly-L-lysine coated slides.  
Sections at the level of the injection tract were stained with haematoxylin and eosin 
in order to visualise ischaemic neurons.  Adjacent sections were mounted in 
Vectashield (Vector, UK) for fluorescent visualisation of MHP36 cells or processed 
for immunohistochemistry.  
 
3.3.6   Quantification of ischaemic damage 
Haematoxylin and eosin stained sections were used to assess the extent of ischaemic 
damage in the same fields used to quantify the immune response using a 25mm2 grid 
(attached to the microscope optics) at 400x magnification.  The number of neurons 
exhibiting ischaemic cell change and morphologically normal neurons were counted 
in each grid.  Ischaemic neurons were defined by an intense, darkly stained pyknotic 
nucleus surrounded by eosinophilic cytoplasm.  The use of organic solvents in the 
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haematoxylin and eosin stain extracts the PKH26 fluorescent label from the 
membrane, preventing visualisation of ischaemic neurons and PKH26 labelled cells 
on the same section.   
 
3.3.7   Quantification of MHP36 graft survival and migration 
Sections were assessed for MHP36 graft survival at three areas, the injection tract, 
corpus callosum and caudate nucleus.  Two fields were assessed per area using a 
100mm2 grid (attached to the microscope optics) at 200x magnification.  Two 
sections were analysed per animal.  MHP36 graft survival was semi-quantitatively 
assessed based on the extent of red fluorescence on the stem cells with PKH26 
labelling.  The degree of cellular red PKH26 fluorescence based on percentage 
coverage of the grid was assessed using a scoring system as follows; 0, no labelled 
cells, 1, <25% labelled cells, 2, 25-50% labelled cells, 3, 50-75% labelled cells, 4, 
>75% PKH26 labelled cells.  Migration of PKH26 labelled MHP36 cells was 
assessed in a medial, lateral and ventral direction away from the injection tract.  The 
distance of migration in each direction was measured using a 100mm2 grid (attached 
to the microscope optics) at 200x magnification. 
 
3.3.8   Immunohistochemistry 
The inflammatory response was assessed using two antibody markers, that recognise 
reactive astrocytes (mouse monoclonal anti-human GFAP) or microglia / 
macrophage (rat anti-mouse F4/80).  Neuronal differentiation of MHP36 cells was 
assessed using a marker for neuronal nuclei (mouse monoclonal anti-NeuN).  The 
ApoE response was assessed using a marker for ApoE (Goat anti-human apoE).  The 
immunohistochemistry protocol is described in Chapter 2, Section 2.8. 
 
3.3.9   Quantification of immune response 
Sections were assessed for GFAP, F4/80 and ApoE immunoreactivity in 6 different 
fields in the caudate nucleus using a 100mm2 grid (attached to the microscope optics) 
at 400x magnification.  Two sections were analysed per animal, and in each section 
the grid was positioned throughout the caudate nucleus such that medial, dorsal, 
ventral and lateral aspects of the nucleus were sampled.  GFAP positive reactive 
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astrocytes with defined cell bodies and processes were counted within each grid.  
Individual microglia / macrophage were difficult to define with precision and thus a 
semi-quantitative assessment was used.  The degree of F4/80 immunostaining based 
on percentage coverage of the 100mm2 grid was assessed using a scoring system as 
follows; 0, no staining, 1, < 25% staining, 2, 25-50% staining, 3, 50-75% staining, 4, 
> 75% staining. ApoE-positive cells were counted within each grid. 
 
3.3.10  Immunofluorescent analysis 
Sections were assessed for co-localization of phenotypic markers for neurons (NeuN) 
and microglia / macrophage (F4/80) with PKH26 as a marker for transplanted 
MHP36 cells in 4 different fields in the caudate nucleus using a confocal laser 
scanning microscope (Zeiss).  Neuronal differentiation was determined by counting 
the number of cells co-localizing with PKH26 after counting the number of PKH26 
positive cells within the same field. In addition, confocal laser microscopy was used 
to assess the co-localisation of PKH26 labelled cells with the DNA marker To-pro-3.  
 
3.3.11  Statistical analyses 
Differences in the extent of ischaemic damage between vehicle and MHP36 grafted 
animals were assessed using the Mann-Whitney U-test.  Differences in the 
percentage of PKH26 positive cells co-localizing with NeuN between saline and CsA 
treated mice were assessed using the Mann-Whitney U-test.  For multiple 
comparisons, the Kruskal–Wallis test followed by Dunn’s post test was used to test 
statistical differences in MHP36 graft survival, migration, GFAP, F4/80 and ApoE 
immunoreactivity between saline and CsA treated animals and between 1 week and 4 
week mice.  Correlations between MHP36 graft survival and migration to ischaemic 




3.4   Results 
 
3.4.1   Ischaemic damage 
At 1 week post-transplantation (Figure 3.1), there was a statistically significant 
reduction in the percentage of ischaemic neurons in MHP36 grafted mice as 
compared to vehicle grafted mice treated with saline (vehicle; 34 % ± 4.6 % vs. 
MHP36; 26 % ± 4.3 % ischaemic neurons, p = 0.0013).  There was no difference in 
the percentage of ischaemic neurons in MHP36 grafted mice as compared to vehicle 
grafted mice treated with CsA at 1 week (vehicle; 30 % ± 4.2 % vs. MHP36; 38 % ± 
5.9 % ischaemic neurons, p > 0.05).  At 4 weeks post-transplantation (Figure 3.1) 
there was no significant difference in ischaemic neuronal damage between MHP36 
and vehicle grafted mice treated with saline (vehicle; 34 % ± 6.1 % vs. MHP36; 26 
% ± 24 %, p > 0.05).  However, it was noted that one of the MHP36 grafted mice 
exhibited a marked increase in ischaemic neuronal damage as compared to the other 
5 MHP36 grafted mice and 5 vehicle mice.  MHP36 grafted mice treated with CsA 
exhibited a statistically significant reduction in ischaemic neuronal damage 
compared to vehicle mice (vehicle; 41 % ± 23 % vs. MHP36; 13 % ± 7.9 %, p = 
0.0173). Representative images of normal and ischaemic neurons are shown in 
Figure 3.2.   
 
3.4.2   MHP36 graft survival and migration 
MHP36 cells were labelled with a red fluorescent marker, PKH26, which delineates 
the membrane with red punctate staining in order to facilitate visualisation post-
transplantation.  Transplanted PKH26 labelled MHP36 cells were clearly detected at 
both 1 and 4 weeks post-transplantation.  There were no fluorescent cells observed in 
vehicle-grafted mice (Figure 3.3).  
 
At 1 week post-transplantation, PKH26 labelled MHP36 cells were observed 
predominantly in the injection tract with fewer cells in the caudate nucleus and 
corpus callosum.  CsA immunosuppression had no statistically significant effect on 
graft survival at this time point in any of the regions examined (Figure 3.4).  At 4 


















































MHP36 grafts reduce the extent of ischaemic neuronal damage
Percentage of ischaemic neuronal damage in vehicle and MHP36 grafted mice at 
1 week (A) and 4 weeks (B) post-transplantation in saline and CsA
 
treated mice. 










Representative images of normal and ischaemic neurons, reactive 
astrocytes
 
and macrophage / microglia
 
immunostaining
(A-B)  Comparison of haematoxylin and eosin stained tissue from the
 
caudate nucleus 
from vehicle (A) and MHP36 grafted (B) mice at 1 week post-transplantation.  Ischaemic 
neurons are clearly identified by the intensely stained pyknotic
 
nucleus surrounded by 
eosinophilic
 
cytoplasm (arrows).  Scale bar = 20μm. 
(C-D)  Comparison of GFAP stained tissue from the caudate nucleus from vehicle (C) 
and MHP36 grafted (D) mice at 1 week post-transplantation.  The number of GFAP 
positive reactive astrocytes
 
(brown) is similar in both vehicle and MHP36 grafted mice.  
The number of reactive astrocytes
 
decreases in both vehicle and MHP36 grafted mice 
over time.  Scale bar = 20μm. 
(E-F)  Comparison of F4/80 stained tissue from the caudate nucleus from vehicle (E) 





in MHP36 grafted mice compared to vehicle 
grafted mice.  Sections were counterstained with haematoxylin.  Scale bar = 20μm. All 
















Visualisation of PKH26-labelled MHP36 cells
(A-B) Comparison of the injection tract after vehicle (A) and MHP36
 
cell (B) injection at 4 weeks post-
 
transplantation.  Scale Bar = 100μm.  There is no fluorescence visible along the injection tract in the 
vehicle treated mouse, whilst in the MHP36 grafted mouse the injection tract is clearly labelled with red 
PKH26 fluorescence, indicating the presence of labelled MHP36 cells.  Both mice received CsA
 
immunosuppression.  No difference was observed with saline-treated animals. At a higher
 
 
magnification, MHP36 cells labelled with PKH26 are visible in the corpus callosum
 
(C) and the caudate 
nucleus (D) at 4 weeks post-transplantation. Scale bar = 10μm.  
Transplanted MHP36 cells (PKH26, red label) are shown in (F) and
 
in the same section neurons are 
identified (E) with a neuronal nuclei marker (NeuN, green label) at 4 weeks post-transplantation.  The 
merged image shows the distribution of membrane bound PKH26 around the neuronal nucleus (G).  (E-
 
G Scale bar = 10μm).  Transplanted MHP36 cells (PKH26, red label) co-localise with a nuclear DNA 
stain (To-pro-3, blue label) at 1 week post-transplantation (I). In the same section 
microglia/macrophage (H) are identified (F4/80, green label).  The merged
 
image (J) indicates that the 
MHP36 cells do not co-localise with microglia/macrophage. (H-J, Scale bar = 20μm). 
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the regions.  There was no statistically significant effect on MHP36 graft survival by 
CsA immunosuppression in any of the regions examined 4 weeks post-
transplantation (Figure 3.4).  There was no significant difference in the extent of cells 
surviving in any of the regions at 4 weeks as compared to 1 week post-
transplantation.  However, there was a visible trend towards a reduction in the extent 
of cells surviving within the injection tract at 4 weeks post-transplantation as 
compared to 1 week post-transplantation, in conjunction with an increase in the 
extent of cells surviving within the surrounding caudate nucleus and corpus 
callosum. 
 
Migration of MHP36 cells occurred in a medial, lateral and ventral direction away 
from the injection tract.  At 1 week post-transplantation, the distance migrated was 
variable between the individual mice and ranged from 0.1 to 0.8 mm.  The cells 
migrated a similar distance in all directions (Figure 3.5).  CsA immunosuppression 
did not significantly affect the migration of MHP36 cells in any direction (p > 0.05).  
Similarly at 4 weeks post-transplantation there was no statistically significant effect 
of CsA immunosuppression on cell migration in any direction (p > 0.05) (Figure 
3.5).  Although not statistically significant, the cells displayed a trend to migrate 
further at 4 weeks post-transplantation in comparison to 1 week post-transplantation.  
No MHP36 cells were detected in the hemisphere contralateral to the injection 1 
week or 4 weeks post-transplantation.  There was no significant correlation between 
the extent of ischaemic damage and the extent of graft survival or migration. 
 
3.4.3   Neuronal differentiation of MHP36 cells 
PKH26 labelled MHP36 stem cells were co-localised with the neuronal nuclei 
marker NeuN in the caudate nucleus at both 1 week and 4 weeks post-transplantation 
(Figure 3.3).  Approximately 50% of PKH26 labelled MHP36 cells co-localized with 
NeuN, in both saline and CsA treatment groups at both 1 week and 4 weeks post-
transplantation  (Figure 3.6). There was no statistical difference between saline and 
CsA treated mice in the percentage of PKH26 labelled MHP36 stem cells co-










































Robust survival of MHP36 cells
MHP36 cell survival as assessed by grading PKH26 fluorescently labelled cells at 
1 week and 4 weeks post-transplantation with saline and CsA
 
treatment. There 





did not statistically affect the 


























Migration of MHP36 cells
Distance migrated (mm) by MHP36 cells at 1 week and 4 weeks post-
 
transplantation with saline and CsA
 
treatment.  Data are expressed as a 
scattergram
 
(A) and as a bar graph (B). Migration was assessed in medial, lateral 
and ventral directions from the injection tract. There was a trend towards an 












































































Neuronal differentiation of MHP36 cells
Percentage of PKH26 labelled MHP36 stem cells co-localising with NeuN
 
at 1 week 
(A) and 4 weeks (B) post-transplantation in saline and CsA
 
treated mice.  There 
was no statistical difference between saline and CsA
 
treated mice at both 1 week 




3.4.4   Astrocytic response 
At 1 week post-transplantation, in vehicle grafted mice that underwent global 
ischaemia there were reactive astrocytes predominantly at the site of needle injection 
and to a lesser extent in the caudate nucleus (Figure 3.7).  Representative images of 
reactive astroctyes are shown in Figure 3.2. In MHP36 grafted mice, reactive 
astrocytes were evident in the injection site but also along the corpus callosum and in 
the caudate nucleus, mirroring the location of the MHP36 stem cells.  There was a 
trend towards an increase in reactive astrocytes in MHP36 grafted mice as compared 
to vehicle, although this did not achieve statistical significance.  There was no 
significant difference in the number of reactive astrocytes between CsA and saline 
treated mice that received MHP36 grafts (p > 0.05) or vehicle (p > 0.05).  Similarly, 
at 4 weeks post-transplantation, there was no significant difference in the number of 
reactive astrocytes between CsA and saline treated mice that received MHP36 grafts 
(p > 0.05) or vehicle (p > 0.05).  However, the number of reactive astrocytes 
significantly decreased at 4 weeks compared to 1 week in three groups (MHP36 
grafted mice treated with CsA, p < 0.05, MHP36 grafted mice treated with saline, p < 
0.05, vehicle grafted mice treated with CsA, p < 0.05) There was no statistically 
significant decrease in the number of reactive astrocytes between 1 and 4 weeks in 
vehicle grafted mice treated with saline (p > 0.05) (Figure 3.7). MHP36 cell survival 
and migration did not correlate with the number of astrocytes in any treatment group. 
 
3.4.5   Microglial and macrophage response 
At 1 week post-transplantation, MHP36 grafted mice expressed microglial 
aggregates and macrophage along the injection tract and in the caudate nucleus with 
a lesser degree of staining in the corpus callosum.  Representative images of 
macrophage and microglia are shown in Figure 3.2. Vehicle grafted mice exhibited a 
diffuse stain along the injection tract, with few microglia in the caudate nucleus or 
corpus callosum.  There was no statistically significant difference in the number of 
microglia / macrophage between CsA and saline treated mice that received MHP36 
grafts (p > 0.05) (Figure 3.8).  However, there was a significant increase in the 
number of microglia / macrophage in MHP36 grafted mice as compared to vehicle 





































MHP36 grafts do not influence reactive astrocytosis
Number of GFAP positive reactive astrocytes after vehicle or MHP36 cell injection 
and receiving saline or CsA
 
treatment at 1 week and 4 weeks post-
 
transplantation. At both time points, there are no statistically
 
significant 
differences between saline and CsA
 
treated mice receiving either vehicle of 
MHP36 grafts.  Mice examined at 1 week post-transplantation exhibit more 
reactive astrocytes compared to mice examined at 4 weeks in all treatment 
groups (Kruskal-Wallis test with Dunn’s post test, MHP36 grafted mice treated 
with CsA
 
* p < 0.05, MHP36 grafted mice treated with saline * p < 0.05, vehicle 
grafted mice treated with CsA
 








































MHP36 grafts influence microglial
 
immunoreactivity
Grade of F4/80 positive microglia
 
after vehicle or MHP36 cell injection and 
receiving saline or CsA
 
treatment at 1 week and 4 weeks post-transplantation. At 
both time points, there are no statistically significant differences between saline 
and CsA
 
treated mice receiving either vehicle or MHP36 grafts.
 
There is 
significantly increased expression of F4/80 staining at 1 week in MHP36 grafted as 
compared to vehicle grafted mice treated with saline (Kruskal-Wallis test with 





mice although this was not statistically significant.  This response was not present 
at 4 weeks transplantation when there was no significant difference in the extent of 
F4/80 immunoreactivity
 
between vehicle and MHP36 grafted mice.  MHP36 grafted 
mice treated with saline exhibit significantly reduced expression of F4/80 staining 
at 4 weeks compared to 1 week post-transplantation (Kruskal-Wallis test with 





CsA treated mice, although this was not statistically significant (p > 0.05) (Figure 
3.8).  At 4 weeks post-transplantation, microglia / macrophage staining was distinctly 
localised to the injection tract, with only occasional microglia present in the caudate 
nucleus.  There was no statistically significant difference in the number of microglia 
/ macrophage between CsA and saline treated mice that received MHP36 grafts or 
vehicle (p > 0.05).  There was a statistically significant reduction in the number of 
microglia / macrophage between 1 and 4 weeks in MHP36 grafted mice treated with 
saline (p < 0.01) although no significant reduction was observed in CsA treated mice 
(Figure 3.8).  MHP36 cell survival and migration did not correlate with the number 
of macrophage or microglia in any treatment group (1 week: Saline treated; p = 
0.665, r =0.18, CsA treated; p = 1.050, r = 0.00. 4 weeks: Saline treated; p = 0.297, r 
= -0.508, CsA treated; p = 0.419, r = 0.403).  In addition, co-localisation of PKH26 
staining with the DNA marker, To-pro-3, demonstrated that the PKH26 label 
delineated the membrane of To-pro-3 labelled cells. This was observed at both 1 
week and 4 weeks post-transplantation (Figure 3.3). The compressed image of triple 
co-localisation with To-pro-3, PKH26 and F4/80 (Figure 3.3J) suggests that some 
MHP36 cells may be phagocytosed by macrophage. However, examination of the 
individual confocal z-sections indicated that there was minimal co-localisation of 
PKH26 labelled MHP36 stem cells with F4/80 labelled microglia/macrophage in the 
caudate nucleus at either 1 week or 4 weeks transplantation, suggesting that the 
majority of MHP36 cells did not undergo phagocytosis. 
 
3.4.6   ApoE immunoreactivity 
At 1 week post-transplantation, apoE positive cells were evident along the injection 
tract and within the caudate nucleus.  There was a trend towards a reduction in the 
number of apoE positive cells between CsA and saline treated mice that received 
vehicle grafts, although this was not statistically significant (p > 0.05) (Figure 3.9).  
ApoE expression was highly variable between animals. There was no significant 
difference in the number of apoE positive cells between CsA and saline treated mice 
that received MHP36 grafts (p > 0.05) (Figure 3.9).  At 4 weeks post-transplantation, 
apoE positive cells were still visible within the caudate nucleus.  At this time point, 
there was no significant difference in the number of apoE positive cells between CsA 
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and saline treated mice that received MHP36 grafts (p > 0.05) or vehicle (p > 0.05) 
(Figure 3.9).  There was a trend towards a reduction in the number of apoE positive 
cells at 4 weeks compared to 1 week post-transplantation, although this was only 
statistically significant in the group of MHP36 grafted mice treated with CsA. 
MHP36 grafts did not induce increased apoE expression compared to vehicle grafts 


































MHP36 grafts do not influence apoE
 
immunoreactivity
Number of ApoE positive cells after vehicle or MHP36 cell injection and receiving saline 
or CsA
 
treatment at 1 week and 4 weeks post-transplantation. At both time points, there 
are no statistically significant differences between saline and CsA
 
treated mice receiving 
either vehicle of MHP36 grafts. There is an overall trend towards reduced ApoE 
immunoreactivity
 
at 4 weeks post-transplantation as compared to 1 week post-
 
transplantation, although this is only statistically significant
 
in the MHP36 grafted mice 
treated with CsA.
Vehicle MHP36 Vehicle MHP36
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3.5   Discussion  
The present study aimed to characterise transplantation of the MHP36 neural stem 
cell line in a mouse model of diffuse neuronal damage induced by global ischaemia.  
MHP36 cells were demonstrated to survive and migrate in host ischaemic brain.  
Furthermore, MHP36 grafted mice exhibited a reduction in the extent of ischaemic 
damage as compared to vehicle grafted mice, associated with differentiation of 
MHP36 cells to a neuronal phenotype. 
 
In the present study, global ischaemia performed in C57Bl/6J mice by bilateral 
occlusion of the common carotid arteries for 17 min induced selective and delayed 
neuronal damage in the caudate nucleus.  The occlusion time of 17 min was chosen 
based on previous studies (Horsburgh et al., 1999, 2000) in order to produce 
moderate and reproducible levels of neuronal damage.  Grafting of stem cells took 
place three days following induction of global ischaemia, in order to intervene when 
the ischaemic damage is maximal (Kelly et al., 2001).  There are few prior studies 
investigating stem cell transplantation in global ischaemia.  Previous studies have 
utilised the rat four-vessel occlusion model of global ischaemia, which causes a 
reproducible, focused loss of pyramidal neurons in the hippocampal CA1 region 
(Saporta et al., 1999, Sinden et al., 1997), in contrast to the highly diffuse neuronal 
damage observed in the mouse BCCAo model.  Many other animal studies on neural 
stem cell transplantation have studied their effects in focal ischaemia models, 
associated with a unilateral infarct affecting all tissue elements (Kelly et al., 2004, 
Modo et al., 2002, 2002, Riess et al., 2002, Toda et al., 2001, Veizovic et al., 2001).  
Previous transplantation studies using MHP36 cells grafted into focal ischaemic rat 
brain have demonstrated the ability of these cells to migrate to the lesion site and 
reduce lesion volume (Veizovic et al., 2001).  The present study builds and extends 
on this work to provide novel information on the ability of MHP36 cells to survive, 
migrate, differentiate and reduce the extent of ischaemic damage in a model of 
diffuse neuronal injury.  This information is also relevant to the potential grafting of 
stem cells in human neurodegenerative diseases such as Alzheimer’s disease in 
which cell death is diffuse and widespread.   
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3.5.1 MHP36 grafts reduce the extent of ischaemic neuronal 
damage 
The results from this study indicated that the percentage of ischaemic neuronal 
damage was reduced in MHP36 grafted mice at both 1 week and 4 weeks post-
transplantation.  It is unlikely that this is a protective response and more likely that 
this is due to an increase in normal neurons within the area of damage.  The data 
indicate that transplanted MHP36 cells are able to express a neuronal phenotype and 
that approximately 50% of grafted MHP36 cells differentiate into neurons.  
Interestingly, this percentage is not affected by either saline treatment or CsA 
immunosuppression or at the time point observed.  MHP36 cells grafted following 
the 4VO rat model of global ischaemia primarily repopulated the lesioned CA1 field, 
with approximately 38% of grafted MHP36 cells expressing a neuronal phenotype 
(Hodges et al., 2000). Rapid expression of neuronal differentiation markers by 
MHP36 cells has been shown by Mellodew et al (2004), and is linked with 
downregulation of neural stem cell marker Nestin.  In the same study, approximately 
30-35% of grafted MHP36 cells differentiate into neurons in a quinolinic acid lesion 
model of damage (Mellodew et al., 2004) and a similar percentage was observed in a 
focal model of ischaemia (Modo et al., 2002).  In both these studies, transplantation 
of the MHP36 cells took place 2-3 weeks after the lesion, which may account for the 
reduced percentage of differentiated MHP36 cells observed as compared to our 
study.  The model of damage used may also affect the differentiation of transplanted 
MHP36 cells.  Global ischaemia induces selective neuronal damage, in contrast to 
the indiscriminate damage to all cell types caused by focal ischaemia.  Increased 
neuronal differentiation of MHP36 cells following global ischaemia suggests that the 
cells are able to selectively differentiate in response specific damaged environment.  
The extent of neuronal differentiation post-transplantation may also be cell-specific. 
For example, transplanted bone marrow stem cells undergo minimal neuronal 
differentiation (up to 2%) as demonstrated in a model of focal ischaemia, (Chen et 
al., 2001).  The present study illustrates the potential of stem cell therapy in a mouse 
model of global ischaemia and supports other studies on the cell replacement 




3.5.2 MHP36 stem cells survive and migrate in host ischaemic 
brain 
The results show that MHP36 grafts survive for up to 4 weeks in host ischaemic 
brain, and that they migrate over time.  These results support previous studies using 
the MHP36 neural stem cell line.  MHP36 grafts have been shown to survive for up 
to 20 weeks post-transplantation and repopulate the lesioned CA1 layer in global 
ischaemic rat brain (Sinden et al., 1997).  In other models of damage, MHP36 grafts 
migrate extensively to the infarcted hemisphere when transplanted into the intact 
hemisphere in a rat model of focal ischaemia (Veizovic et al., 2001).  Interestingly, 
MHP36 grafts migrated differently depending on the extent of damage in the 4VO rat 
model of global ischaemia. 15 minutes of 4VO resulted in primarily CA1 cell loss, 
with some variable damage in the striatum and frontal cortex. MHP36 cells were 
observed in the CA1 field as soon as 1 week after the injury, but few MHP36 cells 
were observed elsewhere. However, after 30 minutes of 4VO, CA1 hippocampal cell 
loss was more extensive, with the CA3 field also afflicted. The extent of striatal and 
cortical damage was also increased. In these rats, MHP36 cells densely engrafted 
both the CA1 and CA3 fields, with some cells also observed in the striatum and 
cortex. These results suggest that to some degree, migration of MHP36 cells is 
dependent on the severity of damage (Hodges et al., 2000).  
 
In our study, at 1 week post-transplantation, most MHP36 cells remained within the 
injection tract.  At 4 weeks post-transplantation, surviving MHP36 grafts have a 
different pattern of expression compared to 1 week grafts.  There were fewer MHP36 
cells present in the injection tract, with increased numbers of cells in the surrounding 
areas at 4 weeks post-transplantation.  Cells were observed in the caudate nucleus, a 
region that undergoes selective neuronal damage after global ischaemia, suggesting 
that the grafts were migrating in response to damage.  MHP36 cells were also seen 
along the corpus callosum.  Cells migrated away from the injection tract in medial, 
lateral and ventral directions to an average distance of 0.4mm.  Analysis of overall 
migration between the groups indicated a trend towards an increase in distance 
migrated at 4 weeks compared to 1 week post-transplantation.  Interestingly, the 
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furthest distance migrated by MHP36 cells in an individual mice was observed at 1 
week rather than 4 weeks post-transplantation.  This correlates with work showing 
that neural stem cells transplanted into intact rat striatum start migrating away from 
the injection tract at 3 days post-transplantation, reaching the maximal distance of 
1.5mm away from the injection tract at 5 days post-transplantation (Lundberg et al., 
1997).  The NSCs used by Lundberg et al., exhibited a similar radial pattern of 
migration to the MHP36 cells in our study.  Kelly et al., (2004) demonstrated similar 
findings with human neurospheres transplanted in and around the vicinity of the 
ischaemic core following distal MCAO.  Neurospheres survived up to 4 weeks post-
transplantation, and migrated up to 1.2 mm towards the lesion.  Migration was lesion 
dependent in this study, with neurospheres migrating a distance of 0.2mm in non-
lesioned rats.  Chu et al., (2003), subjected rats to transient global cerebral ischaemia 
and then injected NSCs intravenously into the tail vein.  These NSCs were observed 
in the damaged hippocampus at 56 days post-injection, suggesting that migratory 
cues from global ischaemic damage are able to target stem cell migration from the 
bloodstream towards the brain.  It should be noted that all of these studies used the 
rat as the graft recipient and comparisons between migration distances should take 
into account the size differences between mouse and rat brain.   
Although global ischaemia induces bilateral neuronal damage, no MHP36 cells were 
observed in the contralateral hemisphere.  However, as the graft was placed in one 
damaged hemisphere, the grafted cells may predominantly remain in that region as 
previously shown (Modo et al., 2002).  Migration of MHP36 cells along the corpus 
callosum was observed and this may be indicative of early migration to the 
contralateral hemisphere. Longer survival periods post-transplantation may 
determine whether cells can migrate to the contralateral hemisphere.  MRI mapping 
of transplanted MHP36 cells after transient global ischaemia in the rat demonstrated 
migration from the injection tract along the corpus callosum towards the contralateral 
hemisphere by 7 days post-transplantation, suggesting that the MHP36 cells are 
capable of migrating in a bilateral lesion model (Modo et al., 2002).  It should be 
noted that Modo et al., grafted stem cells above the hippocampus, which may have 
facilitated migration along the corpus callosum in contrast to the present study in 
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which MHP36 cells were transplanted in to the caudate nucleus, thereby potentially 
impeding the migration. 
One caveat which should be considered is the limitation of PKH26 staining as a 
method of detecting transplanted cells. As not all of the MHP36 cells will survive the 
graft procedure, it is possible that the PKH26 label will leach out of these dead cells 
into the surrounding environment or be taken up into phagocytosing macrophage. 
Similarly, MHP36 cells that undergo cell division will have half the fluorescence 
intensity of the parent cell. This raises the issue of whether it is possible to accurately 
identify intact, viable MHP36 cells via the PKH26 label and use of fluorescent 
microscopy. In order to address these issues, we have used a To-pro-3 counterstain 
for labelling of nuclear DNA. MHP36 cells can therefore be identified via a To-pro-3 
positive nuclei and a PKH26 delineated cell membrane. Staining with the 
microglia/macrophage marker F4/80 also suggests that the majority of PKH26 
labelled MHP36 cells survive in the host brain and are not phagocytosed by 
macrophage. Unfortunately, current attempts to insert a green fluorescent protein 
(GFP) tag into the MHP36 cell line have not been successful due to gene silencing 
(Professor J. Price, Personal communication).  
 
3.5.3 MHP36 stem cell grafts provoke a mild acute host 
inflammatory response 
In this study, there were a number of mechanisms by which the inflammatory 
response (as visualised by reactive astrocytes, microglia and macrophage) could be 
modified including the effects of global cerebral ischaemia and needle injection.  
Additionally, the MHP36 cells are derived from the H-2Kb-tsA58 transgenic mouse, 
which was generated on a CBA/Ca x C57BL/10 background.  The H-2Kb 
histocompatibility of the MHP36 cells may provoke a mild inflammatory response in 
the H-2B C57BL/6J host.  Reactive astrocytes were present in all treatment groups 
associated with the effect of global ischaemia.  However a localised glial scar in both 
MHP36 grafted and vehicle mice indicated that injury caused by physical insertion of 
the syringe had additionally induced an inflammatory response.  Furthermore, there 
was an elevation in reactive astrocytosis and in particular a marked increase in 
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microglia / macrophage in MHP36 grafted mice as compared to vehicle mice 
indicating that the MHP36 cells evoked a further inflammatory response.  
Interestingly, this extensive inflammatory response decreased dramatically at 4 
weeks post-transplantation to levels approaching that of vehicle mice.  This suggests 
that the MHP36 cells are no longer recognised as foreign by host microglia and 
macrophage and are indicative of an acute, rather than a chronic inflammatory 
response. It may be that the heightened sensitivity of the host brain following the 
major inflammatory actions of global ischaemia and syringe injection are the cause 
for the increased response to the MHP36 stem cells. In addition, there was no 
fluorescent co-localisation of macrophage with MHP36 stem cells, indicating that 
these cells were not undergoing phagocytosis.  Taken together, these results suggest 
that MHP36 grafts do not induce a marked and prolonged inflammatory response in 
host ischaemic mouse brain. A previous study on the immunological response 
induced by MHP36 grafts following a rodent model of focal ischaemia suggested 
that MHP36 stem cells have low immunogenic properties (Modo et al., 2002). The 
extent of immune response elicited by MHP36 grafts was investigated through a 
lymphocyte proliferation assay, grading of graft survival and expression of immune 
response markers. The trauma induced by focal ischaemia resulted in increased 
lymphocyte proliferation and upregulation of the immune markers MHC Class I, 
CD45 and CD11b around the injection tract. In particular, MHC Class I expression 
paralleled that of the glial scar produced from the syringe induced trauma, similar to 
the expression of microglial F4/80 observed in our study. Importantly, this pattern of 
immunoreactivity was not affected by MHP36 stem cell grafts, strongly suggesting 
that the host inflammatory response was directed against the focal ischaemic insult 
and the physical act of grafting. These results confirm the findings from our study 
that MHP36 stem cell grafts do not provoke a significant immune response from host 
brain. 
 
Microglial inflammation has been shown to have a varying effect on NSC grafts.  
The pro-inflammatory effects of microglia have been well documented (Vilhardt et 
al., 2005) with graft rejection strongly associated with macrophage and microglial 
infiltration (Duan et al., 1995).  Kelly et al., (2004) demonstrated a clear negative 
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correlation between graft survival and the number of IB4 positive inflammatory 
cells, with improved graft survival observed following transplantation into non-
ischaemic tissue rather than into the ischaemic core.  In the present study there was 
no correlation between graft survival or migration with the extent of the 
inflammatory response. Microglia can also have a beneficial effect on NSC grafts, 
aiding in migration, axonal growth and differentiation, possibly by secretion of 
growth factors or through cell-cell contact (Vilhardt et al., 2005).  It has also been 
postulated that the common inflammatory response in all forms of brain damage may 
provide an intrinsic migratory signal for NSCs (Imitola et al., 2004).  Grafting was 
timed to coincide with the peak ischaemic injury in an attempt to intervene as rapidly 
as possible.  However, it is possible that the host ischaemic and inflammatory 
environment might impair graft survival.  It may be advantageous to postpone 
transplantation until the ischaemic response has subsided.  Further work is therefore 
necessary to determine the optimum time of transplantation in this global ischemic 
model. 
 
3.5.4 Cyclosporin A immunosuppression does not affect MHP36 
graft integration 
The present study investigated whether immunosuppression influences MHP36 cell 
survival and migration.  CsA is a cyclic undecapeptide that exhibits potent 
immunosuppressive activity by specifically blocking T-cell activation.  In the T-cell 
cytoplasm, CsA binds to its immunophilin, cyclophilin to form a complex.  This 
complex binds and inhibits the action of the enzyme calcineurin, preventing the 
dephosphorylation of the cytoplasmic component of the nuclear factor of activated T 
cells (NF-ATc).  Therefore, NF-ATc is unable to translocate to the nucleus and bind 
to the nuclear component of nuclear factor of activated T cells (NF-ATn).  Formation 
of the NF-ATc--NF-ATn complex is required for production of cytokines such as 
interleukin 2 (IL-2) and interferon-γ (IFN-γ).  Both cytokines play an important role 
in the continuing immune response, with IL-2 essential for the proliferation and 
maturation of T-cells, and IFN-γ critical for the activation of macrophages.  CsA 
immunosuppression has been commonly used in transplantation studies using NSCs 
(Chu et al., 2001, Kelly et al., 2004, Saporta et al., 1999) although few studies have 
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examined the effect of immunosuppression on graft survival and migration.  During 
this study, mice were immunosuppressed with CsA prior to grafting and during the 
initial phase of graft survival.  However, CsA did not have any statistically 
significant effect on the microglia / macrophage or reactive astrocyte response.  
There was also no statistically significant effect of CsA immunosuppression on 
MHP36 graft survival or migration.  A possible explanation for the lack of an 
immunosuppressive effect is the inability of CsA to cross the blood-brain barrier 
(BBB) (Sakata et al., 1994).  However, in this study, the blood-brain barrier has been 
physically broken following insertion of the needle.  It has previously been shown 
that intravenous CsA is able to ameliorate ischaemic damage as long as the BBB has 
been opened (Uchino et al., 1995), although there was no clear evidence of this in 
our study.  Another reason for the failure to observe any immunosuppressive effect 
may simply be down to the time points assessed.  At 1 week post-transplantation, the 
immune response would be at a peak, making it difficult to assess any effect of 
immunosuppression.  Conversely, at 4 weeks post-transplantation, CsA 
administration ended 2 weeks prior to assessment and the immune response has 
decreased naturally over time.  This can be seen from comparing the reactive 
astrocyte and microglia / macrophage response at 1 week to the 4 week mice.  Modo 
et al., (2002) have also demonstrated that there is no discernible effect of CsA 
immunosuppression on the expression of immune markers or the proliferation of 
lymphocytes in the cervical lymph nodes in MCAo lesioned brain within 2 weeks 
following grafting of MHP36 stem cells. Surprisingly, comparison of all 
experimental groups indicated better graft survival was achieved in the absence of 
CsA immunosuppression. The lack of an effect of CsA immunosuppression may 
simply be down to the mild inflammatory response provoked by the MHP36 cells. 
The low antigen presentation of the grafted MHP36 cells would not markedly 
stimulate activation of the immune system and upregulate lymphocyte proliferation, 
therefore negating the need for CsA immunosuppression. It would represent an 
enormous advantage if neural transplantation could be carried out in the absence of 
immunosuppression, given the side effects associated with immune suppression. 
However, other studies have shown that a triple combination of immunosuppressive 
drugs promote improved graft survival to CsA alone or no immunosuppression 
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(Pedersen et al., 1995, 1997).  It is clear that the effectiveness of immunosuppression 
in neural grafts requires further investigation.  
 
3.5.5  ApoE immunoreactivity 
Upregulation of ApoE has been shown to take place following varying forms of brain 
damage; focal and global ischaemia, traumatic brain injury (Horsburgh and Nicoll, 
1996, Iwata et al., 2005). In the present study, an immediate upregulation of apoE 
expression was observed at 1 week followed by a decrease at 4 weeks post-
transplantation. The upregulation of apoE following brain damage is traditionally 
associated with breakdown and clearance of ischaemic cells, although it is also 
speculated to play an important role in repair and regeneration. There was no 
difference in the extent of apoE immunoreactivity between vehicle and MHP36 
grafted mice. The upregulation of apoE may occur primarily as a result of global 
ischaemia, rather than as a response to the MHP36 cells. However, MHP36 cells 
grafted in a rodent model of focal ischaemia have been associated with upregulation 
and long-term maintenance of apoE levels (Dr. I. Reuter, Personal communication).  
Modo et al., (2003) investigated the pattern of apoE expression following MHP36 
grafts in a rodent model of focal ischaemia.  Sham operated animals exhibited 
minimal apoE expression. Intraparenchymal grafts of MHP36 cells were associated 
with increased apoE expression, in contrast to intraventricular grafts.  Interestingly, 
intraparenchymal grafts also resulted in increased contralateral expression of apoE, 
suggestive of remodelling and reorganisation processes.   
 
3.5.6 Summary 
This study demonstrated that grafted MHP36 stem cells survive and migrate in a 
mouse model of global ischaemia. Grafted MHP36 cells differentiated into neurons 
and were able to reduce the extent of ischaemic neuronal damage. There was a 
minimal host immune response to the MHP36 grafts. The successful transplantation 
and characterisation of MHP36 grafts in mouse brain opens the door for future 
investigation into the genetic factors underlying stem cell graft integration via the use 














Influence of endogenous murine apoE on 
neural stem cell grafts in a mouse model 
of global ischaemia 
4.1  Introduction 
Apolipoprotein E (apoE) has many important roles in neurobiology, particularly in 
neurodegeneration, regeneration and repair (Herz and Beffert, 2000). In normal 
brain, apoE is synthesized and secreted by astrocytes. Following injury, apoE 
expression is induced in neurons. Thus, apoE can potentially regulate neuronal 
integrity. This has been observed in models of excitotoxicity (Boschert et al., 1999, 
White et al., 2001), focal ischaemia (Kitagawa et al., 2001) and global ischaemia 
(Hall et al., 1995, Kida et al., 1995, Horsburgh and Nicoll, 1996). Modo et al (2003) 
investigated the expression and distribution of apoE following grafting of MHP36 
cells in a rat model of focal ischaemia. ApoE was upregulated in grafted animals and 
found to associate with differentiated neurons and astrocytes. These data suggested 
that apoE may be involved in the integration of neural stem cell grafts.  Another 
preliminary study has shown upregulation and continued expression of apoE in 
association with MHP36 grafts, which was paralleled with functional recovery over a 
period of 6 weeks (Dr Iris Reuter, Personal Communication). ApoE has been 
implicated in mechanisms of anti-oxidation, excitotoxicity and cytoskeletal support 
(Miyata and Smith, 1996, Horsburgh et al., 2000, Boschert et al., 1999, Buttini et al., 
1999, Strittmater et al., 1994, Masliah et al., 1996) which could all influence the 
survival and migration of transplanted stem cells. Interactions between apoE and the 
respective family of LDL receptors can affect a variety of downstream signalling 
pathways which may account for alterations to stem cell survival, migration and 
differentiation. In chapter 3, I demonstrated that MHP36 cells are able to survive, 
migrate and differentiate in a mouse model of global ischaemia, and also reduce the 
extent of ischaemic neuronal damage. With the availability of transgenic mice 
deficient in apoE (Piedrahita et al., 1992, Van Ree et al., 1994, Plump et al., 1992), it 
is now possible to address the question of whether endogenous apoE influences 
neural stem cell grafts in a mouse model of global ischaemia. 
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4.2  Aim 
The aim of the study was to investigate whether apoE influences the survival, 
migration and differentiation of neural stem cell grafts in a mouse model of diffuse 
neuronal injury induced by global ischaemia, and also to examine cell signalling 
pathways which may be involved in these processes. 
 
4.3 Materials and Methods 
 
4.3.1  Study outline 
Adult male wildtype C57Bl/6J (WT) mice and APOE-KO mice were used in this 
study (Chapter 2, Section 2.1) Transient global ischaemia was induced by bilateral 
occlusion of the common carotid arteries (BCCAo).  Different durations of ischaemia 
were used, based on previous observations after studying different duration of global 
ischaemia in C57Bl/6J mice (Kelly et al., 2001) and studies demonstrating that 
APOE-KO mice are more susceptible to global ischaemia (Horsburgh et al., 1999). 
To ensure the extent of ischaemic neuronal damage was similar in WT and APOE-
KO mice, an occlusion time of 17 minutes was chosen for WT mice, and occlusion 
times of 15 minutes and 17 minutes were chosen for APOE-KO mice.  
 
Mice were immunosuppressed with CsA. Two weeks following global ischaemia, 
PKH26 labelled MHP36 cells (Passage number 59-67) were unilaterally grafted into 
the caudate nucleus and hippocampus (Chapter 2, Section 2.3). All mice received 
MHP36 grafts. Pre-graft viability averaged 91% and post-graft viability averaged 
81%. 4 weeks post-transplantation, mice were transcardially perfused (Chapter 2, 
Section 2.5). The caudate nucleus and hippocampus was dissected from 14 animals 
(WT, 17m BCCAo, n = 5, APOE-KO, 15m BCCAo, n = 4, APOE-KO, 17m BCCAo, 
n = 5).  23 animals (WT, 17m BCCAo, n = 7, APOE-KO, 15m BCCAo, n = 9, 
APOE-KO, 17m BCCAo, n = 8) were processed for histology using the Callis 
method of freezing (Chapter 2, Section 2.6). Coronal cryostat sections (10μm) were 
mounted onto poly-L-lysine coated slides.  Slides containing sections at the level of 
the injection tract were stained with haematoxylin and eosin in order to visualise the 
number of normal neurons.  Slides adjacent to the ones taken for haematoxylin and 
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eosin staining were mounted in Vectashield for fluorescent visualisation of MHP36 
cells or processed for immunohistochemistry using markers against NeuN and 
GFAP. 
 
4.3.2  Quantification of ischaemic damage 
The majority of studies investigating the extent of damage following global 
ischaemia terminate the animal within a week of the ischaemic insult (Horsburgh et 
al., 1999, Kelly et al., 2001). At this time point, damaged neurons undergoing 
ischaemic cell change are still clearly visible and morphologically distinct from 
normal neurons.  In the present study, animals were examined six weeks following 
induction of ischaemia.  The vast majority of ischaemic neurons have been degraded 
and cleared away by this time point, although a few neurons that are still undergoing 
homogenising cell change may be identified from their ghostlike appearance.  As 
such, the classical method of identifying ischaemic damage (Auer & Sutherland, 
2002, Lipton, 1999) becomes problematic. Therefore, another method of assessing 
neuronal damage was required. The number of morphologically normal neurons 
remaining was assessed as an index of ischaemic damage. H & E stained sections 
were used to assess the number of normal neurons using a 25mm2 grid (attached to 
the microscope optics) at 400x magnification.  Six fields were quantified in the 
ipsilateral and contralateral caudate nucleus, and one field for the ipsilateral and 
contralateral CA2 region of the hippocampus.  
 
4.3.3  Quantification of MHP36 graft survival and migration 
Sections were assessed for the number of surviving PKH26 labelled MHP36 cells 
using a confocal laser scanning microscope. Within the caudate nucleus, confocal z-
series images were captured at six regions surrounding the injection tract and 
quantified for the number of MHP36 cells. Within the hippocampus, five confocal z-
series images were captured along the granule cell layer of the CA region starting 
from the CA2 and progressing along the CA1 towards the septum. Migration of 
PKH26 labelled MHP36 cells was assessed in a medial, lateral and ventral direction 
away from the injection tract in both the caudate nucleus and hippocampus.  The 
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distance of migration in each direction was measured using a 100mm2 grid (attached 
to the microscope optics) at 200x magnification. 
 
4.3.4   Immunofluorescent analysis 
Sections were assessed for co-localization of phenotypic markers for neurons (NeuN) 
and astrocytes (GFAP) with PKH26 as a marker for transplanted MHP36 cells. 
Within the caudate nucleus, confocal z-series images were captured in five different 
fields medial, lateral and ventral to the injection tract in the caudate nucleus. Within 
the hippocampus, confocal z-series images were captured in four different fields 
along the granule cell layer of the CA region starting at the CA2 and progressing 
along the CA1.  Neuronal and astrocytic differentiation was determined by counting 
the number of cells co-localizing with PKH26 after counting the number of PKH26 
positive cells within the same field.  
 
4.3.5  Western blotting 
Frozen caudate and hippocampal samples were homogenized and assayed for protein 
concentration (Chapter 2, Section 2.10).  25μg of protein from ipsilateral and 
contralateral regions were loaded and separated on a SDS polyacrylamide gel along 
with a molecular weight marker.  Separated protein samples were transferred onto a 
PVDF membrane overnight. Following transfer, the gel was stained with Coomassie 
blue to confirm equal loading of protein in each lane. The membrane was placed, 
protein side up, in a 50ml centrifuge tube and blocked in 10% non-fat dried milk in 
PBS-T before probing with antibodies (Table 2.3). Antibodies bound to the 
membrane were detected using enhanced chemiluminescence. Membranes were 
sequentially stripped and reprobed with a variety of antibodies. The relative optical 
density of protein bands were measured (Chapter 2, Section 2.10.8) and quantified. 
 
4.3.6  Statistical analyses  
A Kruskal-Wallis test followed by Dunn’s post-test was used to assess statistical 
differences between the groups. 
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4.4  Results 
 
4.4.1  Ischaemic damage 
The number of morphologically normal neurons was assessed as an index of 
ischaemic neuronal damage. Within the contralateral caudate nucleus, there were 
significantly higher numbers of normal neurons in WT mice compared to APOE-KO 
mice subjected to 15 minutes BCCAo (18.14 ± 2.37 vs. 13.70 ± 1.92 normal neurons 
per 0.0625mm2, p < 0.05). A similar trend was observed compared to APOE-KO 
mice subjected to 17 minutes BCCAo, although this difference was not statistically 
significant (18.14 ± 2.37 vs. 14.13 ± 2.93 normal neurons per 0.0625mm2, p > 0.05). 
The number of morphologically normal neurons was assessed in the ipsilateral 
caudate nucleus which received the graft of MHP36 stem cells. In this hemisphere 
the number of normal neurons was similar between WT (16.38 ± 1.53 normal 
neurons per 0.0625mm2) and APOE-KO mice subjected to 15 minutes BCCAo 
(16.63 ± 1.48 normal neurons per 0.0625mm2), although neurons were reduced in 
number in APOE-KO mice subjected to 17 minutes BCCAo (13.56 ± 2.01 normal 
neurons per 0.0625mm2) (Figure 4.1). Taken together, the data show that in the 
ungrafted contralateral caudate nucleus, APOE-KO mice have a reduced neuronal 
number than WT mice, consistent with increased susceptibility to ischaemic damage. 
However, in the grafted ipsilateral caudate nucleus, APOE-KO mice subjected to 17 
minutes BCCAo maintain reduced neuronal number compared to WT mice. 
Interestingly, APOE-KO mice subjected to 15 minutes BCCAo also have comparable 
numbers of normal neurons to WT mice. This could be suggestive of neuronal 
replacement by the grafted stem cells or alternatively explained by the MHP36 cells 
exerting a neuroprotective effect.  
 
The number of neurons remaining was also assessed in the CA2 region of the 
hippocampus (Figure 4.2). In the contralateral CA2 region, APOE-KO mice 
subjected to 17m BCCAo have fewer normal neurons compared to APOE-KO mice 
subjected to 15 minutes BCCAo (14.50 ± 6.37 vs. 23.00 ± 5.87 normal neurons per 
0.0625mm2, p < 0.05) and WT mice (14.50 ± 6.37 vs. 21.71 ± 3.73 normal neurons 




























Number of morphologically normal neurons within the caudate 
nucleus
Number of normal neurons per 0.0625 mm2
 
in WT mice subjected to 17m BCCAo and 
APOE-KO mice subjected to 15m and 17m BCCAo within the contralateral (A) and 
ipsilateral
 
(B) caudate nucleus. Data are expressed as individual data points, with the bar 
indicating the median. In the contralateral hemisphere, WT mice have significantly more 
normal neurons compared to APOE-KO mice subjected to 15m BCCAo. However, in the 
ipsilateral
 
hemisphere, APOE-KO mice subjected to 17m BCCAo have significantly fewer 
normal neurons compared to the other two groups. * p < 0.05, ** p < 0.01 using Kruskal-
 






















































































































Number of morphologically normal neurons within the hippocampus
Number of normal neurons per 0.0625 mm2
 
in WT mice subjected to 17m BCCAo and 
APOE
 
-KO mice subjected to 15m and 17m BCCAo within the contralateral (A) and 
ipsilateral
 
(B) hippocampus. Data are expressed as individual data points, with the bar 
indicating the median. APOE
 
-KO mice subjected to 15m BCCAo have significantly more 
normal neurons than APOE
 
-KO mice subjected to 17m BCCAo in the contralateral 
hemisphere. * p < 0.05 using Kruskal-Wallis test with Dunn’s post-test.
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significant. A similar trend was observed in the grafted ipsilateral CA2 region. WT 
mice exhibited a similar neuronal density to APOE-KO mice subjected to 15 minutes 
BCCAo (21.14 ± 30.2 vs. 19.33 ± 6.87 normal neurons per 0.0625mm2, p > 0.05). 
APOE-KO mice subjected to 17 minutes BCCAo exhibited the fewest number of 
normal neurons (16.38 ± 4.21 normal neurons per 0.0625mm2), although there are no 
statistically significant differences between the groups (Kruskal-Wallis test, p > 
0.05). 
 
4.4.2  MHP36 graft survival and migration 
Survival of MHP36 stem cells in the caudate nucleus was significantly improved in 
WT mice compared to APOE-KO mice subjected to 15 minutes BCCAo (8.06 ± 2.25 
vs. 1.77 ± 0.56 PKH26 positive MHP36 cells per 0.0350mm2, p < 0.01) and 17 
minutes BCCAo (8.06 ± 2.25 vs. 1.68 ± 0.81 PKH26 positive MHP36 cells per 
0.0350mm2, p < 0.01) (Figure 4.3). Similarly, survival of MHP36 stem cells in the 
hippocampus is significantly improved in WT mice compared to APOE-KO mice 
subjected to 15 minutes BCCAo (5.17 ± 1.57 vs. 2.42 ± 1.14 PKH26 positive 
MHP36 cells per 0.0350mm2, p < 0.05) and 17 minutes BCCAo (5.17 ± 1.57 vs. 2.31 
± 0.94 PKH26 positive MHP36 cells per 0.0350mm2, p < 0.05) (Figure 4.4). These 
data strongly suggest that apoE is an important factor in promoting MHP36 stem cell 
survival.  
 
Migration of MHP36 stem cells was assessed in a medial, lateral and ventral 
direction away from the injection tract. Within the caudate nucleus, there was an 
overall trend towards increased migration in all three directions in WT mice as 
compared to APOE-KO mice (Figure 4.5). The migration of stem cells was 
significantly greater in WT mice compared to APOE-KO mice subjected to 15 
minutes BCCAo in both a lateral axis (0.75 ± 0.28 vs. 0.35 ± 0.17 mm, p < 0.05) and 
a ventral axis (0.67 ± 0.18 vs. 0.26 ± 0.16 mm, p < 0.01). There was no significant 
difference in MHP36 migration between WT and APOE-KO mice within the 


















































































Survival of MHP36 cells within the caudate nucleus
Number of PKH26 positive MHP36 cells per 0.0350 mm2
 
in WT mice subjected to 17m 
BCCAo and APOE-KO mice subjected to 15m and 17m BCCAo within the caudate nucleus 
(A) and the corpus callosum (B). Data are expressed as individual data points, with the bar 
indicating the median. In both regions, the survival of MHP36 cells is significantly higher in 
WT mice compared to both groups of APOE-KO mice. 











































Survival of MHP36 cells in the hippocampus
Number of PKH26 positive MHP36 cells per 0.0350 mm2
 
in WT mice subjected to 17m 
BCCAo and APOE-KO mice subjected to 15m and 17m BCCAo within the 
hippocampus. Data are expressed as individual data points, with the bar indicating the 
median. Significantly more MHP36 cells survive in WT mice compared to both groups of 























Migration of MHP36 cells within the caudate nucleus
Distance migrated (mm) by MHP36 cells in WT mice subjected to 17m BCCAo and 
APOE-KO mice subjected to 15m and 17m BCCAo within the caudate nucleus. 
Migration was assessed in medial, lateral and ventral directions
 
away from the injection 
tract. Data are expressed as individual data points, with the bar indicating the median. 
Migration was significantly further in WT mice subjected to 17m BCCAo compared to 
APOE-KO mice subjected to 15m BCCAo in lateral and ventral directions.  






















Migration of MHP36 cells in the hippocampus
Distance migrated (mm) by MHP36 cells in WT mice subjected to 17m BCCAo and 
APOE-KO mice subjected to 15m and 17m BCCAo within the hippocampus. Migration 
was assessed in medial, lateral and ventral directions away from
 
the injection tract. Data 
are expressed as individual data points, with the bar indicating
 
the median. There was 
no statistical difference in distance migrated in the hippocampus between the three 
groups of mice.
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4.4.3  Neuronal differentiation of MHP36 cells 
Within the caudate nucleus, a significantly higher proportion of grafted MHP36 cells 
differentiated into a neuronal phenotype in WT mice compared to APOE-KO mice 
subjected to 15 minutes BCCAo (79.79 ± 6.90 % vs. 25.02 ± 17.14 % MHP36 cells 
colocalised with NeuN, p < 0.01) and 17 minutes BCCAo (79.79 ± 6.90 % vs. 17.84 
± 13.76 % MHP36 cells colocalised with NeuN, p < 0.01) (Figures 4.7 and 4.8). A 
similar distinction between the genotypes was observed in the hippocampus, 
although the percentage of neuronally differentiated cells was reduced compared to 
the caudate nucleus. Significantly more grafted MHP36 cells differentiated into a 
neuronal phenotype in WT mice compared to APOE-KO mice subjected to 15 
minutes BCCAo (30.58 ± 4.25 % vs. 14.55 ± 14.52 % MHP36 cells colocalised with 
NeuN, p < 0.05) and 17 minutes BCCAo (30.58 ± 4.25 % vs. 9.36 ± 10.39 % 
MHP36 cells colocalised with NeuN, p < 0.05) (Figures 4.9 and 4.10). These data are 
summarised as pie charts in Figure 4.15. 
 
4.4.4  Astrocytic differentiation of MHP36 cells 
Within the caudate nucleus, WT mice exhibited a trend towards reduced astrocytic 
differentiation of grafted MHP36 cells compared to APOE-KO mice, although this 
was not statistically significant (Figures 4.11 and 4.12).  Approximately 8.31 ± 6.95 
% of MHP36 cells expressed an astrocytic phenotype in WT mice compared to 19.10 
± 10.65 % of MHP36 cells in APOE-KO mice subjected to 15 minutes BCCAo and 
24.21 ± 27.77 % of MHP36 cells in APOE-KO mice subjected to 17 minutes 
BCCAo. However, the converse situation was observed within the hippocampus. A 
significantly higher proportion of grafted MHP36 cells differentiated into an 
astrocytic phenotype in WT mice compared to APOE-KO mice subjected to 15 
minutes BCCAo (48.62 ± 11.23 % vs. 20.61 ± 10.74 % MHP36 cells colocalised 
with GFAP, p < 0.05) and 17 minutes BCCAo (48.62 ± 11.23 % vs. 14.30 ± 10.05 % 
MHP36 cells colocalised with GFAP, p < 0.01) (Figures 4.13 and 4.14). These data 















































Neuronal differentiation of MHP36 cells within the caudate nucleus
Percentage of PKH26 positive MHP36 cells co-localising with NeuN in WT mice 
subjected to 17m BCCAo and APOE-KO mice subjected to 15m and 17m BCCAo within 
the caudate nucleus. Significantly more MHP36 cells differentiate into a neuronal 
phenotype in WT mice compared to both groups of APOE-KO mice. Data are expressed 
as individual data points, with the bar indicating the median. 





























images illustrating neuronal differentiation 
of MHP36 cells in the caudate nucleus
Confocal images of PKH26 positive MHP36 cells (red) co-localised with the neuronal 
marker NeuN
 
(green) in WT mice subjected to 17m BCCAo (Panels A-C) and APOE-KO 
mice subjected to 15m (Panels D-F) and 17m BCCAo (Panels G-I) within the caudate 
nucleus. Increased neuronal differentiation was observed in WT mice. The survival of 
MHP36 cells was also improved in the WT mice compared to both groups of APOE-KO 

















































Neuronal differentiation of MHP36 cells within the hippocampus
Percentage of PKH26 positive MHP36 cells co-localising with NeuN in WT mice 
subjected to 17m BCCAo and APOE-KO
 
mice subjected to 15m and 17m BCCAo within 
the hippocampus. Data are expressed as individual data points, with the bar indicating 
the median. Significantly more MHP36 cells differentiate into a neuronal phenotype in 
WT mice compared to both groups of APOE-KO
 
mice. 






























Figure 4.10 Representative confocal
 
images illustrating neuronal differentiation 
of MHP36 cells in the hippocampus
Confocal images of PKH26 positive MHP36 cells (red) co-localised with the neuronal 
marker NeuN
 
(green) in WT mice subjected to 17m BCCAo (Panels A-C) and APOE-KO 
mice subjected to 15m (Panels D-F) and 17m BCCAo (Panels G-I) within the 
hippocampus. Increased neuronal differentiation was observed in WT mice. The survival 




KO mice (Panels B, E and H). Scale bar = 20 μm.

















































differentiation of MHP36 cells in the caudate nucleus
Percentage of PKH26 positive MHP36 cells co-localising with GFAP in WT mice 
subjected to 17m BCCAo and APOE
 
-KO mice subjected to 15m and 17m BCCAo 
within the caudate nucleus. There is a trend towards reduced astrocytic differentiation in 
WT mice as compared to APOE
 
-KO mice. Data are expressed as individual data 
points, with the bar indicating the median. 
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differentiation of MHP36 cells in the caudate nucleus
Confocal images of PKH26 positive MHP36 cells (red) co-localised with the neuronal 
marker NeuN
 
(green) in WT mice subjected to 17m BCCAo (Panels A-C) and APOE-KO 
mice subjected to 15m (Panels D-F) and 17m BCCAo (Panels G-I) within the caudate 
nucleus. The survival of MHP36 cells was also improved in the WT
 
mice compared to 
both groups of APOE-KO mice (Panels B, E and H). Scale bar = 20 μm.















































differentiation of MHP36 cells within the hippocampus
Percentage of PKH26 positive MHP36 cells co-localising with GFAP in WT mice 
subjected to 17m BCCAo and APOE-KO
 
mice subjected to 15m and 17m BCCAo within 
the hippocampus. Data are expressed as individual data points, with the bar indicating 
the median. Significantly more MHP36 cells differentiate into a astrocytic phenotype in 
WT mice compared to APOE-KO
 
mice. 





































differentiation of MHP36 cells in the hippocampus
Confocal images of PKH26 positive MHP36 cells (red) co-localised with the astrocytic 
marker GFAP (green) in WT mice subjected to 17m BCCAo (Panels A-C) and APOE-
 
KO mice subjected to 15m (Panels D-F) and 17m BCCAo (Panels G-I) within the 
hippocampus. Increased astrocytic differentiation was observed in WT mice. The 
survival of MHP36 cells was also improved in the WT mice compared to both groups of 
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4.4.5   Protein levels 
In a separate study, the protein levels of ERK 1/2, JNK 1/2 and their respective 
phosphorylated forms were measured in homogenates derived from the caudate 
nucleus and hippocampus of the three groups of mice. A single protein band was 
detected at 44kDa for ERK 1, 42 kDa for ERK2, 46kDa for JNK1 and 54kDa for 
JNK2. The phosphorylated forms of these proteins were detected at the same 
molecular weights. Within the caudate nucleus, there was no significant change in 
levels of ERK 1 or 2 (both unphosphorylated and phosphorylated) in either the 
ipsilateral or contralateral hemisphere within the three groups (Figures 4.16 and 
4.17).  However, there was a trend towards an increase in phosphorylated ERK 1 and 
2 in APOE-KO mice subjected to 15 minutes BCCAo (Phosphorylated ERK1; 
Contralateral hemisphere, WT, 0.219 ± 0.06 vs. 15m BCCAo, 0.301 ± 0.14 vs. 17m 
BCCAo, 0.244 ± 0.04 R.O.D., p > 0.05; ipsilateral hemisphere, WT, 0.188 ± 0.07 vs. 
15m BCCAo, 0.336 ± 0.10 vs. 17m BCCAo, 0.234 ± 0.03 R.O.D., p > 0.05. 
Phosphorylated ERK2; contralateral hemisphere, WT, 0.078 ± 0.02 vs. 15m BCCAo, 
0.147 ± 0.05 vs. 17m BCCAo, 0.115 ± 0.05 R.O.D., p > 0.05; ipsilateral hemisphere, 
WT, 0.061 ± 0.02 vs. 15m BCCAo, 0.160 ± 0.07 vs. 17m BCCAo, 0.103 ± 0.06 
R.O.D., p > 0.05). There was no significant difference in levels of JNK 1 or 2 in 
either the ipsilateral or contralateral caudate nucleus within the three groups (Figure 
4.18), although a difference in the levels of phosphorylated JNK 1 and 2 was 
observed (Figure 4.19). Significantly higher levels of phosphorylated JNK 2 were 
observed in the ipsilateral hemisphere of APOE-KO mice subjected to 15 minutes 
BCCAo compared to WT mice subjected to 17 minutes BCCAo. This group of 
APOE-KO mice also exhibited a trend towards increased levels of phosphorylated 
JNK 1 in the same hemisphere. 
 
Within the hippocampus, there was no significant change in the levels of ERK 1 and 
2 or JNK 1 and 2 (unphosphorylated or phosphorylated) in the ipsilateral or 
contralateral hemisphere within the three groups (Figures 4.20 to 4.23). However, 
similar to that observed in the caudate nucleus, there was a trend towards an increase 
in levels of phosphorylated JNK 1 and 2 in the ipsilateral hemisphere of APOE-KO 







































Western blot analysis of ERK1 and 2 in the caudate nucleus
Erk
 
1 and 2 immunoreactivity
 
in the contralateral and ipsilateral
 
caudate nucleus from 
WT mice subjected to 17m BCCAo and APOE-KO
 
mice subjected to 15m and 17m 
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1 and 2 immunoreactivity
 
in the contralateral and ipsilateral
 
caudate 
nucleus from WT mice subjected to 17m BCCAo and APOE-KO
 
mice subjected to 15m 
and 17m BCCAo. Relative optical density measurements were taken for both pErk
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(44kDa) and 2 (42kDa). Data are mean ±
 
















































Western blot analysis of Jnk1 and 2 in the caudate nucleus
Jnk
 
1 and 2 immunoreactivity
 
in the contralateral and ipsilateral
 
caudate nucleus from 
WT mice subjected to 17m BCCAo and APOE-KO
 
mice subjected to 15m and 17m 
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1 and 2 immunoreactivity
 
in the contralateral and ipsilateral
 
caudate 
nucleus from WT mice subjected to 17m BCCAo and APOE-KO
 
mice subjected to 15m 
and 17m BCCAo. Relative optical density measurements were taken for both pJnk
 
1 
(46kDa) and 2 (54kDa). Data are mean ±
 
































































Western blot analysis of Erk1 and 2 in the hippocampus
Erk
 
1 and 2 immunoreactivity
 
in the contralateral and ipsilateral
 
hippocampus from WT 
mice subjected to 17m BCCAo and APOE-KO
 
mice subjected to 15m and 17m BCCAo. 
Relative optical density measurements were taken for both Erk
 
1 (44kDa) and 2 
(42kDa). Data are mean ±
 



































































1 and 2 immunoreactivity
 
in the contralateral and ipsilateral
 
hippocampus from WT mice subjected to 17m BCCAo and APOE-KO
 
mice subjected to 
15m and 17m BCCAo. Relative optical density measurements were taken for both pErk
 
1 (44kDa) and 2 (42kDa). Data are mean ±
 







































































Western blot analysis of Jnk1 and 2 in the hippocampus
Jnk
 
1 and 2 immunoreactivity
 
in the contralateral and ipsilateral
 
hippocampus from WT 
mice subjected to 17m BCCAo and APOE-KO
 
mice subjected to 15m and 17m BCCAo. 
Relative optical density measurements were taken for both Jnk
 
1 (46kDa) and 2 
(54kDa). Data are mean ±
 



































































1 and 2 immunoreactivity
 
in the contralateral and ipsilateral
 
hippocampus from WT mice subjected to 17m BCCAo and APOE-KO
 
mice subjected to 
15m and 17m BCCAo. Relative optical density measurements were taken for both pJnk
 
1 (46kDa) and 2 (54kDa). Data are mean ±
 










































4.5   Discussion 
This study demonstrated that endogenous apoE has a major role in MHP36 neural 
stem cell survival, migration and differentiation in a mouse model of global 
ischaemia. The presence of apoE was linked to improved MHP36 survival and 
migration and enhanced neuronal differentiation. This enhancement was associated 
with changes in JNK signal transduction, a protein associated with cell survival. 
 
4.5.1  Endogenous apoE influences the ability of stem cells to 
reduce ischaemic neuronal damage 
At the outset of this study it was recognised that APOE-KO mice are more 
susceptible than WT mice to ischaemia (Laskowitz et al., 1997, Horsburgh et al., 
1999). Thus, in APOE-KO mice, two durations of ischaemia were employed (one of 
a shorter duration, and one of an exact duration to WT mice) to produce ischaemic 
neuronal damage comparable and more extensive than WT mice. This was so that 
any differences observed could not be attributed to the variation in the extent of 
ischaemic damage. However, despite lowering the duration of ischaemia, in the 
ungrafted contralateral caudate nucleus, WT mice had greater numbers of normal 
neurons than both APOE-KO groups. Interestingly, in the grafted ipsilateral 
hemisphere, grafts of MHP36 cells result in an increased number of normal neurons 
in WT and APOE-KO mice subjected to a comparable degree of damage. However, 
MHP36 grafts were not able increase the number of normal neurons in APOE-KO 
mice subjected to a greater degree of ischaemic neuronal damage. A similar trend is 
observed in the grafted ipsilateral hippocampus. Overall, the data suggest that 
following grafting with MHP36 cells,  an increase in the number of normal neurons 
is observed in APOE-KO mice with comparable damage to that of WT mice, but not 
to the same degree in APOE-KO mice with more extensive neuronal damage. All 
three groups of mice received equal numbers of MHP36 stem cells, suggesting that 
the regenerative properties are similar. The APOE-KO mice subjected to 17 minutes 
BCCAo might require a larger infusion of MHP36 cells in order to repair or replace 
the more extensive ischaemic damage. However, a major point that needs to be 
addressed is whether the increase in number of normal neurons following MHP36 
grafts occurs as a result of neuronal replacement (i.e. regeneration), or as a result of 
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protection against ischaemic cell loss (i.e. neuroprotection). The haematoxylin and 
eosin stain used for identifying normal and ischaemic neurons does not distinguish 
between host and grafted cells. Therefore, it is not possible in this thesis to 
equivocally identify which mechanism is utilised by the grafted MHP36 stem cells. 
Clearly, it would be advantageous to use a fluorescent method to identify normal and 
ischaemic neurons as this would allow for co-localisation with PKH26 to be 
performed. There are a number of fluorescent DNA-binding stains which can be used 
to label neurons, such as DAPI and propidium iodide. However, whilst these stains 
provide neuronal morphology which can be used as an indicator for ischaemic 
neurons, the clarity of identification fails to reach that observed in haematoxylin and 
eosin staining. An eosin dye containing a fluorescein derivative, termed EA 50, has 
been demonstrated to provide fluorescent identification of ischaemic neurons, in 
correlation with Fos and Jun AP-1 immunoreactivity (Chen and Liu, 1996). 
However, technical aspects precluded the use of this dye in our study, as the activity 
of the dye was dependent on freshly fixed tissue and paraffin sections of less that 
4μm thickness. There is also the possibility that the transplanted stem cells influence 
the extent of ischaemic damage through both the mechanisms described. This is 
illustrated through the multipotent differentiation of MHP36 cells into neurons, 
suggestive of replacement, and also astrocytes, suggestive of support and protection. 
Importantly, in this study, grafted MHP36 cells underwent neuronal and astrocytic 
differentiation in both WT and APOE-KO mice, although the proportions of 
differentiated cells varied significantly depending on genotype.  
 
Alternatively, it may be that the extent of damage and the resultant environment 
influences the response of the transplanted stem cells. Neural transplantation studies 
in focal ischaemic models have demonstrated that transplantation into the ischaemic 
core usually results in failure of the grafted cells to survive, whereas the likelihood of 
survival is increased by transplantation away from the core, i.e. into the ischaemic 
penumbra or the undamaged hemisphere (Kelly et al., PNAS, 2004, Lundberg et al., 
1997, Modo et al., 2002). The deleterious survival may be due to the total lack of 
trophic and structural support in the ischaemic core. Similarly, in our study, the 
extensively damaged environment in APOE-KO mice subjected to 17 minute 
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BCCAo may negatively influence the ability of MHP36 cells to repair and replace 
lost neurons.  
 
4.5.2 MHP36 graft survival and migration is impaired in APOE-
KO mice 
This study demonstrates that MHP36 neural stem cells exhibit a significant 
impairment in survival when grafted into APOE-KO mice as compared to APOE-
expressing WT mice. MHP36 cell survival is approximately five-fold greater in the 
caudate nucleus, and approximately two-fold greater in WT mice as compared to 
APOE-KO mice in the hippocampus. These results strongly suggest that endogenous 
apoE aids the survival of grafted MHP36 cells. The ability of apoE to mediate lipid 
transport and redistribution has been linked with regeneration in damaged PNS and 
CNS. ApoE scavenges free cholesterol from the damaged environment and 
subsequently redistributes this cholesterol for biosynthesis during axonal 
regeneration following sciatic nerve injury (Boyles et al., 1989). A similar 
regenerative role in the CNS has been demonstrated for apoE in after deafferation of 
the entorhinal cortex in vitro (Teter et al., 1999) and in vivo (Poirier et al., 1993, 
White et al., 2001). In the latter studies, upregulation and expression of apoE 
paralleled clearance of cholesterol and other lipid debris in the acute phase post-
injury. This was followed by increased neuronal uptake of lipoproteins, concomitant 
with cholinergic reinnervation. Interestingly, apoE expression was also observed at a 
longer term, in association with markers of synaptic regeneration and remodelling. 
Recently, it has been suggested that apoE may affect regeneration through 
modulation of the astroglial inflammatory response (Champagne et al., 2005). This 
regenerative role of apoE may assist the survival of transplanted MHP36 cells. ApoE 
performs a number of other functions which may also be implicated in stem cell 
survival. It has been demonstrated that in the absence of apoE, the extent of damage 
is amplified following brain injury (Horsburgh et al., 1999, Sheng et al., 1999, 
Laskowitz et al., 1997, Lomnitski et al., 1997). ApoE has been shown to modulate 
excitotoxicity, anti-oxidation and inflammation (Miyata and Smith, 1996, Horsburgh 
et al., 2000, Boschert et al., 1999, Buttini et al., 1999, Laskowitz et al., 2000). These 
three processes are all components of the pathophysiological cascade that occurs 
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after ischaemic events and traumatic injury (Chapter 1, Figure 1.1). As discussed 
previously, the extent of ischaemic damage and subsequent pathological environment 
may negatively impact on MHP36 survival. Therefore, the beneficial effects of apoE 
in this study may be due to the neuroprotective effects of apoE following brain 
injury, rather than through a direct interaction between apoE and the MHP36 stem 
cells.  
 
A number of studies have shown that addition of neurotrophins and other pro-
survival molecules can aid the survival of grafted stem cells. Martinez-Serrano et al 
(1995) transduced nerve growth factor (NGF) cDNA into a line of Hib5 neural 
progenitor cells. These NGF-expressing Hib5 cells were transplanted into rat 
striatum one week prior to induction of MCAo (Andsberg et al., 1998). It was found 
that these cells were able to ameliorate ischaemic damage 48 hours after the 
ischaemic insult. However, non-NGF producing cells did not exert a protective 
effect, leading the authors to conclude that NGF secretion alone was responsible for 
the reduction in ischaemic damage.  
 
Given that the majority of cells transplanted into the CNS fail to survive, Wei et al., 
(2005) investigated whether transplantation of ES cells overexpressing the anti-
apopototic gene bcl-2 would affect cell survival and functional outcome. Seven days 
after an episode of MCAo, rats were grafted with either unmodified ES cells or Bcl-2 
overexpressing ES cells. Western analysis confirmed that there was still a high level 
of Bcl-2 in the grafted brain up to 35 days following transplantation. Analysis of cell 
death using a TUNEL assay showed that significantly fewer Bcl-2 ES cells were 
TUNEL positive compared to WT ES cells. Interestingly, overexpression of Bcl-2 
also appeared to affect differentiation. Approximately 58% of Bcl-2 ES cells were 
NeuN positive, compared to approximately 34% of WT ES cells. Functional 
recovery was also improved with Bcl-2 ES cells compared to WT ES cells, although 
this was only evident 21 days after transplantation. Similarly, mouse ES cells 
transfected with the cell adhesion molecule L1 survive better than non-transfected ES 
cells following transplantation after spinal cord injury (Chen et al., 2005). However, 
all these studies have genetically modified stem cells in order to overexpress the 
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protein of interest. This is the first study to demonstrate that intrinsic genetic factors 
expressed at physiological levels may affect graft survival.  
 
Migration of grafted MHP36 stem cells is also affected by the presence of apoE. 
Within the caudate nucleus, MHP36 stem cells migrated further away from the 
injection tract in WT mice compared to APOE-KO mice. Medial migration was 
around 0.5 mm throughout all three groups, probably due to the fact that the injection 
site was located approximately 1 mm from the ventricles (Chapter 2, Figure 2.1). 
Therefore, the distance of medial migration from the injected cell bolus would be 
restricted. It would be interesting to investigate whether transplanted MHP36 cells 
enter the ventricles and migrate along the rostral/caudal axis. However, migration of 
MHP36 cells was not restricted in lateral and ventral directions in the caudate 
nucleus. In these directions, there was a definite trend towards improved migration in 
WT mice. Migration was significantly further compared to APOE-KO mice 
subjected to 15 minutes BCCAo. A smaller, non-significant difference in migration 
was observed compared to APOE-KO mice subjected to 17 minutes BCCAo, as 
migration in this group was more variable. It should be noted that this group was also 
subjected to more extensive ischaemic neuronal damage. Interestingly, these results 
differ from a previous study demonstrating more extensive MHP36 migration in 
conjunction with increased cell loss in the 4-VO model of rat global ischaemia 
(Hodges et al., 2000). Migration and engraftment of the lesioned hippocampus was 
more prevalent after the damage caused by 30 minutes occlusion compared to 15 
minutes occlusion. This discrepancy could result from the difference between the 
species and models of global ischaemia. The 4-VO model selectively damages CA1 
pyramidal neurons in the rat, compared to the CA2 damage induced by BCCAo in 
the mouse.  
 
However, no APOE-dependent effects on migration were observed in the 
hippocampus. Whilst migration distances were further in the hippocampus as 
opposed to the caudate nucleus, migration between the three groups was similar. This 
may be due to the location of the hippocampal graft. Cells were injected above the 
CA1 pyramidal cell layer, in close proximity to the corpus callosum. MHP36 cells 
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were able to migrate easily in medial and lateral directions along the white matter 
tract of the corpus callosum, irrespective of other factors (Figure 4.6).  On average, 
MHP36 cells migrated around 1 mm in a medial direction and around 0.7 mm in a 
lateral direction.  The average migration distance in a ventral direction was a shorter 
0.55 mm.  
 
A previous study within the thesis investigated the survival and migration of grafted 
MHP36 cells 4 weeks post-transplantation in WT mice (Chapter 3, Wong et al., 
2005). MHP36 survival was semi-quantitatively assessed in that study, whereas a 
fully quantitative approach was used in the present study, making it difficult to 
accurately compare survival between the two studies. In the previous study, grafted 
MHP36 cells in WT mice examined at 4 weeks post-transplantation were found to 
migrate approximately 0.4 mm in all directions from the injection tract. In this study, 
MHP36 cells in WT mice migrated further in all directions, to distances of 
approximately 0.51 mm in a medial direction, 0.71 mm in a lateral direction and 0.66 
mm in a ventral direction. The major difference between the studies was the time of 
graft. In the previous study, MHP36 cells were grafted 3 days post-ischaemia, at the 
time of maximal ischaemic damage. Whilst this time point is ideal for a therapeutic 
intervention, survival and subsequent migration of stem cells depends on the host 
environment. The ischaemic caudate nucleus is a multifaceted environment of 
pathophysiological mechanisms including glutamate induced excitotoxicity, oedema, 
free radical activation and inflammation (Chapter 1, Figure 1.1). These conditions 
will dramatically impair the likelihood of stem cell survival (Kelly et al., 2004). In 
contrast, grafting took place in this study 2 weeks post-ischaemia. At this time point, 
the pathophysiological response has decreased. Therefore, the enhanced survival 
observed in this study may be a result of transplantation into a less hostile 
environment, which may also account for the subsequent increase in migration 
distance. This suggests that neural stem cell replacement therapies for stroke may be 




ApoE may influence stem cell migration through interactions with cytoskeletal 
proteins. ApoE-deficient mice exhibit impaired dendritic structure and a reduction in 
levels of MAP2, α and β-tubulin (Masliah et al., 1996). ApoE has also been linked to 
polymerisation and stabilisation of microtubule assemblies (Nathan et al., 1995), the 
regulation of which is a postulated mechanism by which apoE can modulate neurite 
outgrowth (Bellosta et al., 1995, Handelmann et al., 1992). Taken together, these 
data suggest that the presence of apoE is integral for optimal migration of 
transplanted stem cells. The presence of apoE may provide structurally stable 
synaptic and dendritic architecture in host brain for the integration of transplanted 
stem cells. Once the stem cells are stably integrated, apoE may then assist in the 
reorganisation of microtubule formations in order to provide a framework for the 
migration of stem cells away from the graft site.  
 
4.5.3   Differentiation of stem cells is impaired in APOE-KO mice 
There was a marked difference in the differentiation profiles of surviving MHP36 
stem cells in WT mice and APOE-KO mice. Interestingly, the differentiation profile 
also varied depending on whether the graft was placed in the caudate nucleus or the 
hippocampus (Figure 4.15). Within the caudate nucleus, the presence of apoE is 
associated with significantly increased differentiation of grafted MHP36 cells to a 
neuronal phenotype. In WT mice, approximately 80% of MHP36 cells were positive 
for NeuN. Out of the remainder, 12% were positive for GFAP, leaving 8% of cells 
non-neuronal or astrocytic. These cells may have remained in an undifferentiated 
state following transplantation or express a different phenotype. In APOE-KO mice, 
approximately 20% of MHP36 cells were positive for neuN and GFAP, whilst the 
majority (approximately 60%) were non-neuronal or astrocytic. Taken together with 
the previous data, it appears that in WT mice, MHP36 stem cells are being driven 
towards neuronal differentiation in order to replace dead and damaged neurons 
following a global ischaemic insult. This supports the previous data showing the 
increase in the number of normal neurons in the ipsilateral caudate nucleus, and 
lends further credence to the suggestion that MHP36 grafts ameliorate ischaemic 
neuronal damage through a mechanism of neuronal replacement. However, in 
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APOE-KO mice, a critical factor or factors may be missing in order to drive neuronal 
differentiation. As described previously, APOE-KO mice subjected to 15 minutes 
BCCAo exhibit a similar neuronal number to WT mice subjected to 17 minutes 
BCCAo, yet these APOE-KO mice have impaired MHP36 survival and neuronal 
differentiation. It is obvious that any observed increase in neuronal number cannot be 
down to neuronal replacement by MHP36 grafts in these APOE-KO mice. This 
suggests that either intrinsic repair mechanisms ameliorated damage in these mice, or 
that the MHP36 grafts are providing support and repair without neuronal 
replacement. The increased astrocytic differentiation observed in APOE-KO mice 
may reflect this provision of trophic support. These differentiation results support the 
hypothesis that MHP36 stem cells are able to replace lost cells through neuronal 
differentiation, whilst still maintaining the ability to exert a neuroprotective 
influence. We have provided strong evidence that the presence of apoE is a critical 
factor in determining the proportion of MHP36 cells that undergo neuronal 
differentiation. It is likely that other factors also influence stem cell differentiation. 
These factors may be spatial/physical, such as the location of insult, severity of 
damage, and specific cell types affected. Other biological markers other than apoE 
may also be involved, such as inflammatory cytokines and chemokines. 
 
Within the hippocampus, MHP36 cells grafted into APOE-KO mice have a similar 
differentiation profile to that observed in the caudate nucleus. The majority of cells 
(64% in APOE-KO mice subjected to 15m BCCAo, 77% in APOE-KO mice 
subjected to 17m BCCAo) do not express a neuronal or astrocytic phenotype. In WT 
mice the differentiation profile is altered so that the largest proportion (48%) of 
MHP36 cells were determined to be GFAP positive. 31% of the MHP36 cells are 
positive for NeuN, leaving 21% of cells non-neuronal or astrocytic. This WT 
differentiation profile is also distinct from that observed in the caudate nucleus. This 
may be related to the finding that the number of normal neurons remaining in the 
hippocampus was unaltered, which corresponds with the fact that the majority of 
MHP36 cells did not differentiate into neurons in the hippocampus, unlike in the 
caudate nucleus. The increased astrocytic differentiation observed in WT mice may 
be due to the difference in environment. It should be noted that the marked reduction 
 145
in survival in APOE-KO mice may affect the likelihood of differentiation into either 
neurons or astrocytes. Overall the data clearly demonstrate that apoE strongly 
influences the survival and differentiation of MHP36 cells. 
 
The influence of apoE on neuronal differentiation has not been investigated 
previously in vivo but has been investigated in vitro cell culture. It has been shown 
that human neuronal-like cells (SH-SY 5Y and Kelly cell lines) derived from 
neuroblastoma are able to synthesise apoE (Dupont-Wallois et al., 1997). Soulié et 
al., (1999) measured apoE mRNA in human neuroblastoma SH-SY 5Y cells in 
relation to neuronal differentiation. Addition of nerve growth factor (NGF) induced 
differentiation of SH-SY 5Y cells into neuronal cells. During the first 4 days of NGF 
treatment, apoE mRNA decreases and then increases over the subsequent 3 days. The 
observed increase in apoE mRNA synthesis from NGF 4 days to 7 days was 
downregulated by administration of exogenous apoE. Interestingly, this 
downregulation was apoE isoform specific. ApoE4 was most efficient, followed by 
apoE3 and then apoE2. The same group extended these findings by investigating 
apoE protein and mRNA levels in human teratocarcinoma NT2 cells (Ferreira et al., 
2000). Undifferentiated NT2 cells expressed apoE mRNA and protein. Treatment of 
these cells with retinoic acid induced differentiation into hNT neurons, which was 
associated with a downregulation of apoE mRNA and protein levels to the degree 
that fully mature hNT neurons barely expressed apoE. Taken together, these data 
suggest that synthesis and expression of apoE may regulate neuronal differentiation. 
However, it remains to be seen whether apoE expression functions as an effector or 
marker in this system. Harris et al., (2004) carried out further work on neuronal 
expression of apoE and discovered that treatment of mature hNT neurons or mouse 
primary neurons with astrocyte conditioned media rapidly upregulated apoE 
expression. This effect was observed with media obtained from the C6 astrocytic cell 
line and also with media from primary astrocytes derived from APOE-KO mice. 
Interestingly, this astrocyte mediated upregulation of apoE expression could be 
abolished by treatment with U0126, an inhibitor of the ERK signalling pathway, 
whilst inhibition of the JNK pathway had no effect on apoE expression. These results 
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suggest that neuronal expression of apoE is regulated by an astrocyte secreted factor 
or factors and that this expression is dependent on the ERK signalling pathway. 
 
There are number of possible reasons for the disparity in differentiation profile 
between the caudate nucleus and the hippocampus in WT mice. Transient global 
ischaemia is associated with a defined hierarchy of neuronal damage. The caudate 
nucleus is particularly vulnerable, followed by the pyramidal regions of the 
hippocampus. Rosen and Williams (2001) estimated the number of neurons in the 
WT mouse striatum to be 1.72 ± 0.15 million. Approximately 12,500 MHP36 cells 
were grafted into the caudate nucleus and hippocampus. Given the widespread 
neuronal loss observed in the caudate, if grafted cells differentiate in order to replace 
the damaged neurons, this would require the majority of grafted cells. However, the 
CA1 and CA2 hippocampus region is a much smaller, more focused area that also 
undergoes selective neuronal damage. Abusaad et al., (1999) estimated that there are 
437,500 ± 37,500 neurons in the CA1, CA2 and CA3 regions in the pyramidal cell 
layer of C57Bl/6J mice. Based on the proportion of the CA2 region to the rest of the 
pyramidal cell layer (Paxinos and Franklin, 2001), it can be calculated that there 
should be approximately 35,000 ± 3000 neurons in the CA2 region. Therefore, unlike 
the situation in the caudate nucleus, a much smaller proportion of grafted MHP36 
cells would be required to differentiate into neurons in order to repopulate this 
region. It remains to be determined whether transplanted stem cells undergo division 
following grafting, although anecdotal evidence suggests that the cells may undergo 
up to two cycles of division (Dr Tonya Bliss, Personal communication). This may 
leave a sizeable proportion of MHP36 cells for providing trophic support, resulting in 
the increased proportion of MHP36 cells differentiating into astrocytes in the 
hippocampus. The higher proportion of undifferentiated MHP36 cells in the 
hippocampus may either be waiting for a suitable cue, or have differentiated into 
another cell type such as an oligodendrocyte.  
 
In the previous study (Chapter 3, Wong et al., 2005), approximately 56% of MHP36 
cells grafted into the caudate nucleus differentiated into neurons in WT mice at both 
1 week and 4 weeks post-transplantation. This is in comparison to the 80% neuronal 
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differentiation observed in WT mice in this study. As mentioned previously, the 
delay in grafting from 3 days post-ischaemia to 2 weeks post-ischaemia may 
influence the increased differentiation due to the less hostile environment. There is 
also the possibility that enhanced neuronal differentiation was simply due to the 
increased survival time of 6 weeks post-ischaemia for the animals. These factors 
illustrate the variability endemic to in vivo studies when comparing data on survival, 
migration and differentiation. In vitro experiments allow for greater control over 
these variables, allowing for consistent assessment of stem cell properties. Co-culture 
of MHP36 cells seeded onto primary cultures of mouse embryonic cortex revealed 
the temporal progression in differentiation (Mellodew et al., 2004). After four days in 
co-culture, MHP36 cells began to differentiate into astrocytes. The proportion of 
astrocytes stabilised after 8 days in vitro to about 60%. Neurons emerged after 7 days 
in vitro and stabilised at around 17% of the total population. Finally, 
oligodendrocytes appeared after 8 days in vitro to represent about 9% of MHP36 
cells. This differentiation profile varies from what was observed in WT and APOE-
KO mice in this study, demonstrating the extent to which in vivo factors can affect 
stem cell differentiation. 
 
4.5.4   Endogenous apoE may influence cell signalling pathways 
Activation of LDL receptors by apoE or another ligand has been implicated in a 
variety of signal transduction mediated processes, including neuronal migration 
(Dulabon et al., 2000), neurite outgrowth (Qiu et al., 2004) and calcium influx 
(Bacskai et al., 2000, Qiu et al., 2002). These signal transduction pathways may 
directly influence the survival, migration and differentiation of grafted stem cells. 
ApoE mediated induction of signal transduction pathways has been linked with the 
inhibition of cell migration and proliferation, although this was related to smooth 
muscle cells, as opposed to stem cells or neural progenitor cells (Ishigami et al., 
1998, Hui and Basford, 2005). ApoE exerts these inhibitory effects through binding 
to different receptors; inhibition of smooth muscle migration occurs via LRP1 
binding and activation of protein kinase A (Swertfeger et al., 2002, Zhu and Hui, 
2003); inhibition of smooth muscle proliferation takes place via heparan sulphate 
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proteoglycan binding and activation of inducible nitric oxide synthase (Ishigami et 
al., 2000, Swertfeger and Hui, 2001).  
 
We investigated protein levels of ERK 1 and 2, JNK 1 and 2 and their activated, 
phosphorylated forms in the caudate nucleus and hippocampus of WT and APOE-
KO mice in the presence of stem cell grafts post-ischaemia. These proteins were 
selected based on a study by Hoe et al., (2005) who investigated the signalling 
pathways stimulated by apoE in primary neuronal cultures. In this report, apoE 
activation of lipoprotein receptors led to increased levels of phosphorylated ERK1/2 
and decreased levels of phosphorylated JNK1/2. Treatment of the cells with alpha-2-
macroglobulin also increased phosphorylation of ERK1/2, but did not affect JNK1/2 
levels, suggesting that activation of ERK1/2 is governed by the LRP receptor. ERK 
and JNK, along with p38 are members of the mitogen-activated protein kinase family 
(MAPK). The MAPK family act as a convergence point for a number of extracellular 
signal pathways and have been linked to cell proliferation, apoptosis, differentiation 
and inflammation (Johnson and Lapadat, 2002).  
 
The data described in this thesis chapter indicated that levels of unphosphorylated 
ERK1/2 did not vary significantly between the groups, although there was a trend 
towards an increase in phosphorylated ERK1/2 levels in APOE-KO mice subjected 
to 15m BCCAo within the caudate nucleus. This appears to contrast with the results 
from Hoe et al., (2005), who demonstrated apoE-induced activation of ERK1/2 via 
the LRP receptor. However, the LRP receptor has a variety of ligands other than 
apoE. It has been previously shown that neuronal expression of apoE depends on the 
activity of the ERK pathway (Harris et al., 2004). Interestingly, a study by Ohkubo et 
al (2001) showed that apoE4 stimulated transcription of the cAMP-response element 
binding protein (CREB) through activation of the ERK cascade in rat primary 
hippocampal neurons. This activation of CREB led to downstream induction of the 
anti-apoptotic gene Bcl-2, which has been associated with improved neuronal 
survival after brain injury (Honkaniemi et al., 1996, Chen et al., 1997, Asahi et al., 
1997, Clark et al., 1997). In contrast, treatment with apoE3 was unable to activate the 
ERK pathway and therefore did not stimulate CREB transcription. However, all 
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these experiments took place in a carefully regulated in vitro cell culture 
environment, and therefore may not translate similarly to the in vivo situation 
observed in our study.  
 
It should be noted that the western blot analysis carried out in this chapter has a 
technical limitation. The R.O.D. of each protein band were normalised against the 
background intensity of the respective film for semi-quantitative analysis. Ideally, an 
internal control should have been run on each gel for a housekeeping protein such as 
actin or beta-tubulin, in order to control and correct of any loading errors and to act 
as a reference for quantitation. Unfortunately, both these proteins have a similar 
molecular weight to ERK1/2 and JNK1/2, which would have made interpretation of 
the blots difficult. It has also been suggested that the levels of these proteins may 
vary following brain injury, which would also limit their suitability as an internal 
control (Liu and Xu, 2006). In the absence of an internal control, the gel was stained 
with Coomassie blue after transfer to check for equal loading in each lane. However, 
it would have been advantageous to use a non-interfering internal control such as 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in order to bypass this 
limitation. 
 
Stimulation of the ERK1/2 pathway via SDF-1 has also been implicated in 
proliferation of neural progenitor cells in vitro (Gong et al., 2006). Recently, a novel 
rodent gene encoding for a neural regeneration protein (NRP) has been discovered 
(Gorba et al., 2006). This protein appears to act in a similar manner to SDF-1, with 
initial findings suggesting that neural regeneration protein is able to induce neural 
migration, proliferation, enhanced survival and increased neuronal differentiation. Of 
these biological activities, neural regeneration protein was shown to promote neural 
migration through activation of the ERK1/2 pathway. 
 
Activation of JNK1/2 is a well-established marker for neuronal death, although there 
is also some evidence that JNK1/2 plays a role in regeneration and repair (Xia et al., 
1995, Herdegren et al., 1997). The data indicated a trend towards was an increase in 
phosphorylated JNK 1 and 2 associated with the ipsilateral hemisphere in APOE-KO 
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mice compared to WT mice with equivalent levels of ischaemic damage. In vitro 
studies have demonstrated that JNK1/2 activation occurs prior to neuronal apoptosis 
(Xia et al., 1995). This has been supported by in vivo studies, showing upregulation 
of phosphorylated JNK1/2 following transient global ischaemia in the gerbil 
(Kiessling, 1993), and prolonged phosphorylation of JNK1/2 after MCAo in the rat 
(Herdegen, 1998). In the latter study, a large proportion of neurons expressing 
phosphorylated JNK1/2 were also positive for the apoptotic TUNEL marker. As 
described earlier, apoE binding to lipoprotein receptors results in decreased 
phosphorylation of JNK1/2 (Hoe et al., 2005). In concordance with these findings, 
we observed higher levels of phosphorylated JNK1/2 in the ipsilateral hippocampus 
and caudate nucleus of APOE-KO mice subjected to 15 minutes BCCAo compared 
to WT mice. It is reasonable to speculate that this may be linked to the decreased 
survival of grafted MHP36 stem cells in the APOE-KO animals. There is also 
accumulating evidence linking JNK with the regulation of cell migration. Activation 
of JNK is closely associated with an increase in cell migration (Shin et al., 2001, 
Hauck et al., 2001). Inhibition of JNK markedly impedes the rate of migration of a 
variety of different cell types, including smooth muscle cells, embryonic stem cells 
and cortical neurons (Huang et al., 2003, Yamauchi et al., 2003, Kavurma and 
Khachigian, 2003, Kawauchi et al., 2003). The finding that JNK modulates the actin 
cytoskeleton during development of the Drosophila embryo suggests a possible 
mechanism for JNK to regulate cell migration (Martin-Blanco et al., 2000). 
However, the increased activation of JNK1/2 observed in APOE-KO mice did not 
correlate to increased migration of MHP36 stem cells, which was markedly further in 
WT mice. In vitro studies would provide further insight into alterations in signalling 
proteins during stem cell integration. 
 
Although the present study investigated the ERK and JNK pathways, apoE may 
interact with other signalling pathways and other lipoprotein receptors to influence 
neural stem cell integration. Two other members of the lipoprotein receptor family, 
apoER2 and the VLDL receptor are expressed predominantly in the brain and have 
been shown to play an important role in migration and localisation of neurons during 
development. Aside from apoE, the major ligand for these two receptors is Reelin. 
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Binding of Reelin induces phosphorylation of Dab1, which has been implicated in 
neuronal migration and synaptic plasticity. ApoE may also interact with the LRP5/6 
receptors (Kim et al., 1998), which are involved in canonical Wnt signalling. The 
Wnt / β-catenin signalling pathway has been implicated in regulation of neuronal 
differentiation in a variety of stem and precursor cells (Haegele et al., 2003, Otero et 
al., 2004, Hirabayashi et al., 2004). Clearly, mechanistic insight into apoE regulation 
of stem cell integration requires further investigation.  
 
4.5.5   Summary 
This study has demonstrated that the presence of apoE strongly influences the 
survival, migration and differentiation of grafted MHP36 stem cells. While the exact 
signalling mechanisms involved in these APOE-mediated processes have yet to be 
determined, this study provides evidence for the involvement of JNK1/2 signalling. 














Influence of APOE genotype on neural 
stem cell grafts in a mouse model of global 
ischaemia 
5.1  Introduction 
The previous study demonstrated that the presence of endogenous murine APOE 
plays a significant role in the integration and differentiation of MHP36 neural stem 
cell grafts following global ischaemia. However, humans express three different 
isoforms of APOE, namely APOE-ε2, ε3 and ε4 (Zannis et al., 1981). Although these 
isoforms only differ from each other by single amino acid substitutions at amino acid 
residues 112 and 158, these changes have profound effects on APOE structure and 
function. APOE-ε3 is the most common allele found in man, and is regarded as the 
benchmark “normal” APOE. In contrast, the APOE-ε4 allele is regarded as a 
deleterious allele, as it has been shown to be associated with increased risk of heart 
disease (Menzel et al., 1983), atherosclerosis (Davignon et al., 1988, Mahley and 
Huang, 1999), as well as poorer outcome after brain damage (Nicoll et al., 1995, 
1996, Teasdale et al., 1997, and Alzheimer’s disease (Corder et al., 1993, Saunders et 
al., 1993). Given that we have previously shown the importance of APOE on neural 
stem cell graft integration, the next step was to investigate whether different human 
APOE genotypes also influence stem cell grafts. Transgenic mice expressing the 
three human APOE isoforms were generated by introduction of the relevant gene into 
APOE-KO mice (Xu et al., 1996). These results will be pertinent for any future 
translation of stem cell therapies from the laboratory to the clinic.  
 
5.2  Aim 
The aim of the study was to investigate whether APOE genotype (APOE-ε3 or 
APOE-ε4) influences the survival, migration, differentiation of neural stem cell grafts 
and subsequent performance on a motor balance and coordination task following 
diffuse neuronal injury induced by global ischaemia.  
 
5.3  Materials and Methods 
 
5.3.1  Study outline 
Adult male APOE-deficient mice (APOE-KO) and mice expressing human APOE-ε3 
and APOE-ε4 were used in this study (Chapter 2, Section 2.1). The APOE-deficient 
mice used in this study were littermate controls, derived from breeding heterozygous 
 153
human APOE-ε3 or ε4 to homozygous APOE-KO mice. It was decided not to 
include a WT C57Bl/6J control group as the previous chapter had already illustrated 
the influence of endogenous apoE on MHP36 survival, migration and differentiation. 
In the case of the rotarod task, a study of the literature revealed that APOE-KO did 
not differ from WT mice in motor function, negating the need for a control group. 
Transient global ischaemia was induced by bilateral occlusion of the common carotid 
arteries (BCCAo). An occlusion time of 17 minutes was chosen based on the 
preceding chapter and a previous study in which APOE-ε3 and APOE-ε4 mice were 
subjected to BCCAo (Horsburgh et al., 2000). Mice were immunosuppressed with 
CsA as described in Chapter 2. Two weeks after global ischaemia, mice received 
unilateral grafts of PKH26-labelled MHP36 stem cells (Passage number 52-55) into 
the caudate nucleus and hippocampus. Pre-graft viability averaged 95% and post-
graft viability averaged 89%). Mice were tested for functional recovery in motor 
balance and coordination using the rotarod test. The outline of the test is described in 
Chapter 2, Section 2.4. Animals received two sessions per week, starting on the week 
after grafting, giving a total of seven tests. 4 weeks post-transplantation, mice were 
transcardially perfused. 27 animals (APOE-KO; n = 9, APOE-ε3; n = 8, APOE-ε4, n 
= 10) were processed for histology using the Callis method of freezing (Chapter 2, 
Section 2.6). Coronal cryostat sections were cut (10μm) and mounted onto poly-L-
lysine coated slides. Sections at the level of the injection tract were stained with 
haematoxylin and eosin to visualise the number of normal neurons. Adjacent sections 
were mounted and coverslipped in Vectashield for visualisation of PKH26-labelled 
MHP36 cells or stained with immunohistochemical markers against NeuN and 
GFAP as described in Chapter 2, Section 2.8. 
 
5.3.2  Quantification of ischaemic damage 
Haematoxylin and eosin stained sections were used to assess the extent of ischaemic 
damage in the same fields used to quantify the immune response using a 25mm2 grid 
(attached to the microscope optics) at 400x magnification.  The number of neurons 
exhibiting ischaemic cell change and morphologically normal neurons were counted 
in each grid.  Ischaemic neurons were defined by an intense, darkly stained pyknotic 
nucleus surrounded by eosinophilic cytoplasm.  Ischaemic damage was quantified in 
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the ipsi and contralateral caudate nucleus, and the ipsi and contralateral CA2 region 
of the hippocampus. Ischaemic neurons were identified following a haematoxylin 
and eosin stain. As described in Chapter 4, Section 4.3.2, the level of neuronal 
density as an index of surviving neurons was also assessed in the same regions used 
to assess ischaemic damage.  
 
5.3.3  Quantification of MHP36 graft survival and migration 
Sections were assessed for the number of surviving PKH26 labelled MHP36 cells 
using a confocal laser scanning microscope. Within the caudate nucleus, confocal z-
series images were captured at six regions surrounding the injection tract and 
quantified for the number of MHP36 cells. Within the hippocampus, five confocal z-
series images were captured along the granule cell layer of the CA region starting 
from the CA2 and progressing along the CA1 towards the septum. Migration of 
PKH26 labelled MHP36 cells was assessed in a medial, lateral and ventral direction 
away from the injection tract in both the caudate nucleus and hippocampus.  The 
distance of migration in each direction was measured using a 100mm2 grid (attached 
to the microscope optics) at 200x magnification. 
 
5.3.4  Immunohistochemistry 
Neuronal differentiation of MHP36 cells was assessed using a marker for neuronal 
nuclei (mouse monoclonal anti-NeuN).  Astrocytic differentiation of MHP36 cells 
was assessed using a marker for glial fibrillary acidic protein (GFAP). Primary 
antibodies were detected with a biotinylated secondary antibody followed by 
fluorescent strepavidin Alexa 488 (Invitrogen).  The immunohistochemistry protocol 
is described in Chapter 2, Section 2.8. 
 
5.3.5  Immunofluorescent analysis 
Sections were assessed for co-localization of phenotypic markers for neurons (NeuN) 
and astrocytes (GFAP) with PKH26 as a marker for transplanted MHP36 cells. 
Within the caudate nucleus, confocal z-series images were captured in five different 
fields medial, lateral and ventral to the injection tract in the caudate nucleus. Within 
the hippocampus, confocal z-series images were captured in four different fields 
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along the granule cell layer of the CA region starting at the CA2 and progressing 
along the CA1.  Neuronal and astrocytic differentiation was determined by counting 
the number of cells co-localizing with PKH26 after counting the number of PKH26 
positive cells within the same field.  
 
5.4  Results 
 
5.4.1  Ischaemic Damage 
The number of neurons remaining was assessed as an index of ischaemic neuronal 
damage. This was previously utilised and described in Chapter 4.  Within the caudate 
nucleus, there was no difference in the number of normal neurons in the contralateral 
hemisphere between the three groups. In the ipsilateral hemisphere, there was a 
significant increase in the number of normal neurons in APOE-ε4 mice compared to 
APOE-KO mice (19.28 ± 4.63 vs. 16.32 ± 2.80 normal neurons per 0.0625mm2, p < 
0.05) (Figure 5.1). A similar trend was also observed with APOE-ε3 mice compared 
to APOE-KO mice (18.83 ± 2.73 vs. 16.32 ± 2.80 normal neurons per 0.0625mm2, p 
> 0.05) although this comparison is not statistically significant.  
 
The number of normal neurons was also examined in the CA2 region of the 
hippocampus. In the contralateral hemisphere, there was a trend towards increased 
neuronal number on APOE-ε3 mice as compared to both APOE-KO (24.00 ± 6.99 vs. 
16.56 ± 8.90 normal neurons per 0.0625mm2, p > 0.05) and APOE-ε4 mice (24.00 ± 
6.99 vs. 15.90 ± 8.70 normal neurons per 0.0625mm2, p > 0.05) (Figure 5.2). The 
same trend was observed in the ipsilateral hemisphere (APOE-ε3; 21.75 ± 6.76 vs. 
APOE-KO; 16.67 ± 7.00 normal neurons per 0.0625mm2, p > 0.05 and vs. APOE-ε4; 
17.90 ± 9.80 normal neurons per 0.0625mm2, p > 0.05). None of these differences 


























































Number of morphologically normal neurons within the caudate 
nucleus
Number of normal neurons per 0.0625 mm2
 
in APOE-KO, APOE-ε3 and APOE-ε4 mice 
subjected to 17m BCCAo within the contralateral (A) and ipsilateral
 
(B) caudate nucleus. 





nucleus of APOE-ε4 mice compared to APOE-KO mice. Data are expressed as individual 























































Number of morphologically normal neurons within the hippocampus
Number of normal neurons per 0.0625 mm2
 
in APOE-KO, APOE-ε3 and APOE-ε4 mice 
subjected to 17m BCCAo within the contralateral (A) and ipsilateral
 
(B) CA2 region of the 
hippocampus. There was a trend towards increased numbers of normal neurons in APOE-
 
ε3 mice compared to the other genotypes, although this was not statistically significant. 
Data are expressed as individual data points, with the bar indicating the median. p > 0.05, 




5.4.2  MHP36 survival and migration 
In the caudate nucleus, survival of MHP36 stem cells was significantly improved in 
APOE-ε3 compared to APOE-ε4 mice (8.10 ± 2.89 versus 4.75 ± 3.04 PKH26 
positive MHP36 cells per 0.0350mm2, p < 0.05) or APOE-deficient mice (8.10 ± 
2.89 versus 4.15 ± 1.49 PKH26 positive MHP36 cells per 0.0350mm2, p < 0.05) 
(Figure 5.3 and 5.4). However, no significant difference in MHP36 survival was 
observed between the three groups in the hippocampus (Figure 5.5). It should be 
noted that markedly fewer MHP36 stem cells survived in the hippocampus as 
compared to the caudate nucleus.  
 
As before, migration was assessed in a medial, lateral and ventral direction away 
from the injection tract. In the caudate nucleus, there was a marginal trend towards 
improved migration in APOE-ε3 and APOE-ε4 mice compared to APOE-deficient 
mice, although this was not statistically significant (Figure 5.6). In the hippocampus, 
APOE-KO and APOE-ε4 mice exhibited a trend towards increased migration 
compared to APOE-ε3 mice in a medial direction, although there were no significant 
differences in any of the three directions (Figure 5.7). 
 
5.4.3  Neuronal differentiation of MHP36 stem cells 
There was no significant difference in the proportion of MHP36 cells differentiating 
into a neuronal phenotype between the three groups in the caudate nucleus (Figures 
5.8 and 5.9). In APOE-ε3 mice, approximately 35.79% ± 18.78% of grafted MHP36 
cells expressed a neuronal phenotype compared to 26.11% ± 16.33% in APOE-ε4 
mice and 27.96% ± 13.54% in APOE-KO mice. There were also no significant 
differences observed in neuronal differentiation of MHP36 cells between the three 
groups in the hippocampus. The largest proportion of MHP36 cells that differentiated 
into neurons was found in APOE-ε4 mice (26.52% ± 15.24%), followed by APOE-
KO mice (19.33% ± 16.27%) and then APOE-ε3 mice (12.27% ± 17.78%) (Figures 

































Number of PKH26 positive MHP36 cells in the caudate nucleus
The survival of MHP36 cells was significantly higher in APOE-ε3 mice as compared to 
APOE-KO and APOE-ε4. Data are expressed as individual data points, with the bar 


























images illustrating survival of MHP36 cells 
in the caudate nucleus
Confocal images of PKH26 positive MHP36 cells (red) in APOE-KO(A), APOE-e3 (B) 
and APOE-ε4 (C) mice within the caudate nucleus. There was increased survival of 


































Number of PKH26 positive MHP36 cells in the hippocampus
There was a trend towards improved survival in APOE-ε3 and APOE-ε4 mice compared 
to APOE-KO mice,although this was not statistically significant. Data are expressed as 
individual data points, with the bar indicating the median. p > 0.05, using Kruskal-Wallis 





















KO ε3 ε4KO ε3 ε4
Figure 5.6
 
Migration of MHP36 cells in the caudate nucleus
Distance migrated (mm) by MHP36 cells in APOE-KO, APOE-ε3 and APOE-ε4 mice 
subjected to 17m BCCAo within the caudate nucleus. Migration was
 
assessed in medial, 
lateral and ventral directions away from the injection tract. There was no significant 
difference between the three genotypes.
 
Data are expressed as individual data points, 
with the bar indicating the median.
 























KO ε3 ε4KO ε3 ε4
Figure 5.7
 
Migration of MHP36 cells in the hippocampus
Distance migrated (mm) by MHP36 cells in APOE-KO, APOE-ε3 and APOE-ε4 mice 
subjected to 17m BCCAo within the hippocampus. Migration was assessed in medial, 
lateral and ventral directions away from the injection tract. There was no significant 
difference between the three genotypes. Data are expressed as individual data points, 















































in the caudate nucleus
There was significant difference in neuronal differentiation between the three 
genotypes. Data are expressed as individual data points, with the bar indicating the 













images illustrating differentiation of MHP36 
cells in the caudate nucleus
Confocal images of PKH26 positive MHP36 cells (red) co-localising with the neuronal 
marker NeuN
 
(green, Panels A-C) and the astrocytic marker GFAP (green, Panels D-F) 
in APOE-KO, APOE-ε3 and APOE-ε4 mice within the caudate nucleus. There was no 
difference in neuronal and astrocytic differentiation between the three groups of mice. 










































Percentage of PKH26 positive MHP36 cells co-localising with NeuN 
in the hippocampus
There was no significant difference in neuronal differentiation between the three 
genotypes. Data are expressed as individual data points, with the bar indicating the 













images illustrating differentiation of MHP36 
cells in the hippocampus
Confocal images of PKH26 positive MHP36 cells (red) co-localising with the neuronal 
marker NeuN
 
(green, Panels A-C) and the astrocytic marker GFAP (green, Panels D-F) 
in APOE-KO, APOE-ε3 and APOE-ε4 mice within the hippocampus. There was no 
difference in neuronal and astrocytic differentiation between the three groups of mice. 




5.4.4  Astrocytic differentiation of MHP36 stem cells 
Within the caudate nucleus, a similar proportion of MHP36 cells differentiated into 
an astrocytic phenotype in all three groups (Figures 5.9 and 5.12). Approximately 
30.47% ± 15.94% of grafted MHP36 cells co-localised with an astrocytic marker in 
APOE-ε3 mice, compared to 25.14% ± 17.02% in APOE-ε4 mice and 25.51% ± 
19.83% in APOE-KO mice. There was no significant difference between the groups. 
A similar distribution was noted in the hippocampus, where around 19.29% ± 
14.79% of grafted MHP36 cells expressed an astrocytic phenotype in APOE-ε3 mice, 
compared to 13.37% ± 15.00% in APOE-ε4 mice, and 11.09% ± 14.69% in APOE-
KO mice (Figures 5.11 and 5.13). These data are summarised as pie charts in Figure 
5.14. 
 
5.4.5  Rotarod analysis 
All mice learnt how to balance and perform the rotarod task during the training 
session. The graphs showing the performance of each group of mice at the varying 
test speeds are shown in Figures 5.15 to 5.18. At all the rotation speeds, there were 
no genotype specific significant differences between the mice at any week post-
transplantation. However, the latency to fall increased for all groups over time at all 
rotation speeds, suggesting that the mice were improving in motor balance and 
coordination. As expected, increasing the rotation speed resulted in decreased latency 
to fall for all groups of mice.  
  
Due to the similar performance between the genotypes, I chose to calculate the area 
under the curve as an index of performance. At 8 rpm, the areas were as follows: 
APOE-KO: 172.6 ± 10.51 sq units, APOE-ε3: 173.8 ± 5.30 sq. units, APOE-ε4: 
171.1 ± 9.10 sq. units. There was no difference between the three groups at this 
speed. At 16 rpm (APOE-KO: 155.8 ± 17.37 sq units, APOE-ε3: 155.6 ± 21.33 sq. 
units, APOE-ε4: 141.4 ± 25.30 sq. units), APOE-ε4 mice are marginally impaired in 
performance compared to APOE-KO and APOE-ε3 mice. However, this trend has 
altered at the increased speed of 24 rpm (APOE-KO: 97.08 ± 26.48 sq units, APOE-
ε3: 87.10 ± 27.48 sq. units, APOE-ε4: 86.08 ± 37.74 sq. units). The human APOE 



































Percentage of PKH26 positive MHP36 cells co-localising with
 
 
GFAP in the caudate nucleus
There was no significant difference in astrocytic differentiation between the three 
genotypes. Data are expressed as individual data points, with the bar indicating the 







































Percentage of PKH26 positive MHP36 cells co-localising with GFAP 
in the hippocampus
There was no significant difference in astrocytic differentiation between the three
 
 
genotypes. Data are expressed as individual data points, with the bar indicating the 













genotype does not influence MHP36 stem cell differentiation





astrocytic or undetermined phenotype in APOE-KO, APOE-ε3 and APOE-ε4 mice in the 













































Motor performance on the rotarod
 
test at 8 rpm
The latency to fall for each genotype was measured at each week post-transplantation. 
There was no significant difference between the three genotypes at each week. All three 
groups reached a plateau of near-optimal performance by the third week post-
 
transplantation and maintained this through to the final week.. Data are presented as 
mean ±
 
S.E.M. p > 0.05, using repeated measures ANOVA.


















Motor performance on the rotarod
 
test at 16 rpm
The latency to fall for each genotype was measured at each week post-transplantation. 
There was no significant difference between the three genotypes at each week. APOE-
 
ε3 mice reached a plateau in performance by the second week post-transplantation, 
whilst APOE-KO and APOE-ε4 mice reached a plateau by the third week. Data are 
presented as mean ±
 



























Motor performance on the rotarod
 
test at 24 rpm
The latency to fall for each genotype was measured at each week post-transplantation. 
There was no significant difference between the three genotypes at each week. APOE-
 
KO and APOE-ε3 mice improved in performance over the four weeks, whilst APOE-ε4 
mice appeared to reach a plateau in performance by the third week. Data are presented 
as mean ±
 



























Motor performance on the rotarod
 
test at 32 rpm
The latency to fall for each genotype was measured at each week post-transplantation. 
There was no significant difference between the three genotypes at each week. All three 
groups improved in performance over the four weeks. Data are presented as mean ±
 















impaired compared to APOE-KO mice. This trend continues at the maximal speed of 
32 rpm. (APOE-KO: 47.43 ± 26.10 sq units, APOE-ε3: 37.64 ± 16.66 sq. units, 
APOE-ε4: 36.81 ± 20.96 sq. units). None of these differences were statistically 
significant (Kruskal-Wallis with Dunn’s post-test, p > 0.05). However, the trends 
provided by these data suggest that APOE-ε4 mice are marginally impaired on the 
rotarod task of motor balance and coordination compared to APOE-KO mice at 
moderate and high speeds. APOE-ε3 mice are able to perform at the same level as 
APOE-KO mice at moderate speeds, but their performance deteriorates to levels 
approaching that of APOE-ε4 mice at higher speeds.  
 
5.5  Discussion 
This study demonstrated that MHP36 graft survival was improved in APOE-ε3 
transgenic mice compared to APOE-ε4 and APOE-KO mice. However, there was no 
APOE genotype specific influence on the migration and differentiation of grafted 
MHP36 stem cells. There was minimal evidence that motor recovery following 
ischaemia and stem cell grafts was affected by APOE genotype. 
 
5.5.1 APOE genotype influences susceptibility to ischaemic 
damage  
The results indicate that within the caudate nucleus, there was no difference in the 
number of normal neurons between APOE-ε3 and APOE-ε4 mice. Both the human 
APOE-expressing mice exhibited an increased number of normal neurons compared 
to APOE-KO mice. However, in the hippocampal CA2 region, APOE-ε3 mice 
exhibited a trend towards increased neuronal number compared to both APOE-ε4 and 
APOE-KO mice in both hemispheres. These results confirm previous work by our 
group on the differences in susceptibility of human APOE-expressing transgenic 
mice to the effects of global ischaemia (Horsburgh et al., 2000). Histopathological 
analysis of APOE-ε3 and APOE-ε4 mice three days after induction of global 
ischaemia showed similar levels of ischaemic damage in the caudate nucleus in the 
two transgenic lines. However, examination of the CA1 pyramidal cell layer 
indicated a clear genotype specific difference. APOE-ε4 mice had markedly more 
ischaemic damage in this region compared to the APOE-ε3 mice (Horsburgh et al., 
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2000). Although this study investigated ischaemic damage at an acute time point, 
compiling the data from these two studies demonstrates that APOE-ε4 mice have a 
definite regional susceptibility to global ischaemia in the hippocampus. APOE-ε4 
mice have also been shown to be more susceptible that APOE-ε3 mice to other forms 
of brain damage, such as focal ischaemia (Sheng et al., 1998) and traumatic brain 
injury (Sabo et al., 2000). Thus, stem cell integration may be affected differently in 
the caudate nucleus and the hippocampus. 
 
5.5.2 APOE genotype influences MHP36 graft survival but has 
no effect on migration 
The results from this study demonstrate that there was increased survival of MHP36 
stem cells in APOE-ε3 mice as compared to both APOE-ε4 and APOE-KO mice 
within the caudate nucleus. The increased MHP36 cell survival in APOE-ε3 mice 
may reflect the beneficial effects of apoE3 compared to apoE4 described in the 
literature. ApoE3 has been shown to exert a neuroprotective effect through reduction 
of excitotoxicity, whilst apoE4 does not confer protection (Buttini et al., 1999).  The 
anti-oxidative potential of apoE3 is also superior to apoE4 (Miyata and Smith, 1996). 
These two properties of apoE3 could serve to reduce the extent of ischaemic damage, 
therefore providing a less hostile environment for the grafted MHP36 cells, and 
increasing the chances of survival. Alternatively, apoE3 may be involved in 
structural remodelling and support for the grafted stem cells. ApoE3 stimulates 
polymerisation of β-tubulin and microtubule stabilisation, whereas apoE4 
destabilises the assembly or microtubules (Nathan et al., 1995). The ability of apoE3 
to preserve the neuronal cytoskeleton could provide structural support for the 
survival and integration of grafted stem cells into host brain. Linked to this, apoE3 
has been shown to induce neurite outgrowth compared to inhibition of outgrowth by 
apoE4 (Nathan et al., 1994, Bellosta et al., 1995, Nathan et al., 2002), suggesting 
another mechanism by which apoE could aid the survival of transplanted MHP36 
stem cells. Interestingly, apoE3 has been associated with inhibition of cell 
proliferation, particularly endothelial and tumor cells (Ishigami et al., 1998, Vogel et 
al., 1994, Zeleny et al., 2002). In contrast, apoE4 is the least effective of all apoE 
isoforms regarding the inhibition of smooth muscle cell proliferation (Zeleny et al., 
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2002). These findings appear somewhat contradictory with the findings that apoE3, 
not E4 markedly promotes MHP36 neural stem cell survival, and lend further 
credence to the hypothesis that apoE3 assists graft survival through support 
mechanisms. However, it should be noted that the apoE4-mediated inability to inhibit 
cell proliferation is linked with cancerous disease conditions, suggesting that the 
inhibitory role of apoE3 is an essential regulatory function (Liestol et al., 2000, 
Moysich et al., 2000). 
 
Whilst MHP36 stem cells do not survive in the hippocampus to the same degree as in 
the caudate nucleus, there was a slight trend towards improved survival in APOE-ε3 
and ε4 mice as compared to APOE-KO mice in this region. An interesting 
comparison can be made with the previous study. Similar numbers of PKH26 
positive MHP36 cells were observed in the caudate nucleus of C57Bl/6J and APOE-
ε3 mice (approximately 8 cells per 0.0350 mm2). However, more MHP36 cells 
survived in APOE-KO mice from the current study (approximately 4 cells per 
0.0350mm2) compared to the equivalent mice from the previous study (APOE-KO, 
17m BCCAo, approximately 1.7 cells per 0.0350 mm2). Both studies followed the 
same experimental procedure, with the only major difference being the 
administration of behavioural testing on the rotarod in the current study. The 
mandatory exercise on the rotarod may account for the increase in stem cell survival 
in APOE-KO mice in this study as compared to the previous study. It has been well 
documented that exercise can increase endogenous neurogenesis (Van Praag et al., 
1999), and the mechanisms that underlie this may also promote graft survival. 
However, a possible caveat is that exercise-mediated neurogenesis classically takes 
place in the dentate gyrus of the hippocampus (van Praag et al., 1999, van Praag et 
al., 2005) rather than the SVZ, the region where changes relating to striatal grafts 
would be expected. Combined with this, there was no increase in the survival of 
MHP36 cells in the hippocampus of APOE-KO mice from this study compared to 
APOE-KO mice from the previous study.  
 
No significant differences were observed in distance migrated between the three 
groups. However, there was a trend towards improved migration in APOE-ε3 and ε4 
 179
mice as compared to APOE-KO mice within the caudate nucleus. As expected from 
the previous chapter, MHP36 cells migrated further when grafted into the 
hippocampus rather than into the caudate nucleus. Migration in the hippocampus was 
also more variable. Comparison of migration distance between this study and the 
previous study does not reveal any major difference. In vitro data from the literature 
suggests that human apoE inhibits smooth muscle cell migration (Ishigami et al., 
1998, Swertfeger et al., 2002, Zhu and Hui, 2003) via binding to LRP1 and activation 
of cAMP protein kinase A. All three human apoE isoforms inhibit smooth muscle 
cell migration to an equal degree, which could explain why no apoE isoform 
difference was observed for MHP36 stem cell migration. 
 
5.5.3 APOE genotype does not significantly influence MHP36 
stem cell differentiation 
There was no APOE genotype specific significant difference in the percentage of 
MHP36 cells expressing either a neuronal or astrocytic phenotype either in the 
caudate nucleus or hippocampus. Examination of the differentiation profiles (Figure 
5.14) suggests that within the caudate nucleus, there is an overall trend towards 
increased astrocytic and neuronal differentiation in APOE-ε3 mice compared to 
APOE-KO and APOE-ε4 mice. However, this is probably linked to the increased 
survival of MHP36 cells observed in this region in the APOE-ε3 mice (Figure 5.3), 
rather than through any genotype specific effect on differentiation. This is supported 
by the other differentiation profiles which show that the majority of MHP36 cells in 
all three groups of mice do not differentiate into neurons or astrocytes and either 
remain undifferentiated or are expressing a non-neuronal, non-astrocytic phenotype 
(Figure 5.14). The same charts show the similarity in differentiation profile between 
the mice. This consistent similarity suggests that there may be a baseline level of 
differentiation depending on the host region, which may be induced by a factor or 




5.5.4  APOE genotype does not influence motor recovery 
No differences in motor performance on the rotarod were observed between APOE-
KO, APOE-ε3 or APOE-ε3 transgenic mice in this study. All groups improved in 
performance over time, at all four test speeds. Interestingly, APOE-KO mice 
consistently exhibited a trend towards improved motor balance and coordination 
compared to both human APOE-transgenic groups as assessed by comparison of the 
area under the curve, although none of these differences were statistically significant.  
 
The lack of an observable genotype difference may be attributed to the selective 
neuronal damage associated with transient global ischaemia. The striatum is 
intimately involved in motor function and coordination, hence the choice of the 
behavioural rotarod test. However, all three groups exhibited similar numbers of 
normal neurons, and by extension, a similar degree of ischaemic damage in the 
striatum (Figure 5.1). There was a variation in number of normal neurons remaining 
in the hippocampus, with a trend towards increased number in APOE-ε3 mice 
compared to APOE-KO and APOE-ε4 mice, but this is unlikely to affect motor 
performance on the rotarod. It may be possible that motor performance tests are 
simply not sensitive enough to detect any changes in APOE transgenic mice, even in 
the aftermath of brain damage. In particular, it is also important to take into account 
whether the damage induced is unilateral (such as in models of focal ischaemia) or 
bilateral (such as the model of global ischaemia used in this thesis). Unilateral 
models offer greater sensitivity for detection as deficits in one hemisphere manifest 
on a variety of behavioural tasks such as the staircase pellet reaching test (Montoya 
et al., 1991), the rotameter and the rotarod. However, it could be argued the design of 
this thesis has resulted in a unilateral model, as a unilateral injection of neural stem 
cells was delivered into a bilateral model of damage.  
 
Hippocampal deficits are more suited to investigation through spatial learning and 
memory tasks such as the Morris water maze or 8-arm radial maze. Previous studies 
have demonstrated in rats that underwent 4VO induced global ischaemia, MHP36 
grafts were able to repopulate the lesioned CA1 layer and restore ischaemia related 
spatial deficits in acquisition of a hidden platform in the water maze (Sinden et al., 
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1997, Hodges et al., 2000). MHP36 grafted rats showed faster escape latencies and 
shorter swim distances than ischaemic, sham grafted rats. The performance of 
MHP36 grafted rats was similar to that of a group of sham ischaemia control rats.  
 
The Maeda strain of APOE-KO mice used in this study has been thoroughly 
investigated for their behavioural phenotype compared to wildtype C57Bl/6J 
littermate controls in a variety of tasks (Anderson et al., 1998). These investigators 
discovered no difference between APOE-KO and wildtype mice aged between eight 
to ten months in a series of neurological tests, cumulative locomotor activity or 
rotarod performance. These mice were not subject to any lesion which could have 
affected their performance. In the water maze trial, there was no genotype effect on 
the path length required to locate the platform in either the cued or the place task. As 
predicted from the locomotor activity tests, there was no difference in swim speed 
between the APOE-KO and wildtype mice. The probe trial demonstrated that both 
groups also exhibited spatial learning, as evidenced by the fact that they spent an 
equal preference time for the quadrant that previously contained the platform. 
Further evidence suggesting that apoE is not essential for motor recovery after injury 
came from a study by Goldstein et al (2000). There was no difference in the ability of 
APOE-KO mice from the Maeda strain to traverse along a narrow beam compared to 
wildtype C57Bl/6J mice following a unilateral sensorimotor cortex ablation. Both 
groups were virtually identical in their initial motor deficit, subsequent recovery rate 
and final levels of functional performance. 
 
Conflicting results were obtained from different strains of APOE-KO mice. Oitzl et 
al., (1997) also used the water maze to assess spatial learning and memory in the Van 
Ree strain (Van Ree et al., 1994) of APOE-KO mice. In this study, almost all APOE-
KO mice failed to find the underwater platform, whereas heterozygous mice acquired 
the task over time. The APOE-KO mice also did not develop any strategy to locate 
the platform, but instead repetitively swam and bumped against the sidewall of the 
pool for the duration of the trial. No differences in locomotor activity or swim speed 
were found between the APOE-KO mice and the heterozygous group, ruling out the 
possibility that motor disturbances are responsible for the abnormal “wall-bumping” 
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behaviour. The authors conclude that this Van Ree strain of APOE-KO mice suffer 
from a spatial learning deficit. Later studies demonstrated that exposure of these 
APOE-KO mice to a stressful environmental experience (rat stress) resulted in a 
decrease in corticosterone concentration, concomitant with improved spatial learning 
on the water maze (Grootendorst et al., 2001). Interestingly, the APOE-KO mice 
adopted a persistent goal-directed search strategy rather than the concentric “wall-
bumping” strategy observed previously. Another strain of APOE-KO mice created by 
Breslow (Plump et al., 1992) has also been assessed for working and reference 
memory in a water maze task. Over a four-day period, mice were given twice-daily 
trials to locate a submerged platform. Both APOE-KO and control mice displayed 
decreasing latencies to reach the platform over subsequent days, showing an 
improvement over time. However, an APOE genotype dependent effect was 
observed during the two daily trials. Control mice improved their performance in the 
second daily trial as compared to the first trial, but there was no difference in 
latencies between the two daily trials in APOE-KO mice. The data suggest that 
whilst the Breslow strain of APOE-KO mice is not impaired in reference memory, 
they have a deficit in working memory. This deficit has been linked to cholinergic 
impairments in the hippocampus and frontal cortex (Gordon et al., 1995). Common 
to the other two strains of APOE-KO mice, the Breslow strain did not differ from 
control mice in swimming speed. Although APOE-KO mice from the Maeda strain 
exhibited widespread neuronal degeneration throughout the hippocampus after mild 
induction of concussive-like brain injury, this is not paralleled with any deficits in 
motor function (Han and Chung, 2000). However, induction of similar closed head 
injury in APOE-KO mice from the Breslow strain resulted in prolonged motor and 
cognitive deficits as compared to control mice. These behavioural deficits were 
observed in conjunction with overt bilateral neuronal death in the hippocampus of 
the APOE-KO mice. Taken together, these studies demonstrate a clear background 
difference between the three APOE-KO strains in behavioural measures of learning 
and memory.   
 
Exposure to an enriched environment can also influence motor function in APOE 
transgenic mice (Levi et al., 2003). Three week old APOE-ε3, APOE-ε4, APOE-KO 
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(all derived from the Maeda strain) and C57Bl/6J mice were placed either in regular 
cages without additional items or cages containing exploratory items such as tunnels, 
toys, and running wheels. Motor performance was assessed by measuring the latency 
to fall from a rotarod rotating at 10 rpm over a 60s trial. Initially, APOE-ε4 and 
APOE-KO mice housed in a regular environment exhibited a quicker latency to fall 
compared to regularly housed APOE-ε3 and C57Bl/6J mice. However, subsequent 
training improved the performance of APOE-ε4 and APOE-KO mice to the same 
level as control mice. In contrast, all of the mice housed in an enriched environment 
performed equally and optimally in the rotarod trials. Whilst these mice did not 
receive any form of neurological insult, the results suggest that the APOE genotype 
has minimal effects on motor performance and coordination, and that these effects 
can be countered with exposure to an enriched environment. Similarly, all the mice 
in our study were housed with a cardboard tunnel for exercise and exploration, which 
may explain the lack of an observable genotype difference in motor performance 
between the three groups. The same study by Levi et al., (2003) also investigated 
learning and memory using the T-maze paradigm. Environmental enrichment 
increased the speed of learning and also prolonged the duration of working memory 
in wild type mice. APOE-ε3 mice but not APOE-ε4 mice improved in learning and 
memory in response to an enriched environment. An interesting observation was the 
fact that C57Bl/6J mice expressing endogenous mouse apoE performed better on 
these learning and memory tasks compared to the corresponding human APOE-ε3 
expressing mice. One possible explanation for this discrepancy arises from 
differences in the background strain of these mice. Lominska et al., (2001) have 
demonstrated that six month old apoE-deficient mice bred onto the C57BL/6J 
background exhibited impairment in learning on an olfactory based radial arm maze. 
Notably, this impairment was not observed in wildtype C57BL/6J mice, or in apoE-
deficient or wildtype mice on the FVB/N background. It is possible that the APOE-
ε3 and ε4 mice used in our study have inherited the behavioural deficits of the 
APOE-KO mice used for derivation as they are heterozygous for the APOE-KO 




A recent study from our group investigated learning and memory in young and aged 
APOE-KO, APOE-ε3 and APOE-ε4 mice with wildtype C57Bl/6J controls (Kennedy 
et al., in press). On a normal serial spatial learning task, APOE-KO, human APOE 
transgenics and WT mice all learn to the same ability. However, on the more 
demanding Atlantis platform spatial learning task, where the animal has swim to and 
remain within in the region of the platform for a set amount of time before the 
platform rises, APOE-KO mice are impaired compared to WT controls in both young 
and aged mice. Intriguingly, this cognitive impairment was ‘rescued’ in young mice 
expressing human APOE-ε3 or APOE-ε4. However, no rescue effect was observed in 
aged human APOE transgenics. There was no genotype specific difference between 
the APOE-ε3 and ε4 strains. Therefore, it appears that the human APOE transgenic 
mice have a similar cognitive facility to wildtype C57BL/6J mice at a young age, but 
following age-related cognitive decline, their behavioural phenotype shifts to that 
similar to APOE-KO mice, although this can only be detected on a complex learning 
task. Results from this study reiterate the behavioural similarity between WT, APOE-
KO and human APOE transgenic mice and further support previous data suggesting a 
phenotypic difference between endogenous mouse and human apoE. 
 
5.5.5 Murine and human apoE display differences in structure, 
function and synthesis 
A possible reason for results observed in this study may be due to the differences 
between murine APOE and the human form. The mouse and human APOE gene 
sequences share 78% homology and 70% amino acid homology (Rajavashisth et al., 
1985). Like all animal APOE, mouse APOE only exists in one isoform. The gene 
sequence for mouse APOE encodes for the arginine residue at position 112 and 
glutamate at position 255, providing sequence similarity to human APOE-ε4. 
However, at residue 61, the mouse APOE gene sequence encodes threonine, in 
contrast to the arginine in human APOE. The absence of a charged residue at this 
position causes a conformational change, meaning that mouse APOE does not have 
the N-C terminal interaction of human APOE-ε4. Therefore, although mouse APOE 
has sequence similarity to human APOE-ε4, it has structural and functional similarity 
with human APOE-ε3. Still, if mouse APOE had complete functional similarity with 
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human APOE-ε3, we would have expected similar results between the C57BL/6J 
mice grafted with MHP36 cells in the previous study and the APOE-ε3 mice used in 
this study. Astrocytes derived from wildtype C57Bl/6J, APOE-KO and human 
APOE-ε3 and APOE-ε4 expressing mice secrete HDL particles composed of 
phospholipids, free cholesterol, along with apoE and apolipoprotein J (apoJ). 
However, HDL particles secreted from human E3 and E4 astrocytes contained less 
lipid than mouse wildtype particles, even though they contain twice as much apoE 
(Fagan et al., 1999). Endogenous mouse apoE appears to support the production of 
an HDL particle with a greater lipid:apoE ratio than human apoE, suggesting that 
mouse apoE may be more efficient at binding lipid than the human form.  
 
There are other differences between the APOE transgenic mice and C57BL/6J 
wildtype mice, which may account for the difference observed. The pattern of apoE 
expression is altered in the APOE transgenic mice. During the creation of the human 
APOE transgenics, Xu et al. carried out immunocytochemical analysis for the 
location of APOE (Xu et al., 1996). In both wildtype and APOE transgenic mice, 
apoE-immunoreactive glia was present in all brain regions, and especially prevalent 
in the grey matter. Other apoE positive cells include the ependymal cells and 
Bergmann glia in the cerebellum. In the wildtype mice, no neurons were 
immunoreactive for apoE. In contrast, nearly all of the transgenic lines generated 
exhibited some degree of apoE-immunoreactivity in selected neurons. This was 
especially apparent in the cerebral cortex. ApoE positive neurons were always found 
in regions already containing immunoreactive glia. The presence of apoE in neuronal 
cells was validated by electron microscopy. The pattern of apoE expression in these 
transgenic mice mirrored that observed in human and non-human primate brain. This 
localisation of apoE expression was confirmed by in situ hybridisation (Xu et al., 
1998). It should be noted that this constitutive neuronal expression of apoE is 
different from the upregulation of neuronal apoE observed in both human and mouse 
brain after damage.  
 
Another difference between mouse and human apoE relates to its synthesis and 
secretion. Macrophages have long been identified as a source of apoE (Basu et al., 
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1981). Following incubation with acetyl-LDL, macrophages internalise the 
lipoprotein and deliver it to lysosomes, where the cholesterol esters are hydrolysed. 
The free cholesterol re-esterifies in the cytoplasm and accumulates as cholesteryl 
ester droplets. In the presence of a cholesterol binding substance such as HDL in the 
surrounding medium, these cholesterol-loaded macrophages secrete large quantities 
of free cholesterol, along with apoE. This process of reverse cholesterol transport 
serves to regulate the cellular levels of cholesterol. ApoE acts as a ligand for delivery 
of the HDL-bound cholesterol to the liver, where it is excreted. Treatment of mouse 
peritoneal macrophages with acetyl-LDL stimulates in a 24-fold increase in the 
production of apoE, whereas the same treatment only results in a 2-fold increase in 
apoE production in human monocytes (Basu et al., 1982). Along with this reduction 
in apoE synthesis, human monocytes also secrete less apoE than mouse 
macrophages. ApoE constitutes approximately 1-2% of secreted protein in human 
monocytes, compared to approximately 4-5% in the mouse peritoneal macrophage 
(Basu et al., 1982). The marked reduction in the synthesis and secretion of apoE in 
human cells compared to mouse cells could explain the difference in MHP36 
integration. Chapter 4 demonstrated the critical role of apoE on promoting MHP36 
survival and migration, and directing the stem cells towards a neuronal phenotype. 
The in vitro studies suggest that apoE synthesis in mouse cells can be as much as 
1100 % that of synthesis in human cells. This also manifests in the actual secretion of 
apoE, which is increased by at least 100 % in mouse cells as compared to human. 
Taken together, these data suggest that the lack of human apoE mediated effect on 
MHP36 integration may simply be due to insufficient levels of apoE in the human 
transgenic mice. This hypothesis could be investigated through exogenous delivery 
of human apoE to APOE-KO mice after an episode of global ischaemia and 
transplantation of stem cells. Infusion of apoE has been shown to ameliorate 
neurological deficits and exert a neuroprotective influence (Masliah et al., 1997, 
Horsburgh et al., 2000). 
 
In retrospect, it is unfortunate that a wildtype C57Bl/6J control group was not 
included in this study. This would have allowed for replication and verification of the 
results from the previous study regarding WT and APOE-KO mice. Also, it would 
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have been interesting to observe any differences between the human APOE 
transgenic and WT mice. However, the general consensus from the literature outlined 
above strongly suggests that APOE-KO mice are minimally impaired in motor 
function, so any further insight from incorporating a WT group may have been 
limited. With the addition of the rotarod test for investigation of the functional 
integration of MHP36 grafts, it would also have been advantageous if a control group 
for ischaemia had been included, in order to determine the extent of ischaemia 
induced motor impairment. Future work could incorporate these experimental groups 
in order to ascertain the differences between mouse and human apoE. 
 
5.5.6  Summary 
In summary, there was no isoform specific effect (APOE-ε3 or ε4) on MHP36 neural 
stem cell migration, differentiation and motor recovery. The only exception was 
improved and robust MHP36 survival in the caudate nucleus of APOE-ε3 mice. 
However, for all the other endpoints, there was no discernable difference between 
APOE-KO mice and human APOE expressing transgenic mice. The previous study 
demonstrated a clear improvement in MHP36 survival, migration and differentiation 
in APOE-expressing wildtype C57Bl/6J mice compared to APOE-KO mice. 
Therefore, it was hypothesized that the APOE-ε3 and ε4 mice would exhibit a similar 
improvement in this study. The differences between mouse and human apoE and 
their interaction with the murine MHP36 cells may explain these somewhat 
contradictory findings. Further studies should investigate how species specific 

















There has been considerable investigation into the benefits of neural replacement 
therapy for neurological disorders. This thesis has extended on previous work by 
illustrating the therapeutic effects of neural stem cell grafts in a diffuse model of 
brain injury in the mouse, and provided initial evidence that the lipid transport 
protein, apoE, significantly influences the survival, migration and differentiation of 
grafted neural stem cells in host brain. 
 
6.1  Summary of Thesis 
Previous work illustrating the therapeutic potential of the MHP36 stem cell line 
utilised a variety of animal models of brain injury. In the rat, these include the 4-VO 
model of global ischaemia (Sinden et al., 1997), the MCAo model of focal ischaemia 
(Veizovic et al., 2001, Modo et al., 2002), lesion of the cholinergic system similar to 
that observed in Alzheimer’s disease (Grigoryan et al., 2000) and age associated 
deficits (Hodges et al., 2000). In a promising step for future clinical applications, 
MHP36 grafts demonstrated functional reconstruction of the lesioned CA1 
hippocampus in primates (Virley et al., 1999). However, there have been no studies 
into mouse models of brain injury with the MHP36 stem cell line. Overall, a search 
of the literature reveals comparatively few studies investigating neural stem cell 
transplantation as a therapy in mouse models of brain damage. Translating neural 
transplantation research to mouse models opens up the possibility of utilising 
transgenic mice in order to investigate genetic factors which may influence stem cell 
grafts. In this thesis I utilised various strains of APOE transgenic mice, specifically a 
knockout strain (APOE-KO) and strains expressing the human isoforms of apoE 
(APOE-ε3 and APOE-ε4).  
 
However, due to the lack of neural transplantation research conducted with mouse 
models of brain damage, it was initially necessary to characterise MHP36 stem cell 
graft integration prior to conducting studies in transgenic mice. The model of brain 
damage used for all experimental studies in this thesis was the BCCAo model of 
global ischaemia. This model induces diffuse neuronal damage in the regions of the 
striatum and the hippocampus. MHP36 stem cells unilaterally transplanted into the 
striatum of C57Bl/6J mice subjected to 17 minutes global ischaemia survived up to 4 
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weeks post-transplantation. Further investigation into the characteristics of the 
transplanted MHP36 cells revealed that they migrated away from the injected area 
towards the regions of damage. The extent of ischaemic neuronal damage was 
reduced in MHP36 grafted mice compared to vehicle grafted mice, suggesting that 
the therapeutic properties of MHP36 stem cells can be translated to mouse models of 
brain damage. This reduction in neuronal damage was associated with neuronal 
differentiation of approximately half of all MHP36 cells. Importantly, the MHP36 
grafts did not elicit a major, chronic inflammatory response as assessed by astrocytic 
and microglial reactivity. Immunosuppression with CsA did not affect the survival 
and migration of MHP36 stem cells or the degree of the inflammatory response. This 
study demonstrated successful transplantation and integration of MHP36 grafts into 
ischaemic mouse brain, and validated the therapeutic potential of MHP36 grafts.  
 
The subsequent study extended on the initial characterisation results by incorporating 
APOE-KO mice in order to investigate the role of apoE on MHP36 stem cell survival 
migration and differentiation. C57Bl/6J mice with endogenous mouse apoE were 
compared to APOE-KO mice. Endogenous mouse apoE significantly improved 
MHP36 stem cell survival and migration in both the striatum and hippocampus. The 
percentage of MHP36 cells differentiating into a neuronal phenotype was also 
markedly increased in mice containing apoE. ApoE also promoted astrocytic 
differentiation of MHP36 cells in the striatum, but not in the hippocampus. 
Endogenous apoE influenced the ability of MHP36 cells to reduce the extent of 
ischaemic neuronal damage. Protein analysis on these mice revealed selective 
alterations in JNK cell signalling but not ERK signalling in APOE-KO mice but not 
C57Bl/6J mice, suggesting that the JNK pathway may be responsible for apoE 
mediated effects on MHP36 stem cell integration. 
 
With the evidence that endogenous mouse apoE plays a critical role in MHP36 stem 
cell integration, the final study sought to identify whether human APOE genotype 
influenced MHP36 stem cell grafts. It has been well established that human APOE 
genotype can markedly influence outcome after brain injury, with possession of the 
APOE-ε4 allele linked to an unfavourable outcome. As the goal for neural 
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transplantation research is translation to the clinic, it is imperative to investigate 
human genetic factors which could affect patient outcome. APOE genotype is also a 
factor that can be controlled prior to clinical trials. Therefore, this study used 
transgenic mice expressing the human ε3 or ε4 isoforms on an APOE-KO 
background. The presence of human APOE-ε3 significantly improved MHP36 graft 
survival compared to human APOE-ε4. However, no human APOE genotype effect 
was observed on MHP36 graft migration. There was a trend towards increased 
neuronal and astrocytic differentiation in mice expressing human APOE-ε3. 
Functional assessment of motor balance and coordination of these mice did not 
reveal any human APOE genotype influence. These results suggest that human apoE 
has a minimal effect on MHP36 stem cell integration.  
 
The data presented in this thesis support the initial hypothesis that apoE plays 
important roles in MHP36 stem cell integration as measured by survival, migration 
and differentiation. However, there was minimal evidence that this effect of apoE 
was dependent on human APOE genotype.  
 
6.2  Host Mechanisms for Directing Neural Stem Cells 
The finding that apoE significantly influences neural stem cell survival, migration 
and differentiation is a key step in elucidating the various mechanisms by which 
transplanted stem cells are able to exert a therapeutic influence. Few studies of neural 
transplantation therapy have investigated the actual mechanisms which affect stem 
cell integration. The data in this thesis demonstrates that transplanted stem cells 
interact with factors in host brain, and this interaction may be responsible for 
mediating the subsequent action of the grafted cell.  
 
Further work on the role of apoE will revolve around how apoE exerts the ability to 
modulate stem cell integration. The myriad functions of apoE (lipid transport, 
modulation of excitotoxicity, anti-oxidation, and cytoskeletal support, described in 
section 1.7.4) have all been implicated as potential pathways for aiding stem cell 
survival, migration and differentiation. Whilst in vivo studies provide invaluable 
information on whole system interactions and physiologically relevant data, it may 
 191
be more useful to move to in vitro studies to focus on possible mechanism by which 
apoE interacts with stem cells. For example, Soulié et al., (1999) provided the initial 
evidence that apoE influences neuronal differentiation in SH-SY 5Y cells. It will also 
be relevant to discover why endogenous mouse apoE markedly influences MHP36 
neural stem cells integration, but human apoE failed to do the same. Again, in vitro 
studies may be more useful, as data from the literature suggests that synthesis and 
secretion of apoE in mouse cells is markedly higher than in human cells (Basu et al., 
1982, 1982), raising the possibility that a certain level of apoE is required in order to 
influence grafted stem cells. Clearly, the species aspect raises the possibility that we 
may require the use human stem cells in order to observe any beneficial effect of 
human apoE. 
 
As described in Section 4.5.6, apoE may also interact with the Wnt signalling 
pathway through the LRP5/6 receptors (Kim et al., 1998). This is of interest as the 
canonical Wnt / β-catenin pathway has recently been investigated for its role in 
regulating neuronal differentiation. Wnt has been shown to promote neuronal 
differentiation of neurospheres (Muroyama et al., 2004), embryonic stem cells 
(Haegele et al., 2003, Otero et al., 2004), cortical neural precursor cells (Hirabayashi 
et al., 2004) and in dopaminergic precursors (Castelo-Branco et al., 2003, Castelo-
Branco and Arenas, 2006). 
 
Recently, a number of studies have identified another endogenous protein which may 
influence neural stem cell migration and proliferation, namely stromal cell derived 
factor-1 (SDF-1), one of the members of the chemotactic cytokine family. SDF-1 is 
an inflammatory cytokine which is upregulated by astrocytes and the local 
endothelium following injury (Zhou et al., 2002, Rubin et al., 2003).  SDF-1 has only 
one cognate receptor, chemokine (C-X-C motif) receptor 4 (CXCR4). Interestingly, 
NSCs have been demonstrated to express CXCR4 (Tran et al., 2004), suggesting that 
the SDF-1 – CXCR4 pathway may be involved in targeting of stem cell movement.  
The importance of the interaction between SDF-1 and CXCR4 to homing and 
development has been demonstrated in haemotopoietic stem cells (Peled et al., 1999, 
Ponomaryov et al., 2000, Tavor et al., 2004). Recently, the SDF-1 – CXCR4 
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pathway has been implicated in directed migration of transplanted NSCs to the site of 
damage after cerebral hypoxic-ischaemic injury and focal ischaemia (Imitola et al., 
2004, Robin et al., 2006). This pathway also regulates the migration of neural 
progenitors during development in the mouse embryo (Belmadani et al., 2005). As 
well as influencing migration, the SDF1-CXCR4 pathway has also lately been 
postulated to promote neural stem cell proliferation (Guo et al., 2005, Gong et al., 
2006).   
 
Another endogenous protein strongly implicated in regulation of stem cell survival is 
Notch, a cell membrane protein involved in determining cell fate during development 
(Lewis, 1998). Recently, the Notch signalling pathway has been linked with the 
maintenance of stem cell survival (Hitoshi et al., 2002, Oishi et al., 2004, Alexson et 
al., 2006). In the absence of Notch, apoptosis of neural progenitor cells and 
differentiating neurons is increased during development of the nervous system 
(Mason et al., 2006). Conversely, administration of Notch ligands and activation of 
the Notch signalling pathway promotes neural stem cell survival and increases the 
rate of neurogenesis after an ischaemic injury (Androutsellis-Theotokis et al., 2006).  
 
These studies have provided initial information on the various host mechanisms 
which can influence stem cell survival (Notch), migration (SDF-1) and 
differentiation (Wnt). Additionally, data in this thesis has implicated apoE in 
assisting these functions. Further investigation is required into the interactions 
between apoE and these respective signalling proteins. Despite the fact that the 
mechanisms of neural stem cell transplant therapy remain to be completely 
elucidated, the eventual aim for neural transplantation therapy is translation to the 
clinic. Encouraging reports from proof-of-principle animal studies have led to a 
number of Phase I and II clinical trials. These have focused on three diseases, 
Parkinson’s disease, Huntington’s disease and ischaemic stroke.  
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6.3  Clinical Trials of Neural Transplantation 
6.3.1  Parkinson’s disease 
Parkinson’s disease was one of the initial neurological disorders targeted for neural 
replacement therapy. This is due to the unique pathology associated with the 
disorder, namely the selective loss of melanin-pigmented neurons in the substantia 
nigra, leading to a deficiency of dopamine in the striatum. Dopamine replacement 
through administration of the amino acid precursor L-DOPA provides symptomatic 
relief for Parkinson’s disease patients, but the effective duration of this therapy is 
limited. However, this demonstration strongly suggested that replacement of the 
damaged dopaminergic neurons is a viable therapy for long-term treatment. Since 
1987, approximately 350 patients with Parkinson’s disease have received transplants 
of foetal dopaminergic neurons (Bjorklund, 2005). These studies were all open-label 
trials designed for safety and efficacy. Overall data from these trials demonstrate that 
these foetal neurons are able to survive and functionally integrate into Parkinson’s 
disease brain. These grafts typically reduce motor scores on the Unified Parkinson 
Disease Rating Scale (UPDRS) by 30-50%, and this is linked with increased 
dopamine synthesis and retention as visualised by fluorodopa PET scanning in the 
grafted regions. Promisingly, the grafts appear to provide long-lasting symptomatic 
improvement in the majority of grafted patients, with graft-induced recovery of 
function maintained for up to 10 years in a number of patients. Based on these 
encouraging results, in 1993 the NIH supported the setup of two placebo-controlled 
double blind trials of foetal dopaminergic tissue for patients afflicted with advanced 
Parkinson’s disease. The first of these studies to be published was the 
Denver/Columbia study (Freed et al., 2001). A total of 20 patients received grafts 
and no immunosuppression was provided. Overall, the grafted patients did not show 
a significant improvement in scores on the UPDRS compared to sham grafted 
patients, although this appeared to be related to age, as grafts did elicit a marked 
improvement in patients younger than 60 years of age. Five of the grafted patients 
displayed recurrence of dystonias and dyskinesias. However, patients in this study 
received less foetal tissue than in the open-label trials. Two grafted patients died of 
unrelated issues during the follow-up period. Autopsy analysis revealed that the 
numbers of dopaminergic neurons in the putamen ranged from 7000 to 40,000 (Freed 
 194
et al., 2001). This is in stark contrast to overall numbers from the open-label trials, 
which ranged from 80,000 to 135,000 (Kordower et al., 1995), clearly demonstrating 
that functional efficacy is related to the number of functioning dopaminergic 
neurons.  
 
The second double-blind clinical trial was conducted in Tampa/Mount Sinai (Olanow 
et al., 2003). 23 patients received foetal tissue grafts from one or four donors and 
were monitored for 2 years. Patients received CsA immunosuppression for a period 
of 6 months. However, there was no difference between grafted and sham patients in 
UPDRS scores after the 24 months. The patients who did receive tissue from four 
donors did show marked improvement in their UPDRS scores up to six months after 
surgery but this deteriorated over the following months back to pre-operative 
readings. Whilst PET scanning revealed an increase in fluorodopa uptake in the 
grafted patients, approximately half of all grafted patients developed dyskinesias.  
 
The overall results from these double-blind trials were not as promising as hoped. 
Interestingly, both trials showed a short-term improvement in UPDRS score (up to 6 
months post surgery), although improvement plateaued at this time point in 
Denver/Columbia trial and began to deteriorate in the Tampa/Mount Sinai trial. In 
contrast, patients in the open-label trials continued to show improvement between 6 
to 12 months after surgery and in some exceptional cases this extended into the 
subsequent year. As described previously, this difference may be attributable to the 
volume of tissue transplanted. However, another major difference between the trials 
was the use of immunosuppression. In the promising open-label trials, a high-dose 
triple immunosuppression regimen was used for at least 12 months (Wenning et al., 
1997), compared to a 6 month low-dose CsA regimen in Tampa/Mount Sinai and an 
absence of immunosuppression in Denver/Columbia. It is eminently possible that the 
lack of significant functional improvement in the double-blind trials was due to a 
delayed immunogenic response to graft tissue and failure to properly integrate. 
Although this thesis has argued that CsA immunosuppression does not significantly 
influence the effects of grafted MHP36 stem cells, it is important to note the 
difference between a well-established and characterised stem cell line as compared to 
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allogeneic primary human tissue. The acute inflammatory response that may be 
induced from allogeneic grafts may be controlled with immunosuppression but in 
some cases, the response is merely delayed rather than diminished. In this delayed 
state, transplanted dopamine neurons are unable to survive and function optimally 
(Hudson et al., 1994, Shinoda et al., 1995), and there is every risk of the 
inflammatory response flaring up once immunosuppression is halted. The choice of 
patient selection also influences graft efficacy, as observed in the Denver/Columbia 
trial in the case of patient age. Despite the less than encouraging results from the two 
completed double-blind trials, it is promising to note that there were minimal 
complications associated with the procedure and no adverse effects of the graft were 
reported. Most of the problems associated with the trials have been linked to 
technical aspects of study design. 
 
6.3.2  Huntington’s disease 
Five patients with Huntington’s disease received bilateral transplantation of foetal 
striatal tissue. During the initial follow-up, conducted two years after surgery, three 
out of the five patients displayed improvements in motor and cognitive function 
compared to a reference group of untreated patients (Bachoud-Levi et al., 2000). 
These three patients also showed increased metabolic activity in the striatum and 
cortex during MRI and PET scanning, suggesting that the clinical improvement was 
due to functional graft effects (Gaura et al., 2004). Recently, a long term follow-up 
study 6 years after surgery was reported (Bachoud-Levi et al., 2006). The two 
patients who did not show any clinical improvement during the initial assessment 2 
years after surgery continued to decline over the 6 year period. For the other three 
patients, the striking recovery in striatal and cortical regions observed at 2 years post 
surgery persisted over time. Their performance on cognitive tasks remained stable on 
non-timed tests, but progression of motor disability was demonstrated by 
deterioration on timed tasks. However, at this time point, the underlying progression 
of the disease is beginning to countermand the therapeutic effect of the grafts. 
Metabolic function deteriorated in non-grafted regions of the brain, suggesting that 
the foetal grafts have not been able to halt the disease, but merely impede the rate of 
progression. Nevertheless, the clinical improvement observed by the three patients 
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was also reflected in an improvement in their quality of life, with the patients 
regaining the ability to perform activities that they had lost before, such as cycling, 
work and playing a musical instrument. This is a clear demonstration of the potential 
offered through regenerative therapies, as this is the first treatment to induce 
prolonged benefit over the range of symptoms associated with Huntington’s disease. 
Currently, a larger, multicentre Phase II trial in France is recruiting patients.  
 
6.3.2  Stroke 
Cell replacement trials for ischaemic stroke have used LBS neurons (Layton 
Bioscience Inc.) derived from the NT2 teratocarcinoma cell line (Chapter 1). The 
initial Phase I trial was an open study designed to test safety. Twelve patients with 
basal ganglia strokes of 6 months duration and static neurological deficits received 
stereotactic injections of either 2 million or 6 million LBS cells (Kondziolka et al., 
2000). The patients received comprehensive follow-up monitoring with MRI and 
PET scans, and assessment on the National Institutes of Health Stroke Scale 
(NIHSS), European Stroke Scale (ESS) and Barthel Index (BI). No patient suffered 
from adverse effects attributed to the transplantation procedure, although there were 
side effects associated with immunosuppression. There was an overall improvement 
in the ESS, particularly in motor function, which correlated with increased metabolic 
activity on PET (Meltzer et al., 2001). A post-mortem examination of a patient who 
had not shown any clinical improvement upon assessment and died of an unrelated 
cause 2 years after surgery revealed neuronal phenotypes within the region of 
implantation without evidence of plasticity or integration. Importantly, there was no 
indication of safety issues associated with the stem cells (Nelson et al., 2002).  
 
Based on the promising results from the Phase I trial, a Phase II trial was initiated. 
The format for this study was a randomized, open-label trial with blinded 
neurological evaluation (Kondziolka et al., 2005). However, this trial was open to 
patients with intracerebral hemorrhage as well as basal ganglia stroke. The first 
group of patients were randomized to transplantation of 5 million LBS cells in 
conjunction with rehabilitation versus rehabilitation alone. The second group of 
patients followed the same protocol, except transplant patients received 10 million 
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cells. From a safety standpoint, there were minimal complications associated with the 
surgical procedure, and no adverse neurological events were observed after surgery 
during the period of ongoing assessment. However, there was less evidence of 
efficacy in the Phase II trial. The transplant group did improve in ESS compared to 
the control group, but this was not statistically significant. The memory scores of 
transplanted patients were statistically improved compared to controls and pre-
transplant baseline scores. Overall, the encouraging results and absence of severe 
side effects have merited a Phase IIb trial, designed to study efficacy (Kondziolka et 
al., 2005). 
 
6.4  Future Directions 
While a number of clinical trials have been conducted, with promising results in 
safety and efficacy, there is still plenty of basic science required prior to widespread 
clinical use of neural stem cell transplantation. As described previously, it will be 
essential to obtain further knowledge of the mechanisms by which grafted stem cells 
integrate with host tissue. However, there are a number of other issues which require 
investigation prior to widespread clinical adoption of neural transplantation. 
  
It remains to be seen whether there is a universal stem cell which can be used for the 
majority of neural disorders, or whether specialised stem cells would be required for 
particular disorders. As described previously, Parkinson’s disease is characterised by 
a specific loss of dopaminergic neurons, therefore transplantation therapies have 
centred on the use of partially differentiated dopaminergic stem cell progenitors or 
embryonic dopamine neurons (Bjorklund et al., 2003). In contrast, the cell types 
afflicted and the pattern of damage in stroke, Alzheimer’s disease, ageing and 
traumatic brain injury is markedly more diffuse and widespread. In these cases, it 
would be more suitable to use a more naïve cell with multi- or pluripotent capability 
which can differentiate into all the cell types which may be lost in these disorders.  
 
The type of neurological disorder also influences other factors which require further 
research. In disorders such as stroke and traumatic brain injury, the acute onset of 
damage creates a hostile brain environment which can be detrimental to stem cell 
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survival and subsequent migration and differentiation. It may be more advantageous 
in these cases to wait until the full extent of damage has been reached and utilise the 
regenerative capability offered by stem cell transplantation. However, the hostile 
environment causes an upregulation in inflammatory events. This inflammation can 
be detrimental for endogenous neurogenesis in the dentate gyrus (Ekdahl et al., 
2003), but can also be beneficial for directing stem cell migration, such as in the 
example of SDF-1 directed migration (Imitola et al., 2004, Robin et al., 2006). It is 
therefore necessary to find the correct time window for transplantation in order to 
achieve optimal recovery. However, in the case of more chronic neurological 
disorders such as Huntington’s, Parkinson’s and Alzheimer’s disease, neurological 
function decreases over a period of years. In some of these cases, it may take a few 
years before the disease can be clinically diagnosed. While this provides a large 
therapeutic window for transplantation, the progressive nature of these diseases 
means that therapeutic intervention has to take place prior to extensive cell loss.  
 
The region of damage also affects the site of grafting. Some disorders display a 
highly specific region of damage. The particular deinnervation of the striatum in 
Parkinson’s and Huntington’s disease provides a specific target for transplantation. A 
study using focal ischaemia as a model of damage has demonstrated that 
transplanting stem cells into the extensively lesioned infarct markedly hinders stem 
cell survival, due to the pathological environment and the lack of trophic support 
(Kelly et al., 2004). It is generally accepted that transplanting into the intact 
hemisphere raises the likelihood of stem cell survival and allows for migration to the 
region of damage. However, the more diffuse lesions present in Alzheimer’s disease 
and global ischaemia raise the issue of picking a suitable site for grafting.  
 
Some of these technical issues may be overcome by advances in brain imaging. 
Whilst immunohistochemistry and microscopic visualisation allow for high-
resolution imaging of stem cell grafts, this is only feasible in animal studies. It also 
represents a permanent endpoint. This could be carried out to a degree in human 
patients through the use of neural biopsy tissue, but is impractical for widespread 
use. Non-invasive imaging techniques are therefore preferential for long-term 
 199
monitoring of transplanted stem cells. Current molecular imaging techniques in use 
include PET scanning and MRI (Kirik et al., 2005). While the main use for these 
imaging techniques to date has been in observing the progression of neurological 
damage (e.g. dopaminergic system activity in Parkinson’s disease, Kordower et al., 
1995), recent approaches have used PET and MRI to visualise neural cell grafts in 
vivo (Franklin et al., 1999, Kondziolka et al., 2000, Roberts et al., 2006), allowing for 
longitudinal monitoring of grafts in patients. 
 
Further work is also needed on the role of immunosuppression in stem cell 
transplantation therapy. Evidence from the literature is currently contradictory, with 
some studies suggesting that stem cell have a low immunogenic potential and 
therefore do not require immunosuppression (Modo et al., 2002, Weiss et al., 2003, 
Wennersten et al., 2006), which was also the finding from this thesis. However, other 
studies suggest that a comprehensive immune suppression regimen is required for 
optimal stem cell graft transplantation (Pedersen et al., 1995, 1997, Yan et al., 2006, 
Al Nimer et al., 2004). This discrepancy could be accounted for by differences in the 
transplant tissue. The extent of efficacy observed during the clinical trials of neural 
transplantation for Parkinson’s disease have been linked to the immunosuppressive 
regime used (Bjorklund, 2005). 
 
This thesis also successfully demonstrated the use of transgenic mice in the 
application of neural transplantation therapy. Whilst the APOE transgenic strains 
used in this thesis illustrated the influence of an endogenous genetic factor on stem 
cell integration, transgenic mice can be used for other investigations. Transgenic 
mouse models of disease can be used to investigate the potential of neural 
replacement therapy for a variety of conditions. For example, the Jackson Laboratory 
has transgenic mouse models of Alzheimer’s disease, amyotrophic lateral sclerosis, 
epilepsy, Huntington’s disease and Parkinson’s disease. Transgenic mice can also be 
used to investigate the signalling pathways which might influence stem cell 
integration. In Chapter 4, the JNK signalling pathway was implicated in survival of 
MHP36 stem cells. The use of JNK-deficient mice would provide further information 
on the role of this signalling protein. Transgenic mice have also been refined for 
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inducible control of gene expression and region specific gene expression, both of 
which provide an extra regulatory step for investigating gene function.  
 
6.5  Conclusion 
The data presented in this thesis demonstrate that endogenous apoE strongly 
influences MHP36 graft survival, migration and differentiation. Although there was 
minimal evidence that human APOE genotype influences cell migration and 
differentiation, stem cell survival was markedly improved in a human APOE-ε3 
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Slides were placed in racks and soaked in poly-L-Lysine (0.1% solution, Sigma, UK) 
for 5 minutes. Slides were then dried overnight at room temperature or in an oven at 
60oC for 2 hours. The poly-L-Lysine solution was stored in a sealed container at 4oC 
and used to coat up to 1000 glass slides. 
 
10x Phosphate Buffer (PB) 
 
2.57g of NaH2PO4 and 11.95g of Na2HPO4 were dissolved and made up to 1L with 
distilled water. For 10X Phosphate Buffered Saline (PBS) 86.67g of NaCl was added 
and the solution pH adjusted to 7.4.  Both 10X Solutions were filtered prior to 
storage. 10X PB was stored at 4oC, whilst 10X PBS was stored at room temperature. 
 
Paraformaldehyde Fixative 4% (PAM)  
 
40g of paraformaldehyde (weighed in the fumehood) was added to 900ml of 1xPB 
which had been heated to 60-65oC. The temperature was maintained between 60oC 
and 65oC until the paraformaldehyde dissolved. The solution was allowed to cool, 
made up to 1L with PB and filtered for purity. 
 
Citric Acid Buffer 
 
2.1g of citric acid was dissolved in 1L of distilled water. The pH was adjusted to 6.0 
by the addition of 1M NaOH. 
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Acrylamide Gel Solutions  
















10x SDS-PAGE Running Buffer 
 
30g of Tris-Base, 144g of glycine, and 10g of SDS were fully dissolved in 1L of 
distilled water. The final solution was adjusted to pH 8.3. 
 
Western Transfer Buffer 
 
16.66g of Tris-Base and 79.2g of glycine were fully dissolved in 4.4L of distilled 
water. Immediately prior to use 1.1L of methanol was added to the solution, to give a 
final volume of 5.5L. 
 
Modified RIPA Buffer 
 
790 mg of Tris-Base was added to 75 ml distilled water. 900 mg of NaCl was then 
added and the solution stirred until all solids were dissolved. The pH was adjusted to 
7.4 with HCL. 10ml of 10% NP-40 was then added to the solution, followed by 
2.5ml of 10% Na-deoxycholate and the solution stirred until it became clear. 1ml of 
100mM EDTA was then added to the solution and the total volume of the solution 
adjusted to 100ml with distilled water. This modified RIPA buffer was stored at 4oC 
until ready for use. Immediately prior to use, one Complete protease inhibitor tablet 




10% SDS 200 μl 100 μl 
6.6 ml 1.3 ml 30% Acrylamide 
10% APS 100 μl 50 μl 
TEMED 10 μl 10 μl 
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